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ABSTRACT

Local and Systemic Effects of Flavonoid Intake with Submaximal
Cycling Exercise: A Randomized Controlled Trial

by

Stephanie Kung, Doctor of Philosophy
Utah State University, 2021

Major Professor: Dr. Robert Ward
Department: Nutrition, Dietetics, and Food Sciences

Submaximal endurance exercise is a known cause of elevated gastrointestinal
permeability, injury, and inflammation, which may contribute to symptoms such as
intestinal cramps and diarrhea. Preclinical and some clinical studies suggest that dietary
flavonoids, a class of plant secondary metabolites, may regulate intestinal permeability,
reduce chronic low-grade inflammation, and modulate the intestinal microbiota. The
purpose of this study was to determine the local and systemic effects of flavonoid intake,
in addition to cycling performance. A randomized, double blind, placebo controlled
crossover trial was conducted with 12 recreational cyclists (eight men, four women) from
August 2018 to May 2019 (ClinicalTrials.gov identifier: NCT03427879). Subjects were
randomized to a treatment sequence and consumed a high or low flavonoid (490 or 5
mg), pre-workout beverage daily for 15 days. At the end of each intervention, a
submaximal cycling trial (one hour at ~70% maximal oxygen capacity) was conducted in
a controlled laboratory setting (23 °C). Plasma samples were collected pre- and post-

iv
exercise (immediately, 1-h post, 4-h post). Primary outcomes were intestinal injury and
permeability, assessed by within-subject comparisons of plasma intestinal fatty acidbinding protein and urinary sugar excretion. Due to the contribution of the microbiota to
host metabolism, additional studies of the intestinal microbiome, short chain fatty acid
excretion, and plasma metabolomics were conducted.
Food frequency questionnaires estimated total flavonoid intake at 635 ± 195 mg
per week. Overall, subjects had low intestinal inflammation, and no differences in short
chain fatty acids or alpha and beta diversity were found. The treatment tended to increase
force applied during cycling (p = 0.051; effect size, d = 0.16). Despite observing exercise
effects on biomarkers, no treatment effects were found for intestinal permeability or
injury (p > 0.05). Circulating carbohydrates, lipids, and amino acids changed to varying
degrees following exercise, suggesting that multiple fuel substrate pathways were utilized
throughout exercise and recovery.
Sub-chronic supplementation with blueberry, cocoa, and green tea flavonoids did
not significantly affect intestinal health in recreational cyclists. For high intensity
exercise, a high flavonoid beverage performed as well as the control and did not alleviate
exercise-induced intestinal permeability or injury.

(217 pages)
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PUBLIC ABSTRACT

Local and Systemic Effects of Flavonoid Intake with Submaximal
Cycling Exercise: A Randomized Controlled Trial

Stephanie Kung

Moderate to high intensity endurance exercise is a known cause of exerciseinduced gastrointestinal syndrome, a condition often associated with intestinal complaints
such as discomfort, cramps, and diarrhea. Oftentimes, elevated intestinal inflammation
and permeability (a “leaky gut”) are also observed. Previous research has shown that
flavonoids, natural compounds found in many fruits and vegetables, may mitigate these
exercise-induced effects. In particular, certain cocoa powders contain high levels of
flavonoids, and chocolate milk is a good source of protein and sugars for sustaining
intense activity. Thus, the purpose of this study was to evaluate the effects of a dairy preworkout beverage, with flavonoids from cocoa, blueberries, and green tea. We
hypothesized that regular consumption of these flavonoids would alleviate exerciseinduced gastrointestinal syndrome. A clinical trial was conducted with twelve subjects,
who consumed the pre-workout once per day. After 14 days, subjects completed a onehour cycling test to determine the effects of the beverage on performance and
gastrointestinal health. Each participant underwent both the treatment and control in a
randomized order, serving as his or her own control for comparison.
Our results showed that the cycling trial was strenuous and caused measurable
changes in biomarkers of inflammation and intestinal injury, but ultimately, the flavonoid
pre-workout did not differ from the control. These findings suggest that short-term
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flavonoid supplementation from processed food ingredients (cocoa powder, freeze-dried
blueberries, and powdered green tea) may not have protective effects on the gut during
exercise-induced stress. However, the product was well-liked by the subjects and no
negative effects were observed. Nutritional strategies for reducing incidence of exerciseinduced gastrointestinal syndrome is a relatively new area of research, and these results
can help shape future recommendations in sports nutrition for endurance athletes and
coaches. This project contributes to current scientific knowledge regarding the interaction
between flavonoid consumption and intestinal health. Furthermore, similar mechanisms
are thought to drive related conditions such as exertional heat stress, ulcerative colitis,
and inflammatory bowel disease. Due to the prevalence of a leaky gut and inflammation
in not only endurance exercise but also these other conditions, more research—especially
well-controlled human clinical trials—is warranted.
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CHAPTER I

INTRODUCTION

Bill Rodgers, four-time winner of both the Boston and New York City marathons,
said that “more marathons are won or lost in the porta-toilets than at the dinner table.”
The “runner’s trots” (acute exercise-induced diarrhea) and other gastrointestinal (GI)
complaints commonly occur during long distance running and other endurance sports [1].
For example, in one ultramarathon, 85% of athletes reported experiencing debilitating GI
symptoms, resulting in reduced nutritional intake during the race and recovery period [2].
These GI symptoms are thought to be driven by the physiological changes that occur
during high-intensity exercise, during which core temperature steadily rises and oxygen
availability in the intestinal tissues decreases [1,3,4]. Other contributors to GI distress
may include mechanical (e.g., posture, repetitive movement), dietary (e.g., high fat, fiber,
or fluid intake), and neuroendocrine (e.g., cortisol secretion) factors [4].
Furthermore, intense exercise greater than 70% of maximal oxygen uptake
(VO2max) and core temperatures above 39.5 °C consistently result in elevated GI
permeability and inflammation, both of which may contribute further to the etiology of
GI distress [1,5,6]. Gastrointestinal permeability refers to the movement of small
molecules across the GI epithelium, the largest interface between the external
environment and internal milieu; the intestinal epithelium is a selectively permeable
membrane that regulates the absorption of water, ions, and nutrients while excluding proinflammatory agents [7]. While mild GI symptoms are an inconvenience and may impact
athletic performance, exercise-induced intestinal injury and elevated permeability may
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result in the passage of exogenous toxins, microorganisms, and antigens that can further
compromise an athlete’s overall health by triggering a systemic inflammatory response
[8].
Currently, effective nutritional interventions are limited, though many different
products, including bovine colostrum [9], probiotics [10], glutamine [11], nitrate [12],
and carbohydrates [13], have been investigated. A growing body of work suggests that
flavonoids, a diverse class of secondary metabolites abundant in fruits and vegetables,
may have the potential to alleviate exercise-induced GI inflammation and permeability
[14]. Findings from in vitro and animal studies suggest that flavonoids can modulate
intestinal permeability via the intestinal microbiota and tight junction protein complexes,
while downregulating pro-inflammatory pathways [15–23]. A variety of flavonoids have
also been effective in preventing or treating cell culture and animal models of
inflammatory bowel disease (IBD), a condition which also is driven by gut inflammation
and barrier dysfunction [24–27].
However, observations from cell culture and animal studies do not always
translate to the same effect in the human context, and few human clinical trials have been
conducted [14]. In the Polyphenol Study, a randomized controlled trial (RCT) previously
conducted at Utah State University, dietary polyphenols (a larger class of molecules that
includes flavonoids) were demonstrated to have a protective effect on the intestinal
barrier. Chronic administration of a high flavonoid diet (HFD) reduced gut permeability
and inflammation in obese and overweight humans (unpublished data)—a population that
displays elevated intestinal permeability and chronic low-grade inflammation [7,28]. As
intestinal permeability has also been observed to increase with age, another crossover
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trial provided a high polyphenol diet to a population of older subjects (≥ 60 years) and
reported an improvement in intestinal permeability in subjects with high baseline
permeability [29]. We hypothesize that these reductions in GI permeability will translate
to endurance athletes, who are also known to experience an impaired GI barrier as
discussed previously.
Although previous clinical trials have evaluated flavonoid supplementation in
combination with exercise, study endpoints were generally markers of oxidative stress,
and evaluations of GI permeability or injury were not included [30–35]. There were,
however, two recent clinical trials conducted with healthy subjects, investigating
polyphenol intake with exercise-induced GI permeability and inflammation as primary
endpoints. First, Szymanski et al. demonstrated that 3-day supplementation with the
polyphenol curcumin reduced markers of GI damage and the inflammatory response
following 60 minutes of moderate-intensity running in hot environmental conditions [36].
Second, two weeks of moderate flavonoid intake reduced intestinal permeability both at
rest and after 45 minutes walking at ~60% VO2max, though not following a 2.5 hour run
at ~70% VO2max [37]. Taking the findings from pre-clinical studies together with these
recent human studies, dietary flavonoids are a promising intervention to address the
effects of exercise in the GI tract.
Advancements in high-throughput technology and data processing has enabled
scientific inquiries with “-omics” techniques, allowing investigators to gather more
detailed information regarding individuals’ microbiomes and metabolomes.
Metabolomics is a comprehensive analysis used to detect and identify all small molecules
within a biofluid or tissue, and can provide a picture of the real-time metabolic response
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to a combination of external and internal stimuli [38]. The GI tract is colonized by a
dynamic community of commensal microorganisms—the gut microbiota—that performs
many essential functions for the host such as vitamin synthesis and nutrient metabolism
[14,39]. The intestinal microbiome is a key mediator in the effects of the diet.
Microbiome analysis attempts to characterize the diversity and abundance of these
microorganisms within a sample, as well as compare the community structures between
samples [40]. In the lower GI tract, flavonoids are extensively metabolized to a variety of
intermediates and products, and even dependent on the microbiota to be transformed to
more bioavailable and bioactive metabolites [41,42]. Conversely, flavonoid intake can
also shape the composition of the intestinal microbiome—dietary changes can begin to
alter the intestinal community in as little as one day [42,43]. Furthermore, the effects of
dietary flavonoid intake may be highly individualized. Recent microbiome analyses have
revealed a significant effect of inter-individual variation in responding to dietary
interventions [14,29]. Systemic effects of flavonoid intake are mediated by metabolites
(requiring metabolomics analysis), which depend in part on the functions of each
individual’s intestinal microbiota (requiring microbiome analysis) [44]. As a result, a
study of the physiological effects of flavonoid intake would greatly benefit from
including supplementary microbiome and metabolomics analyses.
The overall hypothesis of this project is that sub-chronic supplementation of
flavonoids will ameliorate exercise-induced gut injury, permeability, and inflammation.
Because of the close interaction between the gut microbiome and human health, we
conducted secondary analyses on the effects of flavonoid supplementation on the gut
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microbiome, fecal short chain fatty acid (SCFA) content, and plasma metabolomics
profile. The project objectives were as follows:
1. Formulate a dairy-based, pre-workout beverage that includes flavonoids from
blueberry, cocoa, and green tea at a level similar to those provided in prior clinical
studies where reductions in gut permeability were previously demonstrated.
2. Conduct a RCT with trained cyclists to determine the effect of sub-chronic
consumption of the flavonoid sports nutrition beverage on gut permeability,
injury, inflammation, and performance during an exercise time trial.
3. Determine the effect of chronic consumption of the flavonoid sports nutrition
beverage compared to a low flavonoid control on microbiome composition, SCFA
production, and the plasma metabolome.
The overall goal of our research is to investigate the effects of bioactive
compounds on intestinal health. To this end, it is important to understand the local and
systemic effects of dietary flavonoids. The results from this project will further our
understanding of the interactions among dietary flavonoids, the gut microbiota, and the
GI barrier. If proven effective, such a product could potentially benefit athletes and other
individuals displaying elevated GI permeability, which is also commonly reported in
exertional heatstroke, septic shock, irritable bowel syndrome, celiac disease, food
allergies, obesity, and inflammatory bowel disease [45–50]. Research in these areas is
ongoing, as several of these conditions still lack an effective nutritional treatment
[45,46,51]. Since fluid bovine milk is well-suited for exercise nutrition and generally
liked among athletes, this presents an opportunity to provide a dairy-based product
specifically designed to address exercise-related intestinal changes [52]. The dairy
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industry, nutraceutical companies, and cocoa, tea, and blueberry producers also have
opportunity to benefit from this research. Finally, research findings could extend
knowledge of sports nutrition specifically for endurance athletes, as addressing changes
in gut permeability, injury, and inflammation is a relatively new concern in the field.
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CHAPTER II

LITERATURE REVIEW

1. The Gastrointestinal Barrier
The intestinal epithelium is a selective barrier that separates luminal contents
(molecules, enzymes, and microorganisms) from internal circulation and consists of a
single layer of absorptive enterocytes, secretory goblet cells, peptide- and hormonesecreting enteroendocrine cells, and Paneth cells [1,2]. Adjacent cells are connected
together at the apical (luminal) surface by tight junctions, which are protein complexes
comprised of the transmembrane proteins occludin, claudin, tricellulin, and junctional
adhesion molecules (JAMs) [2–4]. Occludin and claudin are anchored to the cytoplasmic
zonula-occludin proteins, which are bound to cytoskeletal actin and myosin filaments [2].
The intestinal barrier plays an important role in regulating the passage of nutrients
and small molecules from the intestinal lumen to internal circulation [1]. To enter hepatic
and systemic circulation, luminal contents either pass through intestinal cells
(transcellular route) or the interstitial space between cells (paracellular route) (Figure 2-1)
[3]. Disruption of this selective barrier can result in unregulated translocation of
exogenous antigens, toxins, and pathogens, potentially causing local and systemic
inflammation [2]. A “leaky gut” or increased intestinal permeability, may be caused by
several factors, including epithelial damage to the mucosal lining or altered tight junction
protein expression [1,5].
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Figure 2-1. Structure of the intestinal epithelial membrane and the transcellular and
paracellular routes of transport.

2. Endurance Exercise and GI Distress
Intensive endurance exercise is known to cause intestinal barrier dysfunction, and
approximately 30-50% of individuals experience GI symptoms during exercise and
competition [6]. Gastrointestinal complaints such as abdominal cramps, diarrhea,
vomiting, and nausea are commonly experienced by endurance athletes [7]. In one study,
following a bout of high-intensity exercise, symptomatic athletes experienced greater
intestinal permeability than asymptomatic athletes did [8]. Interestingly, the two groups
did not differ in baseline gut permeability measured at rest [8]. On the other hand,
increased gut permeability has also been observed even in the absence of GI symptoms,
which suggests that even asymptomatic athletes may be at risk of exercise-induced
intestinal injury [9].
2.1 Splanchnic Hypoperfusion
Changes in two physiological factors are thought to cause this dysregulation in
intestinal permeability during exercise: splanchnic (abdominal) circulation and core body
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temperature [10,11]. During exercise, up to 80% of splanchnic blood flow is reduced and
redirected to support active tissues (i.e., cardiac, pulmonary, and skeletal muscle tissue)
[10]. Splanchnic blood flow has been shown to decrease 30-60% after 30 minutes of
exercise at 60-70% VO2max [11]. Gut hypoperfusion and ischemia are consequences of
prolonged, inadequate mesenteric blood flow, leading to low oxygen and glucose
availability [7,12]. These effects are greater at higher exercise intensities and
environmental temperatures, and may also be affected by age, prandial state, and training
status [6,11,13]. Depending on the duration and intensity of exercise, mucosal erosions
and ischemic colitis have also been reported [7]. Even in mild or less severe cases,
occurrence of increased intestinal permeability has the potential to hinder athletic
performance and the subsequent recovery period [7].
2.2 Core Temperature
Secondly, elevated GI permeability is believed to be strongly influenced by
changes in core temperature [9,14]. During exercise, localized gut hyperthermia occurs as
core body temperature gradually rises, which causes hypoxia and cellular metabolic stress
in the splanchnic capillary beds [15]. Enterocytes located at villus tips are particularly
vulnerable to hypoxia as there is generally lower oxygen availability due to the
countercurrent exchange in the villi [7,16]. At elevated temperatures of 37-42.5 C, both
in vitro and pre-clinical studies have shown that the intestinal barrier is compromised
[3,17–20]. When rats were heat stressed at 42.5 C, Lambert et al. observed epithelial cell
sloughing, vacuolization, and loss of microvilli [18]. In a systematic review of sixteen
clinical studies, Pires et al. reported that beyond the threshold temperature of 39 C,
increased intestinal permeability was always observed following an exercise test [14].
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Exercise tests in controlled clinical settings at moderate to high intensities (≥ 70%
VO2max) have been shown to elevate core temperature to 38.2-39.6 C [21]. In outdoor
competition, peak core temperatures as high as 41.7 C have been reported [22]. Beyond
the critical thermal maximum of 41.6 C in humans, sloughing and apoptosis of intestinal
cells occur, leaving gaps in the barrier, and without rapid intervention, can result in multiorgan failure and death [3].
2.3 Exercise and Endotoxemia
In some cases of elevated intestinal permeability, paracellular gaps may become
large enough to permit translocation of intestinal microorganisms or their cellular
components—particularly lipopolysaccharide (LPS) [13]. LPS is typically present at high
levels in the intestinal lumen, due to the large population of Gram negative bacteria that
reside there [23]. However in systemic circulation, LPS is a major activator of the
inflammatory cytokine response, recruiting leukocytes and promoting the production of
inflammatory cytokines, nuclear factors, and heat shock proteins [14]. Furthermore, the
presence of LPS in interstitial fluid and at the basolateral side of the intestinal epithelium
can induce tight junction permeability by promoting expression of toll-like receptor 4
(TLR4), the pattern recognition receptor for LPS, which is responsible for activating the
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) inflammatory
signaling cascade [23]. In this way, leakage of LPS due to external stresses like exercise
may result in a prolonged inflammatory response [23]. Higher circulatory levels of antiLPS immunoglobulins have been reported in competitive triathletes, potentially due to
frequent exposure to LPS from intestinal Gram negative bacteria during training and
exercise [24]. Several studies have reported exercise-induced permeability and
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endotoxemia (elevated LPS in circulation) in athletes following competition [24–27]. In
exertional heat stroke, the resulting defects in the intestinal barrier are thought to lead to
LPS leakage, activation of the inflammatory response, and multiple organ failure [25].
2.4 Nutritional Strategies to Mitigate GI Distress
Though exercise-induced gut permeability is a common occurrence, there are few
nutritional strategies that have been shown to prevent it, and this may be due in part to the
fact that the mechanisms are still not well understood [1]. Most recommendations are
general in nature, such as limiting the intake of high fat, fiber, and protein foods and
hyperosmotic beverages immediately preceding exercise [6,7,11,28]. During a triathlon,
incidence of GI symptoms was modestly associated with morning intake of
carbohydrates, caffeine, and total calories [29]. Dietary recommendations are also
dependent on the individual’s training habits, dietary preferences, sport, and genetics
[28]. Some promising strategies have been proposed, though research is still ongoing and
most nutritional interventions have yielded mixed results.
First, adequate hydration is essential, as dehydration can further exacerbate
exercise-induced symptoms [11,13]. Strategic carbohydrate consumption also appears to
reduce GI symptoms, injury, and inflammation, especially when coupled with “gut
training” to increase individual tolerance to consuming carbohydrates during exercise
[30–32]. For example, ingestion of multiple transportable carbohydrates (e.g., 2:1 glucose
to fructose ratio) versus a single carbohydrate reduces osmotic pressure in the gut and
may alleviate symptoms [6,30,33]. On the other hand, Sessions et al. found that ingestion
of a carbohydrate gel during a 60-minute running trial at 70% VO2max increased markers
of intestinal injury and inflammation compared to a non-carbohydrate control [34].
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Another nutritional intervention is to consume compounds such as L-citrulline and
glutamine that increase nitric oxide (NO) production in the gut to stimulate vasodilation
and counteract the exercise-induced reduction in splanchnic perfusion [6,26,35,36].
However, these studies have also yielded mixed results, and GI complaints also appear to
associate with the consumption of vegetables containing dietary nitrate [6,33,37]. Other
potential nutritional strategies under investigation include probiotics and bovine
colostrum supplementation [38–43].

3. Effect of Flavonoids on Human Health and Exercise
3.1 Polyphenols and Flavonoids
Polyphenols are a large class of plant secondary metabolites characterized by one
or more aromatic benzene rings with two or more hydroxyl functional groups [44]. These
compounds are produced in plants for a variety of purposes including pigmentation,
growth, protection from ultraviolet radiation, and microbial or insect resistance [44].
Common dietary sources of polyphenols include fruits, vegetables, coffee, and tea, with
the average individual consuming anywhere from 100 to 2000 mg total polyphenols daily
[45,46]. Diets rich in polyphenols are associated with a reduction in the risk for several
non-communicable diseases, presumably due to the antioxidative, anti-inflammatory, and
antimicrobial properties of polyphenols, and epidemiological data has shown that
populations consuming diets high in fruits and vegetables have lower risk of chronic and
degenerative age-associated diseases [5,45,47–51]. Furthermore, a number of studies
have suggested that plant polyphenols such as procyanidins, (-)epigallocatechin gallate,
quercetin, and (-)-epicatechin may protect epithelial tissue integrity by regulating tight
junction protein expression, assembly, and disassembly [5,52–56].
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Within polyphenols are four main compound classes: lignans, stilbenes, phenolic
acids, and flavonoids [44]. Common dietary flavonoids and food sources are listed in
Table 2-1. In particular, flavonoids, which comprise the major group within polyphenols,
have been of interest in health and nutrition research because of their non-nutritive
bioactive properties—health-promoting effects beyond basic nutritional needs [45,57].
Flavonoids are characterized by two aromatic rings connected by a 3-carbon bridge (C6C3-C6) and further categorized in to six sub-classes: flavonols, flavanols, flavanones,
flavones, anthocyanins, isoflavonoids [55]. Flavanols and anthocyanins are the most
abundant polyphenols in the human diet [45].
Polyphenols are chemically classified as radical scavenging molecules and metal
ion chelators, but due to their low bioavailability and low levels in plasma and tissues,
their health effects in vivo are more likely via modulation of cellular metabolism and
signaling [46]. Maximum plasma levels of polyphenol metabolites in comparison to those
of endogenous phenols and antioxidants (e.g., ascorbate, p-hydroxyphenyl lactate, phydroxyphenyl pyruvate, tyrosine, homogentisic acid, α-tocopherol) (~0.1-22 µM versus
160-380 µM, respectively) also suggest that it is unlikely that polyphenols themselves are
significant contributors to total antioxidant capacity as direct antioxidants [58]. One
possible exception is in the intestinal lumen where flavonoids are present at higher
concentrations and may act directly to chelate redox-active metal ions and scavenge free
radicals [59]. Findings from cell culture and pre-clinical studies suggest that flavonoids
(both purified compounds and polyphenolic plant extracts) have protective effects on the
intestinal barrier, enhance tight junction complex formation, and reduce intestinal
inflammation [53,60–63].
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Table 2-1. Common dietary flavonoids and food sources [44,64].
Flavonoid
Simple Flavonoids
Flavan-3-ols

Flavones

Example compounds

Dietary sources

Catechin, Epicatechin,
Gallocatechin,
Epigallocatechin,
Proanthocyanidins
Luteolin, Apigenin

Green tea, apple, red wine, cocoa

Flavonols

Kaempferol, Quercetin,
Myricetin

Flavanones
Isoflavones
Anthocyanins

Hesperetin, Naringenin,
Eriodictyol, Tangeritin
Genistein, Daidzein
Delphinidin, Pelargonidin,
Cyanidin, Malvidin,
Petunidin

Complex Flavonoids
Proanthocyanidins
(Condensed Tannins
or Flavanol
Polymers)

Procyanidins,
Prodelphinidins,
Propelargonidin

Herbs and spices; parsley,
capsicum pepper, celery
Ubiquitous in plant foods; onions,
leeks, broccoli, cherry tomato,
apple, berries, beans, tea and red
wine
Citrus fruits and herbs (oregano)
Soybeans, soy-based foods
Red, blue, and purple fruits and
berries; wine, blackcurrant,
cherry
Chocolate, stone fruit, grapes,
strawberries, nut skins, beer,
wine, legumes

3.2 Effects on GI Permeability: Tight Junctions
The potential regulatory pathways for the effects of polyphenols at the intestinal
epithelium were discussed in depth by Yang et al. [5]. First, dietary flavonoids such as
anthocyanins and quercetin have been shown to inhibit NF-B signaling, a key
transcription factor involved in many inflammatory pathways, and tumor necrosis factor
alpha (TNF-), a pro-inflammatory cytokine [5]. In addition to the transcription of proinflammatory cytokines, chemokines, cell adhesion molecules, and acute phase proteins,
NF-B activation appears to disrupt the intestinal barrier; inhibition of NF-B signaling
by pyrrolidine dithiocarbamate resulted in increased expression of the tight junction
proteins occludin and zonula occludens-1 (ZO-1) [5]. Epicatechin, a flavan-3-ol
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commonly found in cocoa, can prevent TNF- barrier disruption through NF-B
inhibition [56]. Anthocyanins have also been shown to inhibit membrane
permeabilization by TNF- and activate cellular kinases like p38-MAPK which regulate
tight junctions [65,66]. In another study, anthocyanin supplementation in mice mitigated
high fat diet-induced intestinal permeabilization and increased tight junction protein
expression via production of the intestinal hormone GLP-2 [65]. Other potential
mechanisms of polyphenols acting at the intestinal epithelium include regulation of
protein kinase pathways, reduction of reactive oxygen species (ROS), and suppression of
cellular enzymes like protein phosphatase 2A and Rho GTPases—all of which have
downstream effects on tight junction permeability [5,66].
3.3 Effects on GI Permeability and Inflammation
Polyphenols and polyphenol-derived metabolites have been shown to be likely
regulators of intestinal permeability in preclinical models, but overall, human clinical
data regarding flavonoid supplementation to mitigate intestinal inflammation and
permeability is limited [62,67]. Curcumin, a polyphenolic compound found in turmeric,
may have beneficial effects on exercise-induced inflammation and intestinal permeability
in hot environmental conditions (20 C vs. 37 C) [68,69]. Short term, 3-day
supplementation with 500 mg/day of curcumin reduced measures of intestinal injury and
thermal strain during one hour of sub-maximal treadmill running in hot conditions (37
C) in non-heat acclimated subjects [69]. Typically, plasma I-FABP, an indicator of
intestinal injury, is elevated following exercise, but this effect was blunted with curcumin
supplementation compared to placebo (58% vs. 87% increase from pre-exercise values,
respectively) [69]. Physiological strain index (PSI), an indicator of exertional heat stress
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risk, is determined from core temperature and heart rate, and the PSI was significantly
lower with curcumin supplementation than placebo during the last 20 minutes of the
exercise test [69].
Previously, a study conducted at USU (the Polyphenol Study) demonstrated the
efficacy of chronic consumption of dietary flavonoids in reducing measures of gut
permeability and inflammation in human subjects (unpublished data). A randomized,
double-blind, crossover trial was conducted with two six-week treatment periods
separated by a washout period. Overweight and mildly obese subjects were recruited for
this study, as this population is known to exhibit chronic low-grade intestinal
inflammation [1,70]. A well-controlled whole foods diet was provided to participants
who consumed either 340 mg total flavonoids per 1000 kcals on the high flavonoid diet
(HFD) or 10 mg per 1000 kcals on the low flavonoid diet (LFD). The two macronutrientmatched diets differed in only flavonoid content. The results in Table 2-2 show that the
HFD reduced gastrointestinal permeability compared to the LFD as determined by the
urinary sugar permeability test relative to mannitol excretion. Furthermore, fecal levels of
calprotectin, myeloperoxidase, and eosinophil protein X were also significantly lower
with the HFD treatment, which suggests that dietary flavonoids may reduce intestinal
inflammation. (Calprotectin, a peptide released by activated neutrophils, is a biomarker
for gut inflammation that is stable even at room temperature and resists proteolytic
degradation [2]. Both myeloperoxidase, an enzyme secreted by neutrophils, and
eosinophil protein X are also sensitive biomarkers for inflammation [71].)
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Table 2-2. Effects of HFD and LFD on markers of intestinal permeability and
inflammation (unpublished data).
Endpoint
Sucrose/Mannitol
Lactulose/Mannitol
Sucralose/Mannitol
Fecal Calprotectin (g/g)
Fecal Myeloperoxidase (g/g)
Fecal Eosinophil Protein X (g/g)

LFD
0.0057  0.0007
0.022  0.003
0.055  0.005
3.7  0.4
51.8  16.9
26.1  10.

HFD
0.0031  0.0003
0.014  0.002
0.043  0.003
1.7  0.2
18.0  7.5
7.5  1.6

P-Value
0.009
0.007
0.03
< 0.0001
0.01
0.04

3.4 Effects on Exercise: Performance and Recovery
Flavonoid supplementation may potentially enhance exercise performance by
delaying onset of fatigue and also improve recovery following training [58]. The
mechanisms are thought to be due to the action of flavonoids on several pathways related
to oxidative stress and inflammation: enhancement of endothelial function and muscle
perfusion by the NO pathway, activation of endogenous antioxidant systems via the
Nuclear factor erythroid 2-related factor 2 (Nrf2) and antioxidant response element
(ARE) pathway, inhibition of cyclooxygenase enzymes (COX1 and COX2) to activate
anti-inflammatory pathways, and downregulation of NF-κB signaling [58].
3.4.1 Vascular Function
Findings from clinical studies have shown that polyphenol supplementation can
improve flow mediated dilation (FMD), a marker for vascular function, through increased
NO synthesis and availability [72–74]. Nitric oxide is a potent vasodilator, which affects
cardiac output, tissue perfusion, and subsequently athletic performance [58]. As
discussed previously, one of the nutritional strategies under investigation for mitigating
exercise-related intestinal symptoms involves foods and supplements that increase NO
production and availability in epithelial tissue, to increase tissue perfusion and improve
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oxygen availability [26,33,35,36]. Polyphenols may reduce ROS such as superoxide, and
limiting superoxide can increase NO availability [58]. In addition, polyphenols may also
activate endothelial nitric oxide synthase 3 (eNOS) to increase NO production [58].
Several polyphenol-rich fruits have been investigated for their potential as
ergogenic aids due to their effects on vascular function [75–77]. In a clinical trial with
seven days of Montmorency cherry powder supplementation (463 mg polyphenols/day),
overall 15-km cycling time trial (TT) performance was improved by 4.6% [75]. Resting
tissue oxygenation index, a measure of muscle oxygenation, was significantly higher with
the Montmorency cherry intervention relative to the placebo (70% vs. 69%). In another
study, acute cranberry and grape seed polyphenol supplementation (600 mg) increased
FMD at rest in elite athletes, but there was no effect of the polyphenol extract on 3-km
cycling TT performance [76]. Finally, acute pomegranate extract intake (1000 mg)
significantly increased blood flow and vessel diameter following repeated sprint ability
testing on a cycle ergometer [77]. These findings suggest that polyphenols may increase
muscle oxygenation through the NO-mediated pathways as discussed previously.
3.4.2 Oxidative Stress
Another potential effect of polyphenols on athletic performance is believed to be
through modulation of redox status. Polyphenols can activate native antioxidant systems
and downregulate ROS-generating enzymes such as NADPH oxidase [58]. During
exercise, ROS are produced and increase with exercise intensity, and excess generation of
ROS during high intensity, long duration exercise may slowly drain performance capacity
as endogenous antioxidants are depleted [58,78]. This redox imbalance is believed to
cause quicker fatigue due to vasodilation, reduced calcium sensitivity in active muscle
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tissues, and increased central fatigue via the somatosensory cortex [58]. Dietary
polyphenols are thought to activate the adaptive stress response by acting as oxidative
stressors which modify and inhibit Keap1, an inhibitor of the transcription factor Nrf2
[79]. Upon degradation of Keap1, Nrf2 translocates to the nucleus to activate the ARE
transcriptional pathway, which ultimately has downstream effects of promoting
endogenous antioxidant enzymes like catalase and glutathione peroxidase (Figure 2-2).
An upregulation in native antioxidants via Nrf2 and ARE signaling most likely occurs
with chronic polyphenol supplementation longer than three days [58].

Figure 2-2. Regulation of the Keap1/Nrf2/ARE pathway via oxidative stressors such as
ROS and polyphenols.

28
In one study, 30-day supplementation with lychee fruit polyphenols (~66 mg/day)
increased submaximal running time to exhaustion [80]. During the study, participants
maintained their regular exercise routines, and VO2max did not change significantly over
the 30-day period for the lychee treatment group. The lychee treatment significantly
increased the subjects’ anaerobic threshold, a common indicator of endurance capacity,
while neither the placebo nor a vitamin C and E treatment had an effect on running
performance. The authors proposed that the outcomes of the polyphenol treatment were
likely due to the modulation of multiple redox signaling pathways rather than through
direct free radical scavenging, which would have been the expected mechanism driving
any effects of the vitamin treatment [80]. Several other studies have demonstrated that
polyphenol intake may reduce exercise-related oxidative stress, though no performance
changes were observed [81–85]. For example, dark chocolate consumption (2 weeks, 40
g twice daily) significantly reduced markers of oxidative stress (F2-isoprostanes and
oxidized low density lipoproteins) after an exhaustive endurance cycling trial [81].
However, no differences in time to exhaustion at 90% VO2max were observed between
the dark chocolate treatment and the cocoa liquor-free control.
3.4.3 Inflammation
Under normal conditions, the inflammatory response is a rapid, regulated, and
coordinated response to external or internal perturbations; tissue damage, pathogen
invasion, and exercise are common activators of inflammation [64]. The inflammatory
response is characterized by a series of cascading events: release of pro-inflammatory
molecules, recruitment of specific leukocytes, increased expression of oxidative enzymes,
and production of anti-inflammatory mediators once the initial insult is under control
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[64]. During exercise, skeletal muscle releases the cytokine interleukin (IL)-6,
proportional to relative exercise intensity and duration [86,87]. Heat stress and increased
GI permeability will further elevate IL-6 production [88]. IL-6 has been implicated in
both pro- and anti-inflammatory pathways depending on the target tissues and is involved
in energy substrate mobilization (gluconeogenesis and lipolysis), glucose uptake, and
lipid oxidation [88,89]. Muscle-derived IL-6 is particularly important during endurance
exercise for regulating muscle function and exercise capacity by mediating osteocalcin
production, which acts on muscle tissue to increase exercise capacity [87]. Other
circulating cytokines that increase following exercise include IL-1ra, IL-10, IL-8, and
monocyte chemotactic protein (MCP-1) [89].
Polyphenols can act in several ways to reduce inflammation. First, polyphenols
can inhibit NF-B signaling, a key transcription factor involved in many inflammatory
pathways [90]. Polyphenols can also downregulate expression of the pro-inflammatory
enzymes cyclooxygenase (COX), lipoxygenase (LOX), and phospholipase A2 (PLA2),
which ultimately reduces the release of several pro-inflammatory molecules: arachidonic
acid, prostaglandins, and leukotrienes [90].
Polyphenol intake has been shown to mitigate inflammatory stress with a
multitude of different clinical study designs: free-living and controlled diets, healthy
subjects and those with chronic diseases, short- and long-term interventions [64]. In a
meta-analysis by Peluso et al., 32 placebo-controlled clinical trials showed a decrease in
circulating TNF-α as a result of chronic flavonoid supplementation [91]. In some exercise
studies, a polyphenol intervention resulted in lower levels of IL-6 following exercise
[83,91–94]. In one study, the effect of six-week blueberry consumption on oxidative
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stress and inflammation was evaluated in a group of trained runners [84]. Following a
2.5-hour treadmill run at 72% VO2max, the anti-inflammatory cytokine IL-10 and natural
killer cell counts (related to anticancer activity) were elevated, while oxidative stress
(urinary 5-OHMU and plasma F2-isoprostanes) was reduced.
In another study, investigators aimed to determine the effects of Cavendish
bananas, mini-yellow bananas, a carbohydrate beverage, and water on inflammation and
plasma metabolites prior to and following a 75 km cycling TT [31]. (Cavendish and miniyellow bananas have similar carbohydrate content, but mini-yellow bananas have
approximately 63% higher polyphenol content.) Investigators reported that COX2 mRNA
expression was reduced in THP-1 monocytes cultured in plasma collected during the
recovery period from the banana treatments, suggesting that plasma metabolites
following banana ingestion can downregulate COX2, potentially mediating exerciseinduced inflammation in monocytes. It should be noted that bananas also contain other
components in addition to polyphenols (e.g., amino acids, dopamine, serotonin,
vitamins), and the specific banana metabolites resulting in COX2 inhibition were
unknown. Additionally, both banana treatments and the carbohydrate beverage reduced
inflammatory markers (IL-6, IL-10, IL-1ra, leukocyte counts) to a similar extent, which is
consistent with findings from previous studies regarding the immunomodulatory effects
of carbohydrate intake during exercise.

4. The Gut Microbiota and Dietary Flavonoids
4.1 Introduction to the Gut Microbiota
The intestinal microbiota is a dynamic community of microorganisms that occupy
the GI tract (primarily the colon) and includes bacteria, Eukarya, and Archaea [95]. These

31
microorganisms are thought to have co-evolved in a symbiotic relationship with their
human hosts [95]. Within an individual, the diversity and composition of the gut
microbiota are relatively stable by two to three years of age, but large shifts may still
occur due to host and environmental perturbations such as dietary changes, illness, and
antibiotics treatment; given time, the composition of the intestinal microbiota will return
to normal [95]. The intestinal microbiota can be profiled using metagenomic sequencing
of the 16S ribosomal ribonucleic acid (rRNA) gene [95]. Over 1,000 different species
have been found colonizing the human intestinal tract, and collectively, they have a
combined metagenome and metabolic capability 100-times greater than their human host
[96]. Microbiota diversity varies substantially from one individual to another—though
there are similarities in a few resident microorganisms and the functional genome, or
microbiome [96]. The human gut microbiota primarily consists of bacteria from the phyla
Firmicutes (49-76%), Bacteroidetes (16-23%), Proteobacteria (~8%), and Actinobacteria
(~3%), and the proportions of these microorganisms also vary depending on the location
within the GI tract [97].
An important part of the human intestinal ecosystem, the gut microbiota has been
found to play a key role in several functions and processes. Some metabolic activities of
the microbiota include the catabolism of indigestible carbohydrates and proteins,
xenobiotic transformation, and vitamin synthesis [96]. Microbial degradation of these
nutrients, xenobiotics, and drugs may increase or decrease the bioavailability and activity
of these exogenous compounds [97]. The microbiota is also known to provide benefits to
the host by reducing pathogen adhesion, supporting immune system development, and
regulating intestinal permeability [95]. Additionally, the microbiota may also interact
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with epigenetic modifications and plays a part in maintaining immune homeostasis [95].
Individuals with immune, inflammatory, or metabolic diseases often display gut
dysbiosis, or an imbalanced microbial population [95].
One important function of the gut microbiota is aiding in the development of a
mature intestinal epithelium and maintaining the integrity of the barrier [98]. In the GI
tract, a mucus layer consisting of cross-linked mucin glycoproteins is secreted by
specialized epithelial cells and aids in protecting the host from pathogen invasion;
conversely, a compromised mucus layer results in increased pathogen susceptibility and
localized inflammation [99]. Germ-free mice display thinner colonic mucus and epithelial
cell dysfunction, but following colonization with conventional microflora, the integrity of
the intestinal epithelium can be restored [99]. In one study, when dietary fiber was
restricted, rapid and reproducible shifts were observed in the intestinal microbiota in mice
[99]. Instead, certain strains of commensal bacteria that ordinarily rely on dietary fiber
for energy shifted to metabolize mucin glycoproteins, degrading the protective mucus
layer and increasing susceptibility to pathogen invasion [99]. In contrast, Akkermansia
spp. are mucin-degrading commensal bacteria that are believed to help with maintaining
the protective mucus layer by stimulating further mucus production and may also exhibit
anti-inflammatory effects in the GI tract [100].
Due to the complex nature of the intestinal microbiota, more clinical studies are
needed to elucidate how exercise stress impacts the microbiota and intestinal
permeability. In a study by Karl et al., a strenuous 4-day cross-country ski-march induced
a significant increase in intestinal permeability concomitant with a change in the
intestinal microbiota [101]. The exercise regimen negatively impacted the microbiota by
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reducing abundance of Bacteroides while increasing the abundance of potentially harmful
microorganisms (Peptostreptococcus, Staphylococcus, Peptoniphilus, Acidaminococcus,
and Fusobacterium) [101]. In contrast, Codella et al. have suggested that moderate
exercise can positively shape the microbiota to improve chronic disease health outcomes
due to the release of exercise-associated myokines, reduced intestinal transit time, overall
weight loss, and increased fecal bile acids as a result of exercise [102]. In another study,
exercise improved intestinal health in mice fed a high fat diet by modulating the
microbiota, reducing COX-2 expression in the proximal and distal gut, and preserving
normal intestinal villi morphology compared to sedentary animals [103]. Regular
exercise is also positively associated with the presence of microbial species that promote
barrier integrity (e.g., Akkermansia muciniphila, Lactobacillus plantarum, Bacteroides
fragilis, Bifidobacterium longum, Bifidobacteria bifidum) and appears to increase overall
microbial alpha diversity [104,105].
4.2 Short Chain Fatty Acid Production
Another function of the colonic microflora is the catabolism of indigestible
carbohydrates to produce short chain fatty acids (SCFA) [106]. The three most abundant
SCFA are acetate, propionate, and butyrate—typically present in the GI tract in a ratio
ranging from 3:1:1 to 10:2:1 [107]. Ultimately, these SCFA have different metabolic
fates: butyrate is primarily utilized as an energy source for colonocytes, propionate is
absorbed through hepatic circulation by the liver, and acetate is metabolized by
peripheral tissues such as the brain, muscle, pancreas, and adipose tissue [106]. Other
aspects of the biological significance of colonic SCFA production are less clear and more
research is still needed. Potentially, these exogenous SCFA produced by the colonic
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microflora from undigested material result in greater dietary energy available to the host
[108]. If so, excessive SCFA production may contribute to the development of obesity, as
greater production of total SCFA has been observed in obese and overweight humans
[108]. However, findings from observational studies also suggest that increased fiber
intake, which subsequently increases SCFA production, results in improved health
outcomes [108]. In fact, in colorectal cancer, the protective effect of fiber intake has been
attributed to butyrate production by the intestinal microbiota [108].
Though not yet fully understood, microbial SCFA are increasingly being
recognized as important signaling molecules between the microbiota and host [106].
Many of the microbiota-associated changes observed in human health may in fact be
mediated through the action of SCFA. The SCFA-specific free fatty acid receptors 2 and
3 (FFAR 2/3) have been identified across various tissue and cell types, and the
downstream effects of these receptors appear to be substrate- and tissue-dependent [106].
In the liver, acetate and butyrate are lipogenic while propionate is gluconeogenic and
inhibits lipogenic effects of acetate [106]. Increased circulating SCFA is associated with
lower adipogenesis and reduced lipid accumulation in adipocytes, resulting in smaller
adipocytes [106]. Acetate can also stimulate leptin secretion in adipocytes, which is a
hormone that regulates satiety [106]. Butyrate has received significant attention for its
potential in protecting the intestinal barrier—it appears to regulate the tight junction
protein complex by increasing expression and assembly of tight junction proteins like
claudin-1, ZO-1, and occludin [106,109,110]. Butyrate may also have anti-inflammatory
and anti-cancer properties [98]. In a mouse model of colitis, microbial-derived butyrate
was shown to activate regulatory T cells via epigenetic modification of the Foxp3 gene,
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reducing development of colitis [111]. Interestingly, exercise can positively affect the
presence of butyrate-producing bacteria in the gut like Lachnospiraceae and
Faecalibacterium prausnitzii [104].
Finally, SCFA production can also shape the composition of the microbiota by
reducing the growth of potentially pathogenic species [108]. A diet rich in fiber and
carbohydrates was shown to lead to a greater production of SCFA and consequently, a
reduction in intestinal and colonic pH, creating an environment unfavorable for the
growth of many common human pathogens like E. coli and Enterobacteriaceae [112].
4.3 The Reciprocal Relationship Between Flavonoids and the Gut Microbiota
The relationship between dietary flavonoids and the intestinal microbiota is
complex and bidirectional: dietary flavonoids can shape the diversity and composition of
the microbiota and the microbiota is responsible for the metabolism and transformation of
dietary flavonoids [113]. Only ~5-10% of flavonoids are absorbed in the small intestine,
and those that are not absorbed in the small intestine are extensively metabolized by the
colonic microflora [114]. The colonic microbiota can increase compound bioavailability
through enzymatic catabolism into lower molecular weight metabolites, which can be
either more or less bioactive than the parent compounds [114]. Consequently, the
microbiota are likely mediators in the health effects exerted by dietary polyphenols [114].
A schematic of the host and microbiota co-metabolism of dietary flavonoids is
presented in Figure 2-3. In the small intestine, most flavonoids are deglycosylated by the
brush border enzyme lactase-phlorizin hydrolase (LPH), and a small proportion are
absorbed by epithelial cells and transformed to glucuronide, sulfate, and methylated
conjugates through phase II metabolism [115,116]. Native polyphenols and their

36
conjugates can reach maximal levels in the plasma between 0.5-9 hours after ingestion
[58,117]. In the colon, ingested flavonoids undergo ring fission and are extensively
metabolized by the colonic microflora to phenolic acids, hydroxycinnamate,
phloroglucinol, and other compounds [118]. In addition, phase II flavonoid-derived
metabolites excreted through the enterohepatic pathway into the lower GI tract are
subject to further biotransformation by the microbiota [118]. Microbial polyphenol
metabolites appear in systemic circulation 6-48 hours after ingestion, and display
significant variation among subjects, likely due to large inter-individual differences in
intestinal microflora [58,119]. Additionally, microbial transformation has been found to
be dependent on the degree of polymerization and structure of the polyphenol, as larger
polymers may result in limited accessibility for microbial catabolic enzymes or reduced
cellular uptake. For example, lower bioavailability was observed with procyanidin dimers
and polymers compared to epicatechin monomers [120]. Nonetheless, given the highly
adaptive nature of the microbiota to dietary changes, the gut microbiome may also be
able to adapt to metabolize larger proanthocyanidin oligomers and polymers [121].
Microbial metabolism is a key step in making more bioactive metabolites available to
tissues and organs beyond the intestinal tract. Without the action of the microbiota, not
only would flavonoid metabolite absorption be severely limited, but so would the
potential downstream systemic effects.
Since the microbiota can have a variety of effects on the human host, flavonoidmediated modification of the microbiota population can affect a large array of health
outcomes. Flavonoids have well-documented anti-microbial properties and can inhibit
both pathogenic and beneficial microorganisms [122]. Conversely, specific flavonoids
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can also act to increase the abundance of certain microbial species within the intestinal
community, while other flavonoids may have both inhibitory and stimulatory effects on
different strains [97,123,124]. These effects appear to be structure-dependent and
aglycones may have greater inhibitory activity than their glycated counterparts [125].
Additionally, dietary flavonoids can also increase or inhibit bacterial adhesion, affecting
the presence and diversity of species in the intestinal tract [123].

Figure 2-3. Host and intestinal microbiota co-metabolism of dietary flavonoids and their
downstream effects.

Preclinical studies have demonstrated that polyphenol-rich extracts show potential
to modulate Akkermansia muciniphila abundance and mucin protein expression, though
more clinical data is still needed [65,126]. A polyphenolic cranberry extract ameliorated
the obesogenic effects of a high fat/high sucrose diet (weight gain, visceral obesity,
triglyceride accumulation, insulin resistance), reduced intestinal inflammation and
metabolic endotoxemia, and increased the abundance of Akkermansia spp. in mice [127].
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Similarly, supplementation with grape polyphenols in mice blunted the negative
metabolic effects of a high fat diet while increasing the abundance of Akkermansia spp.
[128]. In another rodent study, supplementation of a high fat diet with blueberries
changed the microbiota composition while preserving ileal villus morphology and
increasing Muc2 gene expression relative to a pair-fed, high fat diet group [129].
Additionally, the probiotic Lactobacillus plantarum also modulates the epithelial barrier;
treatment of IL-10 knockout mice, which display colonic barrier dysfunction compared to
wild type mice, with Lactobacillus plantarum significantly reduced the severity of colitis
development and paracellular permeability [130]. In other rodent studies,
supplementation with bilberry anthocyanin extract, apple procyanidins, and green tea
catechins were shown to modulate the gut microbiota and improve markers of intestinal
permeability [131–133].

5. References
1.

Bischoff, S.C.; Barbara, G.; Buurman, W.; Ockhuizen, T.; Schulzke, J.D.; Serino,
M.; Tilg, H.; Watson, a; Wells, J.M. Intestinal permeability--a new target for
disease prevention and therapy. BMC Gastroenterol 2014, 14, 189,
doi:10.1186/s12876-014-0189-7.

2.

Derikx, J.P.; Luyer, M.D.; Heineman, E.; Buurman, W.A. Non-invasive markers
of gut wall integrity in health and disease. World J. Gastroenterol. 2010, 16, 5272–
5279, doi:10.3748/wjg.v16.i42.5272.

3.

Dokladny, K.; Moseley, P.L.; Ma, T.Y. Physiologically relevant increase in
temperature causes an increase in intestinal epithelial tight junction permeability.
Am J Physiol Gastrointest Liver Physiol 2006, 290, G204-12,

39
doi:10.1152/ajpgi.00401.2005.
4.

Groschwitz, K.R.; Hogan, S.P. Intestinal barrier function: Molecular regulation
and disease pathogenesis. J. Allergy Clin. Immunol. 2009, 124, 3–20,
doi:10.1016/j.jaci.2009.05.038.

5.

Yang, G.; Bibi, S.; Du, M.; Suzuki, T.; Zhu, M.-J. Regulation of the intestinal tight
junction by natural polyphenols: a mechanistic perspective. Crit. Rev. Food Sci.
Nutr. 2016, 8398, 00–00, doi:10.1080/10408398.2016.1152230.

6.

De Oliveira, E.P.; Burini, R.C.; Jeukendrup, A. Gastrointestinal complaints during
exercise: Prevalence, etiology, and nutritional recommendations. Sport. Med.
2014, 44, 79–85, doi:10.1007/s40279-014-0153-2.

7.

van Wijck, K.; Lenaerts, K.; Grootjans, J.; Wijnands, K. a. P.; Poeze, M.; van
Loon, L.J.C.; Dejong, C.H.C.; Buurman, W. a. Physiology and pathophysiology of
splanchnic hypoperfusion and intestinal injury during exercise: strategies for
evaluation and prevention. AJP Gastrointest. Liver Physiol. 2012, 303, G155–
G168, doi:10.1152/ajpgi.00066.2012.

8.

van Nieuwenhoven, M.A.; Brouns, F.; Brummer, R.J.M. Gastrointestinal profile of
symptomatic athletes at rest and during physical exercise. Eur. J. Appl. Physiol.
2004, 91, 429–434, doi:10.1007/s00421-003-1007-z.

9.

Pals, K.L.; Chang, R.T.; Ryan, a J.; Gisolfi, C. V Effect of running intensity on
intestinal permeability. J. Appl. Physiol. 1997, 82, 571–576,
doi:10.1006/jsre.1994.1131.

10.

de Oliveira, E.P.; Burini, R.C. The impact of physical exercise on the
gastrointestinal tract. Curr. Opin. Clin. Nutr. Metab. Care 2009, 12, 533–8,

40
doi:10.1097/MCO.0b013e32832e6776.
11.

Ter Steege, R.W.F.; Kolkman, J.J. Review article: The pathophysiology and
management of gastrointestinal symptoms during physical exercise, and the role of
splanchnic blood flow. Aliment. Pharmacol. Ther. 2012, 35, 516–528,
doi:10.1111/j.1365-2036.2011.04980.x.

12.

Model, T.I.; Schellekens, D.H.S.M.; Grootjans, J.; Dello, S.A.W.G.; Bijnen, A.A.
Van; Dam, R.M. Van; Dejong, C.H.C.; Derikx, J.P.M.; Buurman, W.A. Plasma
Intestinal Fatty Acid – Binding Protein Levels Correlate With Morphologic
Epithelial Intestinal Damage in a Human. 2014, 48, 253–260.

13.

Jeukendrup, A.E.; Vet-Joop, K.; Sturk, A.; Stegen, J.H.; Senden, J.; Saris, W.H.;
Wagenmakers, A.J. Relationship between gastro-intestinal complaints and
endotoxaemia, cytokine release and the acute-phase reaction during and after a
long-distance triathlon in highly trained men. Clin. Sci. 2000, 98, 47–55,
doi:10.1042/CS19990258.

14.

Pires, W.; Veneroso, C.E.; Wanner, S.P.; Pacheco, D.A.S.; Vaz, G.C.; Amorim,
F.T.; Tonoli, C.; Soares, D.D.; Coimbra, C.C. Association Between ExerciseInduced Hyperthermia and Intestinal Permeability: A Systematic Review. Sport.
Med. 2017, 47, 1389–1403, doi:10.1007/s40279-016-0654-2.

15.

Hall, D.M.; Baumgardner, K.R.; Oberley, T.D.; Gisolfi, C. V Splanchnic tissues
undergo hypoxic stress during whole body hyperthermia. Am. J. Physiol. 1999,
276, G1195–G1203.

16.

Zheng, L.; Kelly, C.J.; Colgan, S.P. Physiologic hypoxia and oxygen homeostasis
in the healthy intestine. A Review in the Theme: Cellular Responses to Hypoxia.

41
Am. J. Physiol. Cell Physiol. 2015, 309, C350-60, doi:10.1152/ajpcell.00191.2015.
17.

Moseley, P.L.; Gapen, C.; Wallen, E.S.; Walter, M.E.; Peterson, M.W. Thermal
stress induces epithelial permeability. Am. J. Physiol. 1994, 267, C425-34.

18.

Lambert, G.P.; Broussard, L.J.; Mason, B.L.; Mauermann, W.J.; Gisolfi, C. V
Gastrointestinal permeability during exercise: effects of aspirin and energycontaining beverages. J. Appl. Physiol. 2001, 90, 2075–2080.

19.

Phillips, N.A.; Welc, S.S.; Wallet, S.M.; King, M.A.; Clanton, T.L. Protection of
intestinal injury during heat stroke in mice by interleukin-6 pretreatment. J.
Physiol. 2015, 3, 739–752, doi:10.1113/jphysiol.2014.283416.

20.

Oliver, S.R.; Phillips, N.A.; Novosad, V.L.; Bakos, M.P.; Talbert, E.E.; Clanton,
T.L. Hyperthermia induces injury to the intestinal mucosa in the mouse: evidence
for an oxidative stress mechanism. Am. J. Physiol. Regul. Integr. Comp. Physiol.
2012, 302, R845-53, doi:10.1152/ajpregu.00595.2011.

21.

Dokladny, K.; Zuhl, M.N.; Moseley, P.L. Intestinal epithelial barrier function and
tight junction proteins with heat and exercise. J. Appl. Physiol. 2016, 120, 692–
701.

22.

Byrne, C.; Lee, J.K.W.; Chew, S.A.N.; Lim, C.L.; Tan, E.Y.M. Continuous
thermoregulatory responses to mass-participation distance running in heat. Med.
Sci. Sports Exerc. 2006, 38, 803–810, doi:10.1249/01.mss.0000218134.74238.6a.

23.

Guo, S.; Al-Sadi, R.; Said, H.M.; Ma, T.Y. Lipopolysaccharide causes an increase
in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte
membrane expression and localization of TLR-4 and CD14. Am. J. Pathol. 2013,
182, 375–387, doi:10.1016/j.ajpath.2012.10.014.

42
24.

Bosenberg, A.T.; Brock-Utne, J.G.; Gaffin, S.L.; Wells, M.T.B.; Blake, G.T.W.
Strenuous exercise causes systemic endotoxemia. J. Appl. Physiol. 1988, 65, 106–
108, doi:10.1152/jappl.1988.65.1.106.

25.

Selkirk, G.A.; McLellan, T.M.; Wright, H.E.; Rhind, S.G. Mild endotoxemia, NFkappaB translocation, and cytokine increase during exertional heat stress in trained
and untrained individuals. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008,
295, R611-23, doi:10.1152/ajpregu.00917.2007.

26.

Zuhl, M.; Dokladny, K.; Mermier, C.; Schneider, S.; Salgado, R.; Moseley, P. The
effects of acute oral glutamine supplementation on exercise-induced
gastrointestinal permeability and heat shock protein expression in peripheral blood
mononuclear cells. Cell Stress Chaperones 2015, 20, 85–93, doi:10.1007/s12192014-0528-1.

27.

Barberio, M.D.; Elmer, D.J.; Laird, R.H.; Lee, K.A.; Gladden, B.; Pascoe, D.D.
Systemic LPS and inflammatory response during consecutive days of exercise in
heat. Int. J. Sports Med. 2015, 36, 262–270, doi:10.1055/s-0034-1389904.

28.

Jeukendrup, A.E. Nutrition for endurance sports: Marathon, triathlon, and road
cycling. J. Sports Sci. 2011, 29, S91–S99, doi:10.1080/02640414.2011.610348.

29.

Wilson, P.B. Dietary and non-dietary correlates of gastrointestinal distress during
the cycle and run of a triathlon. Eur. J. Sport Sci. 2015, 1391, 1–7,
doi:10.1080/17461391.2015.1046191.

30.

Costa, R.J.S.; Miall, A.; Khoo, A.; Rauch, C.; Snipe, R.; Camões-Costa, V.;
Gibson, P. Gut-training: the impact of two weeks repetitive gut-challenge during
exercise on gastrointestinal status, glucose availability, fuel kinetics, and running

43
performance. Appl. Physiol. Nutr. Metab. 2017, 42, 547–557, doi:10.1139/apnm2016-0453.
31.

Nieman, D.C.; Gillitt, N.D.; Sha, W.; Esposito, D.; Ramamoorthy, S. Metabolic
recovery from heavy exertion following banana compared to sugar beverage or
water only ingestion: A randomized, crossover trial. PLoS One 2018, 13,
e0194843.

32.

Snipe, R.M.J.; Khoo, A.; Kitic, C.M.; Gibson, P.R.; Costa, R.J.S. Carbohydrate
and protein intake during exertional heat stress ameliorates intestinal epithelial
injury and small intestine permeability. Appl. Physiol. Nutr. Metab. 2017, 42,
1283–1292, doi:10.1139/apnm-2017-0361.

33.

Jonvik, K.L.; Lenaerts, K.; Smeets, J.S.J.; Kolkman, J.J.; Van Loon, L.J.C.;
Verdijk, L.B. Sucrose but Not Nitrate Ingestion Reduces Strenuous Cycling–
induced Intestinal Injury. Med. Sci. Sport. Exerc. 2019, 51.

34.

Sessions, J.; Bourbeau, K.; Rosinski, M.; Szczygiel, T.; Nelson, R.; Sharma, N.;
Zuhl, M. Carbohydrate gel ingestion during running in the heat on markers of
gastrointestinal distress. Eur. J. Sport Sci. 2016, 1391, 1–9,
doi:10.1080/17461391.2016.1140231.

35.

van Wijck, K.; Wijnands, K.A.P.P.; Meesters, D.M.; Boonen, B.; Van Loon,
L.J.C.C.; Buurman, W.A.; Dejong, C.H.C.C.; Lenaerts, K.; Poeze, M. L-citrulline
improves splanchnic perfusion and reduces gut injury during exercise. Med. Sci.
Sports Exerc. 2014, 46, 2039–2046, doi:10.1249/MSS.0000000000000332.

36.

Zuhl, M.N.; Lanphere, K.R.; Kravitz, L.; Mermier, C.M.; Schneider, S.; Dokladny,
K.; Moseley, P.L. Effects of oral glutamine supplementation on exercise-induced

44
gastrointestinal permeability and tight junction protein expression. J Appl Physiol
2014, 116, 183–191.
37.

Ogden, H.B.; Child, R.B.; Fallowfield, J.L.; Delves, S.K.; Westwood, C.S.;
Layden, J.D. The Gastrointestinal Exertional Heat Stroke Paradigm:
Pathophysiology, Assessment, Severity, Aetiology and Nutritional
Countermeasures. Nutrients 2020, 12, 537, doi:10.3390/nu12020537.

38.

Lamprecht, M.; Frauwallner, A. Exercise, intestinal barrier dysfunction and
probiotic supplementation. Med. Sport Sci. 2012, 59, 47–56,
doi:10.1159/000342169.

39.

Pugh, J.N.; Sparks, A.S.; Doran, D.A.; Fleming, S.C.; Langan-Evans, C.; Kirk, B.;
Fearn, R.; Morton, J.P.; Close, G.L. Four weeks of probiotic supplementation
reduces GI symptoms during a marathon race. Eur. J. Appl. Physiol. 2019, 119,
1491–1501, doi:10.1007/s00421-019-04136-3.

40.

Axelrod, C.L.; Brennan, C.J.; Cresci, G.; Paul, D.; Hull, M.; Fealy, C.E.; Kirwan,
J.P. UCC118 supplementation reduces exercise-induced gastrointestinal
permeability and remodels the gut microbiome in healthy humans. Physiol. Rep.
2019, 7, e14276–e14276, doi:10.14814/phy2.14276.

41.

Marchbank, T.; Davison, G.; Oakes, J.R.; Ghatei, M. a; Patterson, M.; Moyer,
M.P.; Playford, R.J. The nutriceutical bovine colostrum truncates the increase in
gut permeability caused by heavy exercise in athletes. Am. J. Physiol. Gastrointest.
Liver Physiol. 2011, 300, G477–G484, doi:10.1152/ajpgi.00281.2010.

42.

Morrison, S.A.; Cheung, S.S.; Cotter, J.D. Bovine colostrum, training status, and
gastrointestinal permeability during exercise in the heat: a placebo-controlled

45
double-blind study. Appl. Physiol. Nutr. Metab. 2014, 1082, 1–13,
doi:10.1139/apnm-2013-0583.
43.

Halasa, M.; Maciejewska, D.; Baskiewicz-Halasa, M.; Machalinski, B.; Safranow,
K.; Stachowska, E. Oral Supplementation with Bovine Colostrum Decreases
Intestinal Permeability and Stool Concentrations of Zonulin in Athletes. Nutrients
2017, 9, doi:10.3390/nu9040370.

44.

Quideau, S.; Deffieux, D.; Douat-Casassus, C.; Pouysegu, L. Plant Polyphenols:
Chemical Properties, Biological Activities, and Synthesis. Angew. Chemie Int. Ed.
2011, 50, 586–621, doi:10.1002/anie.201000044.

45.

Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. J.
Nutr. 2000, 130, 2073S–85S, doi:10.1093/jn/130.8.2073S.

46.

Clifford, M.N. Diet-derived phenols in plasma and tissues and their implications
for health. Planta Med. 2004, 70, 1103–1114, doi:10.1055/s-2004-835835.

47.

Dai, Q.; Borenstein, A.R.; Wu, Y.; Jackson, J.C.; Larson, E.B. Fruit and vegetable
juices and Alzheimer’s disease: the Kame Project. Am. J. Med. 2006, 119, 751–
759, doi:10.1016/j.amjmed.2006.03.045.

48.

Dauchet, L.; Amouyel, P.; Hercberg, S.; Dallongeville, J. Fruit and Vegetable
Consumption and Risk of Coronary Heart Disease: A Meta-Analysis of Cohort
Studies. J. Nutr. 2006, 136, 2588–2593, doi:10.1093/jn/136.10.2588.

49.

Babio, N.; Bullo, M.; Salas-Salvado, J. Mediterranean diet and metabolic
syndrome: the evidence. Public Health Nutr. 2009, 12, 1607–1617,
doi:10.1017/S1368980009990449.

50.

Williamson, G. The role of polyphenols in modern nutrition. Nutr. Bull. 2017, 42,

46
226–235, doi:10.1111/nbu.12278.
51.

Root, M.M.; Mcginn, M.C.; Nieman, D.C.; Henson, D.A.; Heinz, S.A.; Andrew
Shanely, R.; Knab, A.M.; Jin, F. Combined fruit and vegetable intake is correlated
with improved inflammatory and oxidant status from a cross-sectional study in a
community setting. Nutrients 2012, 4, 29–41, doi:10.3390/nu4010029.

52.

Ulluwishewa, D.; Anderson, R.C.; McNabb, W.C.; Moughan, P.J.; Wells, J.M.;
Roy, N.C. Regulation of tight junction permeability by intestinal bacteria and
dietary components. J. Nutr. 2011, 141, 769–776, doi:10.3945/jn.110.135657.

53.

Gentile, C.; Perrone, A.; Attanzio, A.; Tesoriere, L.; Livrea, M.A. Sicilian
pistachio (Pistacia vera L.) nut inhibits expression and release of inflammatory
mediators and reverts the increase of paracellular permeability in IL-1B-exposed
human intestinal epithelial cells. Eur. J. Nutr. 2015, 54, 811–821,
doi:10.1007/s00394-014-0760-6.

54.

Watson, J.L.; Ansari, S.; Cameron, H.; Wang, A.; Akhtar, M.; Mckay, D.M.;
James, L. Green tea polyphenol (-)-epigallocatechin gallate blocks epithelial
barrier dysfunction provoked by IFN-γ but not by IL-4. Am. J. Physiol.
Gastrointest. Liver Physiol. 2004, 287, 954–961, doi:10.1152/ajpgi.00302.2003.

55.

Amasheh, M.; Schlichter, S.; Amasheh, S.; Mankertz, J.; Zeitz, M.; Fromm, M.;
Schulzke, J.D. Quercetin enhances epithelial barrier function and increases
claudin-4 expression in Caco-2 cells. J Nutr 2008, 138, 1067–1073,
doi:138/6/1067 [pii].

56.

Contreras, T.C.; Ricciardi, E.; Cremonini, E.; Oteiza, P.I. (-)-Epicatechin in the
prevention of tumor necrosis alpha-induced loss of Caco-2 cell barrier integrity.

47
Arch. Biochem. Biophys. 2015, 573, 84–91, doi:10.1016/j.abb.2015.01.024.
57.

Crowe, K.M.; Francis, C. Position of the Academy of Nutrition and Dietetics:
Functional Foods. J. Acad. Nutr. Diet. 2013, 113, 1096–1103,
doi:10.1016/j.jand.2013.06.002.

58.

Bowtell, J.; Kelly, V. Fruit-Derived Polyphenol Supplementation for Athlete
Recovery and Performance. Sports Med. 2019, 49, 3–23, doi:10.1007/s40279-0180998-x.

59.

Galleano, M.; Verstraeten, S. V; Oteiza, P.I.; Fraga, C.G. Antioxidant actions of
flavonoids: Thermodynamic and kinetic analysis. Arch. Biochem. Biophys. 2010,
501, 23–30, doi:10.1016/j.abb.2010.04.005.

60.

Suzuki, T.; Hara, H. Quercetin enhances intestinal barrier function through the
assembly of zonula occludens-2, occludin, and claudin-1 and the expression of
claudin-4 in Caco-2 cells. J. Nutr. 2009, 139, 965–974,
doi:10.3945/jn.108.100867.

61.

Vezza, T.; Rodríguez-Nogales, A.; Algieri, F.; Utrilla, M.P.; Rodriguez-Cabezas,
M.E.; Galvez, J. Flavonoids in Inflammatory Bowel Disease: A Review. Nutrients
2016, 8, doi:10.3390/nu8040211.

62.

Romier, B.; Schneider, Y.; Larondelle, Y.; During, A. Dietary polyphenols can
modulate the intestinal inflammatory response. 2009, 67, 363–378,
doi:10.1111/j.1753-4887.2009.00210.x.

63.

Romier-Crouzet, B.; Van De Walle, J.; During, A.; Joly, A.; Rousseau, C.; Henry,
O.; Larondelle, Y.; Schneider, Y.J. Inhibition of inflammatory mediators by
polyphenolic plant extracts in human intestinal Caco-2 cells. Food Chem. Toxicol.

48
2009, 47, 1221–1230, doi:10.1016/j.fct.2009.02.015.
64.

Joseph, S. V.; Edirisinghe, I.; Burton-Freeman, B.M. Fruit Polyphenols: A Review
of Anti-inflammatory Effects in Humans. Crit. Rev. Food Sci. Nutr. 2016, 56,
419–444, doi:10.1080/10408398.2013.767221.

65.

Cremonini, E.; Daveri, E.; Mastaloudis, A.; Adamo, A.M.; Mills, D.; Kalanetra,
K.; Hester, S.N.; Wood, S.M.; Fraga, C.G.; Oteiza, P.I. Anthocyanins protect the
gastrointestinal tract from high fat diet-induced alterations in redox signaling,
barrier integrity and dysbiosis. Redox Biol. 2019, 26, 101269,
doi:10.1016/j.redox.2019.101269.

66.

Valdez, J.C.; Bolling, B.W. Anthocyanins and intestinal barrier function: a review.
J. Food Bioact. 2019, 5, 18–30, doi:10.31665/jfb.2019.5175.

67.

Bernardi, S.; Del Bo’, C.; Marino, M.; Gargari, G.; Cherubini, A.; AndrésLacueva, C.; Hidalgo-Liberona, N.; Peron, G.; González-Dominguez, R.; Kroon,
P.; et al. Polyphenols and Intestinal Permeability: Rationale and Future
Perspectives. J. Agric. Food Chem. 2020, 68, 1816–1829,
doi:10.1021/acs.jafc.9b02283.

68.

Sciberras, J.N.; Galloway, S.D.; Fenech, A.; Grech, G.; Farrugia, C.; Duca, D.;
Mifsud, J. The effect of turmeric (Curcumin) supplementation on cytokine and
inflammatory marker responses following 2 hours of endurance cycling. J. Int.
Soc. Sports Nutr. 2015, 12, 5, doi:10.1186/s12970-014-0066-3.

69.

Szymanski, M.C.; Gillum, T.L.; Gould, L.M.; Morin, D.S.; Kuennen, M.R. Shortterm dietary curcumin supplementation reduces gastrointestinal barrier damage
and physiological strain responses during exertional heat stress. J. Appl. Physiol.

49
2018, 124, 330–340, doi:10.1152/japplphysiol.00515.2017.
70.

König, J.; Wells, J.; Cani, P.D.; García-Ródenas, C.L.; MacDonald, T.; Mercenier,
A.; Whyte, J.; Troost, F.; Brummer, R.-J. Human Intestinal Barrier Function in
Health and Disease. Clin. Transl. Gastroenterol. 2016, 7, e196,
doi:10.1038/ctg.2016.54.

71.

Peterson, C.G.B.; Sangfelt, P.; Wagner, M.; Hansson, T.; Lettesjö, H.; Carlson, M.
Fecal levels of leukocyte markers reflect disease activity in patients with ulcerative
colitis. Scand. J. Clin. Lab. Invest. 2007, 67, 810–820,
doi:10.1080/00365510701452838.

72.

Hooper, L.; Kay, C.; Abdelhamid, A.; Kroon, P.A.; Cohn, J.S.; Rimm, E.B.;
Cassidy, A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health:
a systematic review and meta-analysis of randomized trials. Am. J. Clin. Nutr.
2012, 95, 740–751, doi:10.3945/ajcn.111.023457.

73.

Rodriguez-Mateos, A.; Rendeiro, C.; Bergillos-Meca, T.; Tabatabaee, S.; George,
T.W.; Heiss, C.; Spencer, J.P.E. Intake and time dependence of blueberry
flavonoid–induced improvements in vascular function: a randomized, controlled,
double-blind, crossover intervention study with mechanistic insights into
biological activity. Am. J. Clin. Nutr. 2013, 98, 1179–1191,
doi:10.3945/ajcn.113.066639.

74.

Zhu, Y.; Xia, M.; Yang, Y.; Liu, F.; Li, Z.; Hao, Y.; Mi, M.; Jin, T.; Ling, W.
Purified anthocyanin supplementation improves endothelial function via NOcGMP activation in hypercholesterolemic individuals. Clin. Chem. 2011, 57,
1524–1533, doi:10.1373/clinchem.2011.167361.

50
75.

Morgan, P.T.; Barton, M.J.; Bowtell, J.L. Montmorency cherry supplementation
improves 15-km cycling time-trial performance. Eur. J. Appl. Physiol. 2019, 119,
675–684, doi:10.1007/s00421-018-04058-6.

76.

Labonté, K.; Couillard, C.; Motard-Bélanger, A.; Paradis, M.-E.; Couture, P.;
Lamarche, B. Acute Effects of Polyphenols from Cranberries and Grape Seeds on
Endothelial Function and Performance in Elite Athletes. Sports 2013, 1, 55–68,
doi:10.3390/sports1030055.

77.

Roelofs, E.J.; Smith-Ryan, A.E.; Trexler, E.T.; Hirsch, K.R.; Mock, M.G. Effects
of pomegranate extract on blood flow and vessel diameter after high-intensity
exercise in young, healthy adults. Eur. J. Sport Sci. 2017, 17, 317–325,
doi:10.1080/17461391.2016.1230892.

78.

Bailey, D.M.; Lawrenson, L.; Mceneny, J.; Young, I.S.; James, P.E.; Jackson,
S.K.; Henry, R.R.; Mathieu-Costello, O.; Mccord, J.M.; Richardson, R.S. Electron
paramagnetic spectroscopic evidence of exercise-induced free radical
accumulation in human skeletal muscle. Free Radic. Res. 2007, 41, 182–190,
doi:10.1080/10715760601028867.

79.

Birringer, M. Hormetics: Dietary Triggers of an Adaptive Stress Response. Pharm.
Res. 2011, 28, 2680, doi:10.1007/s11095-011-0551-1.

80.

Kang, S.W.; Hahn, S.; Kim, J.-K.; Yang, S.-M.; Park, B.-J.; Chul Lee, S.
Oligomerized lychee fruit extract (OLFE) and a mixture of vitamin C and vitamin
E for endurance capacity in a double blind randomized controlled trial. J. Clin.
Biochem. Nutr. 2012, 50, 106–113, doi:10.3164/jcbn.11-46.

81.

Allgrove, J.; Farrell, E.; Gleeson, M.; Williamson, G.; Cooper, K. Regular dark

51
chocolate consumption’s reduction of oxidative stress and increase of free-fattyacid mobilization in response to prolonged cycling. Int. J. Sport Nutr. Exerc.
Metab. 2011, 21, 113–123, doi:10.1123/ijsnem.21.2.113.
82.

Morillas-Ruiz, J.M.; Villegas García, J.A.; López, F.J.; Vidal-Guevara, M.L.;
Zafrilla, P. Effects of polyphenolic antioxidants on exercise-induced oxidative
stress. Clin. Nutr. 2006, 25, 444–453, doi:10.1016/j.clnu.2005.11.007.

83.

Lyall, K.A.; Hurst, S.M.; Cooney, J.; Jensen, D.; Lo, K.; Hurst, R.D.; Stevenson,
L.M. Short-term blackcurrant extract consumption modulates exercise-induced
oxidative stress and lipopolysaccharide-stimulated inflammatory responses. Am. J.
Physiol. Integr. Comp. Physiol. 2009, 297, R70–R81,
doi:10.1152/ajpregu.90740.2008.

84.

McAnulty, L.S.; Nieman, D.C.; Dumke, C.L.; Shooter, L.A.; Henson, D.A.; Utter,
A.C.; Milne, G.; McAnulty, S.R. Effect of blueberry ingestion on natural killer cell
counts, oxidative stress, and inflammation prior to and after 2.5 h of running. Appl.
Physiol. Nutr. Metab. 2011, 36, 976–984, doi:10.1139/H11-120.

85.

Fuster-Muñoz, E.; Roche, E.; Funes, L.; Martínez-Peinado, P.; Sempere, J.M.;
Vicente-Salar, N. Effects of pomegranate juice in circulating parameters,
cytokines, and oxidative stress markers in endurance-based athletes: A randomized
controlled trial. Nutrition 2016, 32, 539–545,
doi:https://doi.org/10.1016/j.nut.2015.11.002.

86.

Suzuki, K. Characterization of Exercise-Induced Cytokine Release, the Impacts on
the Body, the Mechanisms and Modulations. Int. J. Sport. Exerc. Med. 2019, 5,
doi:10.23937/2469-5718/1510122.

52
87.

Chowdhury, S.; Schulz, L.; Palmisano, B.; Singh, P.; Berger, J.M.; Yadav, V.K.;
Mera, P.; Ellingsgaard, H.; Hidalgo, J.; Brüning, J.; et al. Muscle-derived
interleukin 6 increases exercise capacity by signaling in osteoblasts. J. Clin. Invest.
2020, 130, 2888–2902, doi:10.1172/JCI133572.

88.

Vargas, N.; Marino, F. Heat stress, gastrointestinal permeability and interleukin-6
signaling — Implications for exercise performance and fatigue. Temperature 2016,
3, 240–251, doi:10.1080/23328940.2016.1179380.

89.

Pedersen, B.K. Muscles and their myokines. J. Exp. Biol. 2011, 214, 337 LP – 346,
doi:10.1242/jeb.048074.

90.

Yahfoufi, N.; Alsadi, N.; Jambi, M.; Matar, C. The immunomodulatory and antiinflammatory role of polyphenols. Nutrients 2018, 10, 1–23,
doi:10.3390/nu10111618.

91.

Peluso, I.; Raguzzini, A.; Serafini, M. Effect of flavonoids on circulating levels of
TNF-α and IL-6 in humans: A systematic review and meta-analysis. Mol. Nutr.
Food Res. 2013, 57, 784–801, doi:10.1002/mnfr.201200721.

92.

Howatson, G.; McHugh, M.P.; Hill, J.A.; Brouner, J.; Jewell, A.P.; van Someren,
K.A.; Shave, R.E.; Howatson, S.A. Influence of tart cherry juice on indices of
recovery following marathon running. Scand. J. Med. Sci. Sports 2010, 20, 843–
852, doi:10.1111/j.1600-0838.2009.01005.x.

93.

Bell, P.G.; Stevenson, E.; Davison, G.W.; Howatson, G. The Effects of
Montmorency Tart Cherry Concentrate Supplementation on Recovery Following
Prolonged, Intermittent Exercise. Nutrients 2016, 8, doi:10.3390/nu8070441.

94.

Nieman, D.C.; Henson, D.A.; Maxwell, K.R.; Williams, A.S.; Mcanulty, S.R.; Jin,

53
F.; Shanely, R.A.; Lines, T.C. Effects of quercetin and EGCG on mitochondrial
biogenesis and immunity. Med. Sci. Sports Exerc. 2009, 41, 1467–1475,
doi:10.1249/MSS.0b013e318199491f.
95.

Thursby, E.; Juge, N. Introduction to the human gut microbiota. Biochem. J. 2017,
474, 1823–1836, doi:10.1042/BCJ20160510.

96.

Shortt, C.; Hasselwander, O.; Meynier, A.; Nauta, A.; Fernandez, E.N.; Putz, P.;
Rowland, I.; Swann, J.; Turk, J.; Vermeiren, J.; et al. Systematic review of the
effects of the intestinal microbiota on selected nutrients and non-nutrients. Eur. J.
Nutr. 2018, 57, 25–49, doi:10.1007/s00394-017-1546-4.

97.

Duda-Chodak, A.; Tarko, T.; Satora, P.; Sroka, P. Interaction of dietary
compounds, especially polyphenols, with the intestinal microbiota: a review. Eur.
J. Nutr. 2015, 54, 325–341, doi:10.1007/s00394-015-0852-y.

98.

Lin, L.; Zhang, J. Role of intestinal microbiota and metabolites on gut homeostasis
and human diseases. BMC Immunol. 2017, 18, 1–25, doi:10.1186/s12865-0160187-3.

99.

Desai, M.S.; Seekatz, A.M.; Koropatkin, N.M.; Kamada, N.; Hickey, C.A.;
Wolter, M.; Pudlo, N.A.; Kitamoto, S.; Terrapon, N.; Muller, A.; et al. A Dietary
Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and
Enhances Pathogen Susceptibility. Cell 2016, 167, 1339-1353.e21,
doi:10.1016/j.cell.2016.10.043.

100. Derrien, M.; Belzer, C.; de Vos, W.M. Akkermansia muciniphila and its role in
regulating host functions. Microb. Pathog. 2017, 106, 171–181,
doi:10.1016/j.micpath.2016.02.005.

54
101. Karl, J.P.; Margolis, L.M.; Madslien, E.H.; Murphy, N.E.; Castellani, J.W.;
Gundersen, Y.; Hoke, A. V; Levangie, M.W.; Kumar, R.; Chakraborty, N.; et al.
Changes in intestinal microbiota composition and metabolism coincide with
increased intestinal permeability in young adults under prolonged physiological
stress. Am. J. Physiol. Gastrointest. Liver Physiol. 2017, 312, G559–G571,
doi:10.1152/ajpgi.00066.2017.
102. Codella, R.; Luzi, L.; Terruzzi, I. Exercise has the guts: How physical activity may
positively modulate gut microbiota in chronic and immune-based diseases. Dig.
Liver Dis. 2018, 50, 331–341, doi:10.1016/j.dld.2017.11.016.
103. Campbell, S.C.; Wisniewski, P.J.; Noji, M.; McGuinness, L.R.; Häggblom, M.M.;
Lightfoot, S.A.; Joseph, L.B.; Kerkhof, L.J. The Effect of Diet and Exercise on
Intestinal Integrity and Microbial Diversity in Mice. PLoS One 2016, 11,
e0150502.
104. Keirns, B.H.; Koemel, N.A.; Sciarrillo, C.M.; Anderson, K.L.; Emerson, S.R.
Exercise and Intestinal Permeability: Another Form of Exercise-Induced
Hormesis? Am. J. Physiol. Liver Physiol. 2020, doi:10.1152/ajpgi.00232.2020.
105. Monda, V.; Villano, I.; Messina, A.; Valenzano, A.; Esposito, T.; Moscatelli, F.;
Viggiano, A.; Cibelli, G.; Chieffi, S.; Monda, M.; et al. Exercise Modifies the Gut
Microbiota with Positive Health Effects. Oxid. Med. Cell. Longev. 2017, 3831972,
doi:10.1155/2017/3831972.
106. Morrison, D.J.; Preston, T. Formation of short chain fatty acids by the gut
microbiota and their impact on human metabolism. Gut Microbes 2016, 7, 189–
200, doi:10.1080/19490976.2015.1134082.

55
107. Rowland, I.; Gibson, G.; Heinken, A.; Scott, K.; Swann, J.; Thiele, I.; Tuohy, K.
Gut microbiota functions: metabolism of nutrients and other food components.
Eur. J. Nutr. 2018, 57, 1–24, doi:10.1007/s00394-017-1445-8.
108. Ríos-Covián, D.; Ruas-Madiedo, P.; Margolles, A.; Gueimonde, M.; de Los
Reyes-Gavilán, C.G.; Salazar, N. Intestinal Short Chain Fatty Acids and their Link
with Diet and Human Health. Front. Microbiol. 2016, 7, 185,
doi:10.3389/fmicb.2016.00185.
109. Wang, H.-B.; Wang, P.-Y.; Wang, X.; Wan, Y.-L.; Liu, Y.-C. Butyrate Enhances
Intestinal Epithelial Barrier Function via Up-Regulation of Tight Junction Protein
Claudin-1 Transcription. Dig. Dis. Sci. 2012, 57, 3126–3135, doi:10.1007/s10620012-2259-4.
110. Plöger, S.; Stumpff, F.; Penner, G.B.; Schulzke, J.-D.; Gäbel, G.; Martens, H.;
Shen, Z.; Günzel, D.; Aschenbach, J.R. Microbial butyrate and its role for barrier
function in the gastrointestinal tract. Ann. N. Y. Acad. Sci. 2012, 1258, 52–59,
doi:10.1111/j.1749-6632.2012.06553.x.
111. Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.;
Nakanishi, Y.; Uetake, C.; Kato, K.; Kato, T.; et al. Commensal microbe-derived
butyrate induces the differentiation of colonic regulatory T cells. Nature 2013,
504, 446–450, doi:10.1038/nature12721.
112. Zimmer, J.; Lange, B.; Frick, J.-S.; Sauer, H.; Zimmermann, K.; Schwiertz, A.;
Rusch, K.; Klosterhalfen, S.; Enck, P. A vegan or vegetarian diet substantially
alters the human colonic faecal microbiota. Eur. J. Clin. Nutr. 2012, 66, 53–60,
doi:10.1038/ejcn.2011.141.

56
113. Ozdal, T.; Sela, D.A.; Xiao, J.; Boyacioglu, D.; Chen, F.; Capanoglu, E. The
Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on
Bioaccessibility. Nutrients 2016, 8, 78, doi:10.3390/nu8020078.
114. Catalkaya, G.; Venema, K.; Lucini, L.; Rocchetti, G.; Delmas, D.; Daglia, M.; De
Filippis, A.; Xiao, H.; Quiles, J.L.; Xiao, J.; et al. Interaction of dietary
polyphenols and gut microbiota: Microbial metabolism of polyphenols, influence
on the gut microbiota, and implications on host health. Food Front. 2020, 1, 109–
133, doi:10.1002/fft2.25.
115. Murota, K.; Nakamura, Y.; Uehara, M. Flavonoid metabolism: the interaction of
metabolites and gut microbiota. Biosci. Biotechnol. Biochem. 2018, 82, 600–610,
doi:10.1080/09168451.2018.1444467.
116. Dueñas, M.; Muñoz-González, I.; Cueva, C.; Jiménez-Girón, A.; Sánchez-Patán,
F.; Santos-Buelga, C.; Moreno-Arribas, M.V.; Bartolomé, B. A Survey of
Modulation of Gut Microbiota by Dietary Polyphenols. Biomed Res. Int. 2015,
2015, 850902, doi:10.1155/2015/850902.
117. Spencer, J.P.E.; Abd El Mohsen, M.M.; Minihane, A.M.; Mathers, J.C.
Biomarkers of the intake of dietary polyphenols: Strengths, limitations and
application in nutrition research. Br. J. Nutr. 2008, 99, 12–22,
doi:10.1017/S0007114507798938.
118. Crozier, A.; Del Rio, D.; Clifford, M.N. Bioavailability of dietary flavonoids and
phenolic compounds. Mol. Aspects Med. 2010, 31, 446–467,
doi:10.1016/j.mam.2010.09.007.
119. van Duynhoven, J.; Vaughan, E.E.; Jacobs, D.M.; Kemperman, R.A.; van Velzen,

57
E.J.J.; Gross, G.; Roger, L.C.; Possemiers, S.; Smilde, A.K.; Doré, J.; et al.
Metabolic fate of polyphenols in the human superorganism. Proc. Natl. Acad. Sci.
U. S. A. 2011, 108 Suppl, 4531–4538, doi:10.1073/pnas.1000098107.
120. Wiese, S.; Esatbeyoglu, T.; Winterhalter, P.; Kruse, H.-P.; Winkler, S.; Bub, A.;
Kulling, S.E. Comparative biokinetics and metabolism of pure monomeric,
dimeric, and polymeric flavan-3-ols: a randomized cross-over study in humans.
Mol. Nutr. Food Res. 2015, 59, 610–621, doi:10.1002/mnfr.201400422.
121. Moco, S.; Martin, F.-P.J.; Rezzi, S. Metabolomics View on Gut Microbiome
Modulation by Polyphenol-rich Foods. J. Proteome Res. 2012, 11, 4781–4790,
doi:10.1021/pr300581s.
122. Xie, Y.; Yang, W.; Chen, X.; Ren, L. Antibacterial Activities of Flavonoids:
Structure-Activity Relationship and Mechanism. Curr. Med. Chem. 2014, 22,
doi:10.2174/0929867321666140916113443.
123. Parkar, S.G.; Stevenson, D.E.; Skinner, M.A. The potential influence of fruit
polyphenols on colonic microflora and human gut health. Int. J. Food Microbiol.
2008, 124, 295–298, doi:10.1016/j.ijfoodmicro.2008.03.017.
124. Oteiza, P.I.; Fraga, C.G.; Mills, D.A.; Taft, D.H. Flavonoids and the
gastrointestinal tract: Local and systemic effects. Mol. Aspects Med. 2018, 61, 41–
49, doi:10.1016/j.mam.2018.01.001.
125. Duda-Chodak, A. The inhibitory effect of polyphenols on human gut microbiota.
J. Physiol. Pharmacol. 2012, 63, 497—503.
126. Espín, J.C.; González-Sarrías, A.; Tomás-Barberán, F.A. The gut microbiota: A
key factor in the therapeutic effects of (poly)phenols. Biochem. Pharmacol. 2017,

58
139, 82–93, doi:10.1016/j.bcp.2017.04.033.
127. Anhê, F.F.; Roy, D.; Pilon, G.; Dudonné, S.; Matamoros, S.; Varin, T. V;
Garofalo, C.; Moine, Q.; Desjardins, Y.; Levy, E.; et al. A polyphenol-rich
cranberry extract protects from diet-induced obesity, insulin resistance and
intestinal inflammation in association with increased Akkermansia spp. population
in the gut microbiota of mice. Gut 2015, 64, 872 LP – 883, doi:10.1136/gutjnl2014-307142.
128. Roopchand, D.E.; Carmody, R.N.; Kuhn, P.; Moskal, K.; Rojas-Silva, P.;
Turnbaugh, P.J.; Raskin, I. Dietary Polyphenols Promote Growth of the Gut
Bacterium Akkermansia muciniphila and Attenuate High-Fat Diet-Induced
Metabolic Syndrome. Diabetes 2015, 64, 2847–2858, doi:10.2337/db14-1916.
129. Lee, S.; Keirsey, K.I.; Kirkland, R.; Grunewald, Z.I.; Fischer, J.G.; de La Serre,
C.B. Blueberry Supplementation Influences the Gut Microbiota, Inflammation, and
Insulin Resistance in High-Fat-Diet-Fed Rats. J. Nutr. 2018, 148, 209–219,
doi:10.1093/jn/nxx027.
130. Chen, H.-Q.; Yang, J.; Zhang, M.; Zhou, Y.-K.; Shen, T.-Y.; Chu, Z.-X.; Zhang,
M.; Hang, X.-M.; Jiang, Y.-Q.; Qin, H.-L. Lactobacillus plantarum ameliorates
colonic epithelial barrier dysfunction by modulating the apical junctional complex
and PepT1 in IL-10 knockout mice. Am. J. Physiol. Liver Physiol. 2010, 299,
G1287–G1297, doi:10.1152/ajpgi.00196.2010.
131. Dey, P.; Sasaki, G.Y.; Wei, P.; Li, J.; Wang, L.; Zhu, J.; McTigue, D.; Yu, Z.;
Bruno, R.S. Green tea extract prevents obesity in male mice by alleviating gut
dysbiosis in association with improved intestinal barrier function that limits

59
endotoxin translocation and adipose inflammation. J. Nutr. Biochem. 2019, 67, 78–
89, doi:10.1016/j.jnutbio.2019.01.017.
132. Masumoto, S.; Terao, A.; Yamamoto, Y.; Mukai, T.; Miura, T.; Shoji, T. Nonabsorbable apple procyanidins prevent obesity associated with gut microbial and
metabolomic changes. Sci. Rep. 2016, 6, 31208, doi:10.1038/srep31208.
133. Li, J.; Wu, T.; Li, N.; Wang, X.; Chen, G.; Lyu, X. Bilberry anthocyanin extract
promotes intestinal barrier function and inhibits digestive enzyme activity by
regulating the gut microbiota in aging rats. Food Funct. 2019, 10, 333–343,
doi:10.1039/C8FO01962B.

60
CHAPTER III

EFFECT OF FLAVONOID SUPPLEMENTATION ON EXERCISE-INDUCED

INTESTINAL INJURY, PERMEABILITY, AND INFLAMMATION

Introduction
The gastrointestinal (GI) barrier is a selectively permeable membrane that
facilitates water and nutrient uptake while excluding potentially harmful antigens and
pathogens [1]. Intestinal permeability refers to the movement of luminal contents to the
internal milieu through either the epithelial cells lining the GI tract or the interstitial space
between neighboring cells, which is regulated by tight junction protein complexes [1].
Both external and internal stimuli can affect intestinal permeability, and elevated
permeability is a common feature of several autoimmune, intestinal, and metabolic
diseases and conditions [1].
In particular, high intensity endurance exercise causes transient, increased
intestinal permeability [2]. Severe or prolonged exercise-induced intestinal permeability
can be problematic and cause local and systemic inflammation—potentially hindering
physical performance and recovery [3]. At rest, 20% of total cardiac output is directed to
the splanchnic organs; during exercise, up to 80% of this blood flow is shunted to muscle
and other peripheral tissues instead [4]. Prolonged hypoperfusion of visceral tissues
causes localized hypoxia and mucosal injury, and reperfusion injury can occur due to
reactive oxygen species (ROS) accumulation and localized inflammation [4]. Exercise
intensity is thought to be one factor affecting intestinal permeability. In a study by Pals et
al., participants ran for 1 hour at 40, 60, and 80% VO2max, and a significant increase in
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intestinal permeability relative to baseline was only observed after running at 80% of
VO2max [5]. Second, heat stress has also been demonstrated to cause epithelial cell
injury and disrupt tight junctions both in vitro and in vivo; thus, the magnitude of change
in core temperature is another important factor in exercise-induced intestinal permeability
[2]. A systematic review of human exercise studies by Pires et al. reported a positive
association between magnitude of core temperature change and increased intestinal
permeability [4]. In studies where post-exercise core temperatures were above 39 °C,
increased intestinal permeability was always observed [4].
Several dietary nutrients have been shown to regulate intestinal permeability [6].
Specifically, flavonoids (plant secondary metabolites abundant in fruits and vegetables)
have been demonstrated to modulate tight junction permeability through several
mechanisms in vitro [7]. Flavonoids can activate the nuclear factor erythroid 2-related
factor 2 (Nrf2) pathway which upregulates endogenous antioxidant capacity, and
flavonoids also have anti-inflammatory activity through the downregulation of nuclear
factor kappa B (NF-κB) signaling (see Chapter II, Section 3) [7–9]. Dietary flavonoids
also exhibit other beneficial effects through NO-related mechanisms—including
vasodilation, regulation of glucose uptake, and improved endothelial function [9,10].
Given these various biological activities and the positive health outcomes commonly
observed with flavonoid-rich dietary patterns, flavonoids are thought to have great
potential as protective agents for the intestinal barrier [11,12]. Furthermore, the
vasoactive, antioxidant, and anti-inflammatory effects of flavonoid consumption may
also enhance exercise performance and improve recovery by increasing muscle perfusion
and delaying onset of fatigue [10].
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Consequently, the purpose of this study was to determine the effects of subchronic (fifteen-day) consumption of a high flavonoid pre-workout beverage (HFB) on
GI permeability and inflammation following a bout of high-intensity endurance exercise.
The flavonoid content of the investigational product was formulated to provide a
moderate dose of flavonoids in one serving (490 mg/day). Previous clinical studies
investigating flavonoid supplementation and exercise performance span a range of doses
from relatively low to several times higher (100-2000 mg/day); however, a review of
these studies concluded that a dose of ~300 mg polyphenols consumed 1-2 h prior to
exercise may be sufficient to improve endurance and repeated sprint performance [10].
Our primary endpoint was intestinal injury as indicated by plasma intestinal fatty acidbinding protein (I-FABP). Secondary endpoints included intestinal permeability (excreted
urinary sugars), inflammatory response (circulating cytokines), and cycling performance
(work output and cycling distance). Based on prior work, we hypothesized that the HFB
would ameliorate exercise-induced intestinal injury and permeability relative to a low
flavonoid control (LFB). Resilience to exercise-induced changes in GI permeability may
also result in a reduction in acute exercise-associated inflammation and improved cycling
performance.

Materials and Methods
Ethical approval
This study was conducted in accordance with the 2008 Helsinki Declaration for
Human Research Ethics and approved by the Utah State University (USU) research ethics
committee (IRB Protocol #9255). Participants were informed of all study requirements
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and provided written informed consent prior to enrollment. This study was registered at
ClinicalTrials.gov prior to study start (ClinicalTrials.gov Identifier: NCT03427879).
Participants
For a complete study recruitment flow diagram, see Appendix A, Figure A-1.
Participants were recruited by word of mouth and through advertisements posted at local
cycling businesses and gyms in Logan, Utah and at USU (Appendix A, Figure A-2).
Seventeen cyclists were screened for study eligibility, and of those, fourteen subjects
were enrolled and randomized to treatments. One subject dropped out due to scheduling
conflicts, and one subject was withdrawn due to failure to adhere to the study protocol.
Twelve recreational cyclists (female n = 4, male n = 8; mean ± SD: age 37 ± 11 years,
body mass 78 ± 13 kg, height 1.74 ± 0.09 m, VO2max 43 ± 6 ml/kg/min) completed both
arms of the study.

Table 3-1. Participant characteristics.
Subject

Age
(years)

Body
Mass (kg)

Height
(cm)

BMI
(kg/m2)

1
2
3
4
5
6
7
8
9
10
11
12
Mean ±
SD
Range

49
33
43
36
40
45
18
33
55
40
18
28
36.5 ±
11.4
18-55

68.5
100.0
58.2
87.0
87.7
69.7
72.8
99.4
79.6
69.1
69.1
72.1
77.7 ±
13.1
58.2-100

161.5
183.6
158.1
182.1
179.9
165.5
182.7
173.1
179.0
178.2
165.0
178.7
174.0 ±
9.0
158.1183.6

26.3
29.7
23.3
26.2
27.1
25.4
21.8
33.2
24.8
21.8
25.4
22.6
25.6 ± 3.3

VO2max
(ml/kg/mi
n)
43.9
39.3
41.4
42.6
51.4
41.0
46.5
28.1
43.5
46.2
44.1
50.1
43.2 ± 5.9

21.8-33.2

28.1-51.4

70%
Power
(W)
130
180
105
160
215
145
165
145
160
160
165
200
160.8 ±
29.3
105-215

Cycling
Experien
ce (years)
10
.
15
.
23
12
12
1
10
5
6
20
11.4 ± 6.7
1-23
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Inclusion/exclusion criteria
Eligibility and general health were assessed with a participation readiness
questionnaire (PAR-Q) and health screening assessment. A complete list of study
inclusion and exclusion criteria is provided in Appendix A, Table A-1. Briefly, key
inclusion criteria were as follows: male or female of any race or ethnicity, age 18-55
years, training at least 3 times per week, participated in a cycling event in the past 12
months, and free of chronic disease and GI conditions. Exclusion criteria included a
medical history of heart disease, hypertension, diabetes, Crohn’s disease, IBS, colitis,
celiac disease, inflammatory or autoimmune disease, allergies to pre-workout ingredients,
and/or lactose intolerance. Participants were also excluded for chronic use of NSAIDs,
flavonoid supplement consumption < 1 month prior, or antibiotic use < 3 months prior.
For women, additional exclusion criteria included those who were pregnant,
breastfeeding, or < 6 months postpartum.
Preliminary assessments
During the screening period, each participant completed a maximal aerobic
capacity (VO2max) test via expired gas analysis to determine power settings for the two
subsequent cycling trials. This preliminary test also allowed participants to be
familiarized with the Velotron cycle ergometer (SRAM LLC; Chicago, IL). The
incremental graded VO2max test began at 100 Watts (W) and increased by 25 W/min
until either volitional exhaustion or rpm < 60. Expired gas samples were collected using a
two-way valve mouthpiece (Hans Rudolph 700 series; Kansas City, MO), and oxygen
consumption was recorded with a computerized on-line metabolic measurement system
(Parvomedics TrueOne 2400; Sandy, UT). After the test and a ten-minute rest, a follow-
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up assessment was performed to validate the predicted power (W) at 70% VO2max for
steady state exercise (fixed power). Power settings were adjusted in 5 W increments as
needed to achieve 70% VO2max for a minimum of 3 minutes before the final power
setting for the exercise trials was determined.
Participants also performed a baseline intestinal permeability assessment with an
overnight, 8-hour urine collection. For the test, participants fasted four hours following
their evening meal. After 4 hours, participants emptied their bladder and drank a 130 ml
sugar solution containing 10 g sucrose, 5 g lactulose, 1 g maltitol, and 1 g sucralose. (The
intended sugar permeability test includes mannitol, but due to a supplier error, maltitol
was provided instead.) For the next eight hours, urine was collected in a 3 L container
with 50 µl of 10% thymol as a preservative. During this time, participants were only
permitted to drink water. In the morning, participants voided into the collection jug and
recorded the total volume. A subsample (50 ml) was aliquoted to another container, and
samples were stored frozen for future analysis.
Investigational product
For each intervention, participants were provided with fifteen individual servings
of pre-workout mix (containing all dry ingredients in Table 3-2), shelf-stable 2% white
milk, and a shaker bottle. Instructions provided to the participants for preparing the preworkout are included in Appendix A, Figure A-3. One package of pre-workout mix (64
g) was prepared with 240 ml milk and consumed once per day, two hours prior to
exercise or the subject’s typical exercise time. One serving of the high flavonoid
beverage (HFB) provided approximately 490 mg total flavonoids, while the low
flavonoid beverage (LFB) contained approximately 4.6 mg flavonoids due to three
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modifications: alkalized cocoa, blueberry placebo powder, and omission of green tea
powder. The green tea extract contained approximately 800 mg/g tea catechins
(PureBulk, Inc; Roseburg, Oregon). High flavonoid cocoa powder (83 mg/g cocoa
flavanols) and alkalized cocoa (10 mg/g flavanols) were provided by Barry Callebaut
(Zurich, Switzerland). Freeze-dried blueberry powder (14.0 mg/g total anthocyanins) and
blueberry placebo powder were supplied by the US Highbush Blueberry Council
(Folsom, California).

Table 3-2. High flavonoid beverage (HFB) and low flavonoid beverage (LFB).
Ingredient
2% Milk
Sugar
Maltodextrin
Blueberry powder
Cocoa powder
Whey protein isolate
Green tea powder

HFB % (w/w)
78.1
8.6
8.6
2.4
1.6
0.6
0.1

Ingredient
2% Milk
Sugar
Maltodextrin
Placebo powder
Alkalized cocoa powder
Whey protein isolate
Green tea powder

LFB % (w/w)
78.2
8.6
8.6
2.4
1.6
0.6
0

Study endpoints
The primary endpoint of this study was I-FABP detected in the plasma, a noninvasive biomarker of intestinal injury and permeability [3]. I-FABP is a cytosolic protein
expressed in mature small and large intestinal enterocytes and present only at low levels
in the plasma unless released from injured or lysed cells [3]. Because circulating I-FABP
is rapidly cleared and has a half-life of only eleven minutes, the change in I-FABP from
baseline is an early marker for intestinal injury [13]. Circulating I-FABP correlates
strongly with abdominal trauma, appearance of inflammatory markers, determination of
gut ischemia with gastric tonometry, and the severity of morphologic epithelial intestinal
damage [3,14]. (In gastric tonometry, a tonometer balloon is inserted with a catheter into
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the gastric cavity to detect accumulated CO2 in the gut mucosa due to underperfusion
[3].)
The second endpoint was the urinary excretion of orally-ingested sugars (sucrose,
lactulose, and sucralose)—a non-invasive method to determine GI permeability. Sucrose,
which is digested by the enzyme sucrase in the small intestine, is an indicator of gastric
permeability, lactulose is fermented by the microbiota in the colon and therefore indicates
of small intestinal permeability, and sucralose is non-digestible, so recovered sucralose in
the urine reflects overall GI permeability [1,15].
The plasma cytokines TNF-, IL-6, and IL-10 were selected as secondary
endpoints. The pro-inflammatory cytokine TNF- increases the rate of epithelial cell
turnover and activates opening of the tight junction, leaving gaps in the intestinal barrier
[1,16]. IL-6 is secreted from skeletal muscle during exercise in response to heat stress and
low energy availability [17]. It can also affect gastric emptying and plays an important
role in attenuating intestinal permeability and mucosal injury caused by a dangerous rise
in core temperature [18]. Lastly, IL-10 is an anti-inflammatory cytokine promoted by IL6 that downregulates further production of pro-inflammatory cytokines [17].

Study design
Figure 3-1. Schematic overview of crossover study design with low flavonoid beverage
(LFB) and high flavonoid beverage (HFB).
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The study design was a randomized crossover trial, with a minimum fourteen-day
washout between the two intervention periods (Figure 3-1). Following completion of
screening and baseline assessments, each participant was randomly assigned a treatment
order. With the exception of high flavonoid foods, flavonoid supplements, and NSAIDs,
participants were free to consume their regular diet and maintain their usual training
schedule. In addition, participants were instructed to abstain from alcohol and strenuous
activity 24 hours prior to each urine collection and cycling trial. Gut permeability
assessments using orally-administered sugar test probes and an overnight eight-hour urine
collection were performed at baseline and on Day 12 of each intervention. On Day 15, a
gut permeability assessment was also performed immediately following the trial with a
six-hour urine collection. Meals consumed during these periods were recorded and
replicated during the second intervention. Each intervention concluded with a one-hour
cycling trial on Day 15, during which blood samples were collected pre-, post-, 1 h post-,
and 4 h post-exercise. The schedule for clinic assessments and specimen collections is
provided in Appendix A, Figure A-4. A pre-loaded time trial (TT) was selected for the
study, as it has been shown to produce more reliable performance results in test-retest
designs and also provides quantitative endpoints of work and distance [19]. In contrast,
within-subject designs with fixed cycling intensities (e.g. 1 hour at 70% VO2max)
typically produce greater variation and are more prone to being affected by psychological
factors [19].
Main exercise visit
On Day 15, two hours prior to the cycling trial, participants consumed their
typical pre-race breakfast (recorded and replicated for Phase 2), the HFB/LFB pre-
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workout, and an ingestible temperature sensor pill (CorTemp, HQ Inc.; Palmetto, FL). At
the clinic, subjects emptied their bladders, body mass was measured, and a blood sample
was taken. Subjects warmed up for five minutes at a self-selected pace prior to starting
the cycling trial. The trial consisted of 45 minutes cycling at a fixed power (70%
VO2max), followed by a fifteen-minute “all out” time trial (TT), during which subjects
were free to adjust the power setting and rode at maximal effort to complete as much
work (J) as possible. Throughout the exercise test, heart rate and core temperature were
recorded at five minute intervals, and a final core temperature measurement was taken
five minutes after completion of exercise. Rating of perceived exertion (RPE) was
recorded at minutes 5, 15, 25, and 35, and expired air was collected to determine VO2 at
10, 20, 30, and 40 min. The visual RPE scale presented to subjects is included in
Appendix A, Figure A-6. Subjects were provided with a small amount of room
temperature water (0.5 ml/kg bodyweight) at 15 minutes. Following the trial, participants
were seated and another blood sample was collected. Participants then ingested the gut
permeability sugar solution and collected urine for six hours. During the first two hours,
subjects were only permitted to drink water, and certain foods and beverages were
restricted to minimize interference with the test. All meals and snacks were recorded in a
food log and repeated during the second intervention. Two final blood samples were
collected one and four hours post-exercise. Adverse events and symptoms experienced in
the 24 hours following the exercise test were noted with brief questionnaire. A sample
schedule for Day 15 is provided in Appendix A, Figure A-5.
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Blood sampling and analysis
Seated venous blood samples were collected via antecubital venipuncture in
K2EDTA-treated Vacutainer tubes and centrifuged (1500 × g, 10 min, 4 °C). Plasma was
aliquoted to 1.5-ml polypropylene microcentrifuge tubes and stored frozen at -80 °C until
further analysis.
A commercial enzyme-linked immunosorbent assay (ELISA) kit was used for
determination of plasma I-FABP in duplicate (Hycult Biotech; Uden, The Netherlands).
High sensitivity ELISA kits were used to analyze TNF-α and IL-10 according to the
manufacturer’s instructions (Invitrogen; Carlsbad, CA). Plasma IL-6 cytokine analysis
was conducted with an ELISA kit according to the manufacturer’s instructions
(Invitrogen; Carlsbad, CA).
Urine sugar analysis for gut permeability
Urinary concentrations of each of the sugar probes (i.e., recovery of the sugars in
urine specimens) were determined with gas chromatography-mass spectroscopy (GCMS) analysis following trimethylsilyl (TMS) derivatization. Due to the low
concentrations of recovered sugars, urine samples were spiked with 7.5 ppm sucrose, 2
ppm sucralose, and 20 ppm lactulose prior to drying and derivatization to increase the
signal to noise ratio for the measurement. For the standards, a synthetic urine matrix was
prepared with 0.33 M urea, 0.12 M sodium chloride, 0.016 M potassium diphosphate
(KH2PO4), 0.007 M creatinine, and 0.004 M sodium monophosphate (NaHPO4).
Additionally, inositol was added to all samples as an internal standard (50 µl, 1 mg/ml).
Samples were prepared in duplicate, and 400 µl of urine or 800 µl of a 1:1 standard and
synthethic urine mix were evaporated to dryness in a speed vacuum centrifuge. After
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drying, 100 µl of O-methoxylamine (CH3ONH2) in pyridine (20.0 mg/mL) was added to
each sample and mixed thoroughly. Samples were heated at 70 C for 1 hour. After
heating, samples were centrifuged at 13,000 x g for 5 minutes, and 50 µl of the
supernatant was combined with 50 µl of N,O-Bis(trimethylsilyl)trifluoroacetamide
(BSTFA). The samples were heated again for 30 minutes at 70 C and then transferred to
a glass sample vial for GC-MS analysis.
The GC-MS platform was a Shimadzu single quadrupole gas chromatograph mass
spectrometer (GCMS-QP2010 SE) with a Zebron ZB-5MS plus (35 m × 0.25 mm
diameter × 0.25 μm film thickness) capillary GC column (Phenomenex, Torrance, CA,
USA). Helium was used as the carrier gas, and the column flow rate was 1.16 ml/min,
with a split ratio of 5:1. The temperatures of the inlet, ion source, and transfer line were
250 °C, 230 °C, and 290 °C, respectively. The column oven temperature program is
included in Table 3-3. Compound peak areas were normalized by the inositol internal
standard, and sugar concentrations were determined from standard curves (Appendix A,
Table A-2). Recovered sugar concentrations were corrected to the actual concentration by
subtracting the spiked concentration. Corrected concentrations were multiplied by total
urine volume to determine recovered mass which was used to determine percent urinary
recovery from the initial amount of sugar ingested.

Table 3-3. Gas chromatography (GC) oven temperature program for sugar separation.
Rate (°C/min)
-20
2.5
20
1
20

Temperature (°C) Hold Time (min)
80
0
180
1
210
1
245
10
255
0
280
0
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Sample size
A previous study demonstrated a treatment difference of 328.6 ng/ml for change
in I-FABP following exercise, with patient standard deviation for repeated measurements
estimated at 389.8 ng/ml [20]. Assuming a similar effect size of 0.84 (α = 0.05), the
probability is 82 percent that the study will detect a treatment difference with a total of
fourteen subjects.
Statistical analysis
All data were checked for normality and homogeneity of variance, and data
violating model assumptions were log-transformed prior to analysis. The TT distance,
work, and cycling cadence were analyzed with paired t-tests. Cohen’s d (d) was used to
determine effect size for cycling work output, and a d value of 0.2, 0.5, and 0.8 indicate
small, medium, and large effect sizes, respectively. Core temperature, heart rate (HR),
VO2, rating of perceived exertion (RPE), plasma I-FABP, IL-10, IL-6, and TNF-α were
analyzed using a two-way repeated measures ANOVA. For IL-6 and TNF-α, statistical
analyses were performed on raw instrumental values. When main or interaction
(intervention  time) effects were significant, Tukey’s HSD was used for post-hoc
comparisons, unless otherwise specified. Negative values for sugar recovery were input
as 0. A one-way repeated measures ANOVA was used to analyze sugar probe recovery
with condition (baseline, HFB Day 12, LFB Day 12) as the independent factor. Intestinal
permeability following the exercise trial on Day 15 was analyzed with a paired t-test.
Correlation analyses (Spearman’s ρ) were conducted to determine if final core
temperature and change in core temperature correlated with primary outcomes (change in
I-FABP, post-exercise I-FABP, % sucrose, % lactulose, % sucralose). No significant
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treatment order effect (HFB-LFB, LFB-HFB) was observed. Data are expressed as means
± SEM, unless otherwise indicated. Statistical analyses were performed with JMP version
15.2.1 for Windows (SAS Institute, Cary, NC) with significance at  = 0.05.

Results
Both the flavonoid and control pre-workout beverages were well-tolerated by the
subjects, with no reported adverse effects.
Physiological responses and exercise performance
The exercise test elicited a similar response in HR, VO2, and RPE regardless of
the treatment (Table 3-4, Figure 3-2). There was a significant effect of exercise on HR (p
< 0.0001), where the HR during the TT (t = 50, 55, 60) was significantly higher than the
pre-load exercise (t = 5-45). Initial HR (t = 0) was significantly lower than all other time
points. Likewise, RPE increased during exercise and was significantly elevated at 25 and
35 min compared to 5 min (p < 0.0001). Final RPE at 35 min was 3.9 ± 0.5 (LFB) and
4.0 ± 0.4 (HFB), where an RPE of 4 is “somewhat hard”. VO2 was significantly lower at
10 min compared to all other times (p = 0.0003), but not different between trials.
For the TT, no differences were observed for cadence (HFB: 93 ± 9 rpm, LFB: 93
± 11 rpm) or total cycling distance (HFB: 19.3 ± 0.7 km, LFB: 18.9 ± 0.8 km). However,
a trend for increased work output was observed for the HFB (p = 0.0511, Cohen’s d =
0.16) (Figure 3-3B).
A significant effect of time (p < 0.0001) and time × treatment interaction (p <
0.0001) was observed for core temperature (Figure 3-4A). Core temperature from 10 min
onwards for both conditions was significantly elevated compared to pre-exercise.
Pairwise comparisons across condition at each time were not significantly different after
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correcting for multiple comparisons. A small decline in core temperature was observed at
20 min when participants were provided water (0.5 ml water/kg bodyweight) after 15 min
of exercise. The maximum core temperatures immediately following exercise were 38.53
± 0.06 °C (HFB) and 38.51 ± 0.23 °C (LFB). Overall changes in core temperature from
pre-exercise (t = -5) to 60 min exercise were 2.24 ± 0.23 °C (LFB) and 1.73 ± 0.13 °C
(HFB) (paired t-test, p = 0.008) (Figure 3-4B).

Table 3-4. Perceptual and physiological measures: rating of perceived exertion (RPE) and
VO2 during 1-h cycling trial.
5 min

15 min

25 min

35 min

2.9 ± 0.3a
2.7 ± 0.4a
0.3 ± 0.2
10 min

3.2 ± 0.3ab
3.3 ± 0.4ab
-0.1 ± 0.2
20 min

3.8 ± 0.4b
3.6 ± 0.5b
0.3 ± 0.2
30 min

4.0 ± 0.4b
3.9 ± 0.5b
0.1 ± 0.3
40 min

RPE
HFB
LFB
HFB-LFB

VO2 (ml/kg/min)
HFB
29.9 ± 1.4a
30.2 ± 1.3b
30.6 ± 1.4b
a
b
LFB
29.6 ± 1.4
30.2 ± 1.5
30.4 ± 1.4b
HFB-LFB
0.37 ± 0.58
-0.01 ± 0.46
0.23 ± 0.33
Values with different superscripts differed significantly (p < 0.05).

Figure 3-2. Heart rate response during 1-h cycling exercise at 70% VO2.

30.5 ± 1.3b
30.4 ± 1.4b
0.10 ± 0.25
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Figure 3-3. Cycling time trial performance. (A) Primary vertical axis: distance completed
during the 15 min TT (LFB: 18.9 ± 0.8 km, HFB: 19.3 ± 0.7 km). Secondary vertical
axis: within-subject treatment difference (0.4 ± 0.3 km, p = 0.181). (B) Primary vertical
axis: work completed during the 15 min TT (LFB: 174.2 ± 11.3 kJ, HFB: 180.9 ± 12.3
kJ). Secondary vertical axis: within-subject treatment difference (6.6 ± 3.0 kJ, p =
0.0511).
(A)

(B)
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Figure 3-4. (A) Core temperature during exercise trial. (B) Overall change in core
temperature during exercise: 2.24 ± 0.23 °C (LFB) and 1.73 ± 0.13 °C (HFB); paired ttest, p = 0.008.
(A)
Core Temperature (°C)

39.0
38.5
38.0
37.5
37.0
36.5

HFB
LFB

36.0
35.5
-5

5

15

25
35
Time (min)

45

55

65

(B)

Inflammatory markers
A main effect of time was observed for plasma IL-6 and IL-10 where both
cytokines were significantly elevated post-exercise and after 1-h recovery (Table 3-5).
Similarly, TNF-α was elevated immediately post-exercise compared to pre-exercise
(Table 3-5). No significant effects were observed for treatment or time × treatment
interaction.
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Table 3-5. Plasma cytokines.
Pre-exercise

Post-exercise
Immediate
1-h
4-h
HFB
n.d.
0.76 ± 0.23*
0.22 ± 0.13*
n.d.
IL-6
LFB
n.d.
0.79 ± 0.38*
0.53 ± 0.20*
n.d.
(pg/ml)
HFB-LFB n.d.
-0.03 ± 0.42
-0.31 ± 0.19
n.d.
HFB
1.49 ± 0.36
3.95 ± 0.69*
3.04 ± 0.44*
1.48 ± 0.28
IL-10
LFB
1.52 ± 0.38
3.76 ± 0.67*
2.69 ± 0.36*
1.86 ± 0.55
(pg/ml)
HFB-LFB -0.02 ± 0.36
0.20 ± 0.69
0.35 ± 0.44
-0.39 ± 0.28
HFB
n.d.
0.28 ± 0.09*
n.d.
n.d.
TNF-α
LFB
n.d.
0.31 ± 0.07*
n.d.
n.d.
(pg/ml)
HFB-LFB n.d.
-0.02 ± -0.06 n.d.
n.d.
Mixed effects, repeated measures 2-way ANOVA performed on raw instrumental values.
n.d., not detected. *Significant difference from pre-exercise, p < 0.0001.

Gut injury and permeability
A significant effect of time was observed for plasma I-FABP (p = 0.001), but
there was no significant treatment effect or treatment × exercise interaction (Figure 3-5).
Plasma I-FABP was significantly elevated immediately post-exercise compared to all
other time points. Mean change in I-FABP from pre- to immediately post-exercise did not
differ between treatments: 300 ± 156 pg/ml (HFB) and 439 ± 162 (LFB) pg/ml. In
addition, no significant correlation was found between final core temperature or change
in core temperature and change in I-FABP.
Percent recovery of 8-h urinary sugars (sucrose, lactulose, and sucralose) at rest
was not significantly different between condition (baseline, LFB, HFB) (Table 3-6).
Similarly, percent recovery of 6-h urinary sugars was not significantly different between
treatments following the exercise trial (Table 3-7). Since a post-exercise sample was
missing for one subject, these analyses were conducted with n = 11. No significant
correlation was found between final core temperature or change in core temperature and
percent recovery of sucrose, lactulose, or sucralose.
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Figure 3-5. Plasma I-FABP measured at t = 0, 1, 2, 5. Peak values of I-FABP
immediately post-exercise (t = 1): 1161 ± 253 (HFB), 1177 ± 250 pg/ml (LFB).
*Significant difference from pre-exercise (t = 0).

Plasma I-FABP (pg/ml)

1600

*

1400

HFB

1200

LFB

1000
800

600
400
200
0
0

1

2

3

4

5

Time (h)

Table 3-6. 8-h Sugar probe excretion at rest, n = 12.

% Sucrose
% Lactulose
% Sucralose

Baseline
0.035 ± 0.010
0.424 ± 0.087
1.206 ± 0.210

HFB (Day 12)
0.069 ± 0.023
0.424 ± 0.081
1.311 ± 0.264

LFB (Day 12)
0.056 ± 0.018
0.324 ± 0.064
1.237 ± 0.448

p-value
0.454
0.354
0.561

Table 3-7. 6-h Sugar probe excretion post-exercise, n = 11.

% Sucrose
% Lactulose
% Sucralose

HFB
0.040 ± 0.008
0.293 ± 0.050
0.775 ± 0.060

LFB
0.066 ± 0.026
0.267 ± 0.085
1.116 ± 0.386

HFB-LFB
-0.026 ± 0.028
0.026 ± 0.085
-0.341 ± 0.404

p-value
0.817
0.384
0.994

Discussion
The purpose of the present study was to determine the effect of flavonoid
supplementation on intestinal inflammation, injury, and permeability following moderateto high-intensity cycling. On the HFB, recreational cyclists consumed ~490 mg of cocoa,
blueberry, and green tea flavonoids daily for two weeks leading up to the cycling trial.
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Contrary to our hypothesis, we observed no treatment effects on GI permeability, injury,
or inflammation. There were no treatment differences between sugar probe recovery
either at rest or post-exercise and no treatment effects on plasma I-FABP, IL-6, IL-10,
and TNF-α before and following the exercise trial. Though there was no difference in
cycling distance or cadence, HFB tended to increase cycling work during the TT.
The 1-hour cycling trials for both conditions were consistent in degree of exercise
intensity, with a similar response in RPE and physiological measures of VO2, HR, and
peak core temperature. Interestingly, we observed a larger increase in core temperature
for LFB due to a lower initial temperature, regardless of treatment sequence. To our
knowledge, this difference in initial core temperature potentially due to two-week
flavonoid supplementation has not been previously reported. However, the maximum
core temperatures were not different, and since the general practice is to assess final core
temperature in relation to epithelial integrity, we do not believe that this difference is a
significant concern in the final outcome.
Both peak core temperature and exercise intensity (measured by %VO2) have a
positive association with exercise-induced GI injury and permeability [4,5]. Several other
cycling studies at similar intensity (70% VO2max) and duration (one hour) reported
increased GI permeability and injury [21–24]. In the present study, average maximal core
temperature was 38.52 ± 0.12 °C, and we observed a significant increase in I-FABP
across both arms from pre- to post-exercise. In a systematic review, Pires et al. reported
that of participants with a final core temperature of 38.5 °C or below, ~36% showed
increased permeability, and within the range of 38.6-39.0 °C, ~48% of participants
showed augmented permeability [4]. Though the cycling protocol employed in the our
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study was comparable in intensity and demonstrated acute GI injury, on average subjects
had relatively lower peak core temperatures than those outlined by Pires [4], which may
be one reason why no treatment effects on I-FABP and intestinal permeability were
observed. When subjects were grouped into high and low peak core temperatures
determined by values above and below the median (38.61 °C), no significant effect of
high or low final core temperature was found for overall change in I-FABP or percent
sugar recovery. Additionally, no correlations were found between final core temperature
and primary outcomes. Perhaps if there was a larger effect of exercise, we may have
observed a difference with the HFB alleviating these acute exercise effects. Additionally,
6- and 8-h urinary sugar probe excretion may not be as sensitive to modest exerciseinduced changes on intestinal permeability, since relatively transient changes in
permeability may recover quickly depending on intensity and duration of exercise [22].
Other studies have reported detecting exercise-induced changes in I-FABP and serum
recovery of sugar probes that were not observed in urinary samples [22,25]. In the present
study, exercise appeared to induce transient intestinal injury, since we only observed
significant time effects for I-FABP immediately post-exercise, but not one or four hours
later. Other exercise protocols ranging from 60-120% VO2max have been shown to
increase I-FABP by 50-250% immediately following exercise [26]. Since the extent of
intestinal injury due to exercise was relatively moderate (~46% average increase in IFABP from pre- to post-exercise), it is not surprising that a treatment effect on sugar
probe permeability was not detected. Finally, other studies evaluating changes in I-FABP
following moderate- to high-intensity exercise reported significant post-exercise
treatment differences of ~300 pg/ml (curcumin supplement vs. placebo), 424 pg/ml (35
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vs. 20 °C environmental temperature), 328.6 pg/ml (bovine colostrum vs. control), 401
pg/ml (ibuprofen vs. control), and 186.8 pg/ml (carbohydrate gel vs. placebo) [20,27–30].
A post-hoc power calculation was conducted for the post-exercise I-FABP response
given the achieved sample size and estimated within-subject standard deviation of 380.8
pg/ml, and this study was powered to detect a treatment effect of ~480 pg/ml, but the
actual mean difference observed was 16 pg/ml—much smaller than the sampling
variation observed within subjects, and not likely a clinically meaningful difference had
there been a true effect.
Exercise modality is also known to affect the incidence of GI symptoms and
stress; cycling induces relatively less inflammation, muscle damage, and oxidative stress
than running [31]. In one study comparing GI permeability during running and cycling,
running caused a larger increase in intestinal permeability [32]. This may be due to the
mechanical impact and posture during running which is not as pronounced in cycling
[33,34]. In previous work conducted with runners, we found that participants struggled to
complete the designated running test in its entirety (1-h at 80% VO2max), which resulted
in the trials being cut short, and no significant changes in gut permeability were observed
(unpublished data). Based on our collaborator’s previous experience, cyclists recruited
from the local community were expected to be capable of reliably completing the cycling
protocol. Studies conducted elsewhere have also demonstrated measurable changes in gut
permeability with cycling [21–24,32].
Another reason why we may not have observed an effect on intestinal
permeability and injury is due to differences in flavonoid bioavailability. In the
Polyphenol Study previously conducted at USU, we observed a significant reduction in
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intestinal permeability and inflammation with a high polyphenol dietary intervention (340
mg flavonoids/1,000 kcal) provided to participants through a mixture of fruits,
vegetables, juice, and chocolate (Chapter II, Section 3.3). In contrast, the investigational
product in this study was prepared from a mixture of food ingredients with some degree
of processing (e.g., drying, freeze-drying, extraction). While the flavonoid content of the
blueberry, cocoa, and green tea powders were supplied by the manufacturers, some
bioactivity may have been reduced during transit, storage, and any time prior to
consumption. Bioavailability and bioaccessibility can vary widely from purified
compounds, to extracts, to fresh whole foods [35]. Compounds in a food matrix can have
either positive and negative effects in terms of flavonoid bioavailability [36]. Some
polyphenols such as procyanidins may be less bioavailable when in a food matrix, while
others may actually be preserved throughout the digestive tract and reach the small
intestine in a greater quantity due to association with the food matrix [37]. Polyphenols
ingested in combination or in the form of food along with other dietary components may
have increased bioavailability or interact to exert synergistic effects [31,38]. Although an
epicatechin (one of the primary flavan-3-ols in cocoa) supplement was shown to have a
negative effect on aerobic and mitochondrial adaptations to cycle training in one study,
others utilizing cocoa products showed neutral or positive effects on performance,
inflammation, and oxidative stress [39–41]. While we cannot say for certain how the food
matrix and processing affected bioavailability and bioefficacy of the investigational
product, we acknowledge that this is a factor that may have impacted the results and one
reason why the results differed from those of the Polyphenol Study.
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Recently, Keirns et al. suggested that individuals who train regularly may be more
resistant to a leaky gut than sedentary individuals when GI integrity is assessed at rest
versus immediately post-exercise—that is, chronic exercise may improve GI integrity
over time [42]. This may be another reason why we observed differences between the
present study with active cyclists and the Polyphenol Study with sedentary,
overweight/obese subjects. Part of the adaptive response to exercise and heat stress is the
upregulation of heat-shock proteins (HSP) in muscle and cardiac tissue, which can help
stabilize cytoskeletal proteins and tight junctions [43,44]. Prior heat stress conditioning
may increase thermotolerance, cell survival, and resistance to barrier dysfunction,
through HSP induction [44,45]. For example, an elevation in incubation temperature from
37 °C to 39 °C increased HSP and tight junction protein (ZO1 and occludin) expression
after four hours in Caco-2 and HT29 intestinal cells [46]. On the other hand, it has not yet
been demonstrated that chronic exercise can upregulate HSP expression in intestinal
enterocytes [42]. More research is warranted, as the data currently available suggesting
that chronic exercise can reduce intestinal permeability is limited to study populations
with various metabolic conditions (insulin resistance, type II diabetes, and obesity) [42].
These studies also reported reductions in visceral fat mass and body weight over the
course of the exercise program, which could be the reason for improvements in intestinal
permeability through reduced circulating inflammatory cytokines [42]. Nevertheless,
others have suggested that flavonoid supplementation may have a greater protective
effect in untrained individuals; the effects of flavonoid supplementation on muscle
mitochondrial biogenesis and performance, if any, may not be as great in trained versus
untrained individuals, since untrained muscle tissue has a lower mitochondrial density
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than trained [31]. Competitive athletes, regularly exposed to oxidative stress during
training, have more active endogenous antioxidant and anti-inflammatory responses and
increased muscular efficiency from years of consistent endurance training [47,48]. In one
study, a fruit and vegetable flavonoid powder fed to highly trained cyclists for seventeen
days did not have an effect on exercise-induced inflammation, but a similar dose of
flavonoids was previously shown to have an effect in non-athletes [49]. The authors
suggested that the intervention may not be as effective may be due to the higher level of
fitness of the study population [49]. In another study, two-week flavonoid
supplementation decreased intestinal permeability relative to placebo in an untrained
population both at rest and after walking at ~62% VO2max, while intestinal permeability
was elevated in a group of trained runners following 2.5 h running at 69% VO2max—
though several other differences between the untrained and trained groups may have
contributed to the results [50]. In the present study, subjects were trained, recreational
athletes, with an average maximum aerobic capacity of 43.2 ± 5.9 ml/kg/min (range:
28.1-51.4 ml/kg/min). The cycling protocol was chosen to elicit final core temperatures
above 38.5 °C, to increase the likelihood of observing changes in GI permeability [4].
Though we may have been more likely to observe an effect of flavonoid intake with
untrained subjects, they would have been less likely to successfully complete this
challenging exercise protocol. Also, it may not be as applicable to attempt to alleviate
these exercise-induced GI changes in untrained individuals who do not exercise or
compete regularly.
Physical exertion and hyperthermia are known to cause changes in plasma
cytokine levels [16,51]. We observed relatively low levels of IL-6, IL-10, and TNF-α
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despite the rigorous exercise protocol. As expected, plasma I-FABP and IL-6 increased in
response to exercise and returned to baseline levels during the recovery period, regardless
of the treatment. However, plasma IL-6 and TNF-α were relatively low even immediately
following exercise and mostly undetectable at baseline and after 4 hours of recovery.
Similarly, Osborne et al. found that I-FABP increased 140% from pre- to post-exercise,
but no change in circulating pro-inflammatory cytokines or endotoxin following a 60-min
trial at 35 °C (alternating between 40-70% VO2max), with final core temperatures
reaching 39.5 °C [30]. Other studies with a similar intensity (70% VO2max) reported no
changes in TNF-α (< 2 pg/ml pre- to post-exercise) and the plasma cytokines IL-10 and
IL-6 (< 6 pg/ml) despite showing a significant increase in intestinal permeability and core
temperature of 39.5 °C, respectively [52,53]. Short-term curcumin supplementation
reduced the increase in I-FABP relative to placebo following a one-hour treadmill run at
65% VO2max at 37 °C, but no significant interaction effects were observed between the
treatment and time for IL-6, IL-10, and TNF-α [29]. In contrast, other studies have shown
exercise effects on circulating cytokines, with varying effects of polyphenol ingestion.
Two-week supplementation with the flavonoids quercetin and EGCG significantly
reduced IL-6 and IL-10 but not TNF-α relative to placebo following a daily three-hour
cycling protocol for three consecutive days [31]. McAnulty et al. found that six weeks of
blueberry ingestion elevated the anti-inflammatory cytokine IL-10 to a greater extent than
the control immediately following a 2.5 h run at ~72% VO2max [54]. Based on these
varied results, it is possible that shorter duration exercise at temperate conditions, such as
in our study, does not elicit as large of a cytokine response as is more consistently
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observed in hotter environmental temperatures, longer events, or non-controlled
environments, such as a road marathon [55].
Interestingly, HFB supplementation appeared to result in increased work output
with no difference in cadence or total distance during the fifteen-minute TT. Further posthoc analyses showed that cycling power also tended to be greater in the HFB trial (HFB:
201 ± 14 W and LFB: 194 ± 13 W, p = 0.051, data not shown). Because cadence was not
different between conditions, the greater power and work output for the HFB trial was
likely the result of participants applying more force to the pedals. Given the achieved
sample size and an estimated within-subject standard deviation of 9.3 kJ for repeated TT
measurements [56], post-hoc power analysis (α = 0.05, β = 0.80) showed that the study
was powered to detect a minimum treatment difference of 11.7 kJ. However, the small
effect size (d = 0.16) suggests that the observed difference in work (6.6 kJ) is not likely to
have a meaningful impact on overall performance—as was demonstrated with the lack of
an effect on total distance. If these performance effects are related to other factors that
require a longer time to show measurable changes, then an effect may have been
observed with a longer supplementation time. As mentioned previously, dietary
flavonoids can activate endogenous antioxidant pathways via Nrf2 signaling to reduce
oxidative stress and improve muscle perfusion through increased NO availability [8,10].
Presumably, these vascular and antioxidant improvements would have an effect on
performance, perhaps through delaying onset of fatigue. A recent review found consistent
evidence of reduced oxidative stress with both acute and chronic cocoa supplementation,
but changes in exercise performance and recovery were inconsistent with some studies
demonstrating improvements while others did not [57]. Some studies found no effect of
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cocoa intake on inflammatory markers while performance improved [57]. Taub et al.
reported increased VO2max and maximum power with untrained subjects after three
months’ dark chocolate supplementation [40]. These improvements in cycling
performance were observed alongside changes in skeletal muscle cellular metabolism and
improved oxidative stress status (reduced protein carbonyls and increased glutathione)
[40]. Another study with moderately active subjects reported greater distance covered
during a two-minute cycling sprint with two weeks of dark chocolate intake, compared
against white chocolate and no supplementation, and the authors theorized that the
improved performance was due to lower oxygen cost (increased gas exchange threshold)
with dark chocolate [41]. Other studies have found performance benefits with a variety of
other dietary flavonoids and polyphenols. Morgan et al. observed ~4.6% faster 15 km TT
performance with Montmorency cherry supplementation (257 mg anthocyanins/day for
one week) relative to placebo in trained cyclists, which was thought to be driven by an
improvement in muscle oxygenation due to NO availability and potentially reduced
oxidative stress [58]. Several studies with both acute and chronic blackcurrant and
pomegranate anthocyanin supplementation have also demonstrated improved
performance in both trained and untrained subjects [9]. However, our hypothesis was that
any observed performance improvements would be driven by a reduction in intestinal
permeability or GI discomfort, and therefore, our primary endpoints were plasma I-FABP
and urinary sugars; we did not measure markers of oxidative stress as this was beyond the
scope of our study. Based on other studies and the effects of flavonoid ingestion on Nrf2
signaling, it is possible that we would have seen an attenuation in oxidative stress or
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improvement in tissue oxygenation with HFB, which would help explain the slight
performance benefits observed.
A limitation of this study was that there was no monosaccharide available for the
intestinal permeability assessment. Larger molecules (e.g., lactulose, sucralose, and
sucrose) travel paracellularly to enter systemic circulation from the intestinal lumen while
smaller molecules (e.g., mannitol) are absorbed transcellularly [13,59]. As a result, larger
molecules are indicators for changes in paracellular permeability while smaller test
compounds control for gastric emptying, epithelial absorptive area, transit time, and renal
function across individuals [60]. The urinary excretion ratio (the recovery of the larger
probe relative to the smaller) is most often reported and provides a standardized measure
of intestinal permeability at the region of the GI tract where the larger probe is absorbed
[13]. Unfortunately, due to a supplier issue, a monosaccharide probe was not included in
the intestinal permeability assessment. However, the crossover design of the study still
allowed for meaningful within-subjects comparisons for percent recovery of the
disaccharide probes, and some other studies have similarly reported percent recovery of
disaccharide sugars [5,25,61–65]. Another limitation was that the study design restricted
comparisons between different urine collections. The sugar excretion test is ideally
performed fasted to minimize the contribution of dietary sugars, so urine samples
collected at baseline and mid-intervention were fasted, eight-hour overnight collections.
The collection immediately following the cycling trial was a six-hour collection (two
hours fasted) in order to minimize participant burden and shorten the long clinic visit on
Day 15. As a result, comparisons for intestinal permeability are only made among
baseline and mid-intervention samples and between post-exercise samples.
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Finally, another limitation is the potential for carryover effects from one
intervention to the next. It was important to allow a sufficient length of time for any
lingering effects of the prior treatment to dissipate prior to beginning the next arm, while
still being short enough to encourage subject retention. Epithelial intestinal cells undergo
complete turnover within two weeks [66]. Additionally, a two-week washout was used in
the Polyphenol Study and no carryover effects were observed. For these reasons, a twoweek washout period was selected for this study. In the statistical analysis, subjects were
nested within treatment sequence, which accounted for whether the subject was randomly
allocated to the AB or BA treatment order. No significant sequence effects were found in
any of the analyses, suggesting that the two-week washout was sufficient to minimize
potential carryover effects.
In conclusion, a randomized controlled crossover study was conducted to test the
effects of a pre-workout high flavonoid beverage in reducing exercise-induced GI
permeability and injury. During a one-hour, moderate intensity cycling test and TT, the
HFB performed as well as a standard pre-workout mix. Despite the accumulating
evidence suggesting potential for improvement of GI permeability, inflammation, and
athletic performance with supplemental flavonoid intake, we found no differences
between the treatment and placebo. Though there was potentially an effect of increased
cycling work, the difference in means relative to error was small, and no difference in
distance was observed. Due to the importance of addressing epithelial integrity and
inflammation in not only exercise but also exertional heat stress and inflammatory
diseases (e.g., inflammatory bowel disease, ulcerative colitis, type I diabetes), more
work—especially well-controlled human clinical trials—is warranted. Future studies
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should ideally include measurements of tissue perfusion or vascular effects (e.g., flow
mediated dilation, tissue oxygenation index), mitochondrial metabolism (e.g.,
mitochondrial density, citrate synthase), and oxidative stress (e.g., glutathione, protein
carbonyls, total antioxidant status).
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CHAPTER IV

EFFECT OF FLAVONOID SUPPLEMENTATION ON GUT MICROBIOTA

PROFILE, SHORT CHAIN FATTY ACID EXCRETION,

AND INTESTINAL INFLAMMATION

Introduction
Intestinal dysbiosis may occur throughout an individual’s lifetime when the
intestinal microbial community is shifted one way or another, or otherwise displays
aberrant functioning compared to that of a healthy individual [1]. Though it is unclear
whether intestinal dysbiosis is a cause or an effect, it is often observed in conjunction
with inflammatory or metabolic pathologies [1–3]. For example, individuals with low
microbial richness and diversity display more overall adiposity, insulin resistance, and
dyslipidemia than those with greater microbial richness [4]. Low microbial diversity and
dysbiosis are also observed in patients suffering from ulcerative colitis, irritable bowel
syndrome, colorectal cancer, and inflammatory bowel diseases [2,5,6].
One contributing factor in shaping the gut microbial composition is the diet [7].
For example, high animal protein, carbohydrate, or prebiotic intake can all dramatically
affect the species present in the GI tract [8]. Because of the impact of the diet on the gut
microbiota and the gut microbiota on human health, it is important to investigate potential
dietary strategies that can beneficially modulate the gut microbiota and possibly improve
health outcomes later in life [1,9]. Dietary flavonoids, plant secondary metabolites
abundant in fruits, tea, and coffee, have previously been demonstrated to help shape the

102
intestinal microbial population [8]. Due to low bioavailability in the small intestine, the
majority of dietary polyphenols, which encompass flavonoids in addition to other
phenolic compounds, transit to the large intestine and are metabolized by the colonic
microflora [2]. Both parent polyphenols and their metabolites can inhibit or promote the
growth of different microorganisms [10]. Polyphenols consist of thousands of structurally
diverse compounds, and different compounds and doses can have varying effects on the
microbiota [10]. Preclinical and some clinical studies have shown that dietary flavonoids
can stimulate the growth of health-promoting microorganisms including Lactobacillus
spp., Bifidobacterium spp., Akkermansia spp., Roseburia spp., and Faecalibacterium spp.
[2,11–13]. Both Lactobacillus spp. and Bifidobacterium spp. are considered to have
beneficial effects on intestinal health by reducing pathogen colonization and increasing
SCFA production [11]. In one clinical trial, ingestion of 494 mg of cocoa flavanols/day
for four weeks significantly increased Lactobacillus spp., Enterococcus spp. and
Bifidobacterium spp. compared to a low flavanol control at 23 mg/day [14]. The cocoa
flavanol treatment also significantly decreased numbers of the C. histolyticum group, and
changes in the bifidobacteria and lactobacilli significantly correlated with a reduction in
plasma C-reactive protein (CRP), a marker for inflammation [14]. In another clinical
study, six-week consumption of a wild blueberry drink containing approximately 375 mg
anthocyanins and 128 mg chlorogenic acid significantly increased Bifidobacterium spp.
relative to the placebo [15]. In rats, mango polyphenol supplementation increased
abundance of Lactobacillus plantarum, Lactococcus lactis, and Clostridium butyrim,
along with an increase in the SCFAs butyrate and valerate [16]. Other in vitro studies
have shown that cocoa and tea polyphenols can increase growth of commensal organisms
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while inhibiting pathogens [17–19]. However, other clinical studies did not find an effect
of polyphenols on gut microbial composition or SCFA production [20–22].
An interesting aspect of the interaction of between the intestinal microbiota and
human health is short chain fatty acid (SCFA) production from non-digestible
carbohydrates. The microbiota-produced colonic SCFA are believed to act as signaling
molecules through interaction with specific G protein-coupled receptors and through the
regulation of gene expression and disease pathogenesis via histone deacetylase inhibition
[1]. Bacteroidetes are associated with acetate and propionate production while Firmicutes
are the primary producers of butyrate [1]. Butyrate in particular is an important SCFA,
because it plays a key role in the differentiation of colonic regulatory T cells, displays
anti-inflammatory properties, and increases expression of claudin tight junction proteins
[23–25]. Studies have shown that flavonoid supplementation can increase SCFA
production, likely due to flavonoid-mediated changes in the microbiota [11]. For
example, bilberry anthocyanin extract supplementation in rats increased abundance of
butyrate producers (Lactoacillus and Bacteroides) while inhibiting the growth of harmful
species (Verrucomicrobia and Euryarchaeota) [26]. (For additional discussion on SCFA,
refer to Chapter II, Section 4.2.)
Microbial diversity and their collective, functional genome, which dictates the
microbiome’s metabolic capability, are closely tied with human health and disease. The
gut microbiota can affect flavonoid activity by transforming the molecules to more
bioavailable or bioactive metabolites, so the effects of flavonoid intake on human health
may be partially mediated by the composition and metabolic activity of the gut
microflora [3]. Moderate to high dietary flavonoid intake has the potential to positively
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shape the gut microbiota, but the majority of the evidence is from animal and cell culture
studies [2]. Similarly, preclinical studies suggest that intestinal SCFA can influence
signaling of key processes, but clinical data is lacking [27]. As a result, it is important to
further explore the relationship between flavonoid intake, the gut microbiota, and
intestinal health in a controlled, human clinical trial. The present study extends previous
work by exploring intestinal inflammation, microbiota composition, and SCFA excretion
in response to supplemental flavonoid intake. Based on the literature suggesting that
flavonoid intake can impact intestinal health, we hypothesized that an increase in dietary
flavonoid intake of ~490 mg/day would change the proportions of intestinal bacterial taxa
in a group of healthy volunteers, and that changes observed in the microbiome would also
be reflected in altered SCFA excretion. Additionally, we hypothesized that elevated
flavonoid intake would also result in a reduction in intestinal inflammation.

Materials and Methods
Study design
This study was conducted in conjunction with the clinical trial as described in
Chapter III. Briefly, 12 recreationally-active cyclists (female n = 4, male n = 8; mean ±
SD: age 37 ± 11 years, body mass index 25.6 ± 3.3 kg/m2) completed this randomized,
controlled crossover study conducted from August 2018 through May 2019 at Utah State
University (USU). This study was conducted in accordance with the 2008 Helsinki
Declaration for Human Research Ethics and approved by the USU research ethics
committee (IRB Protocol #9255). Participants were informed of all study requirements
and provided written informed consent prior to enrollment. A schematic of the study
design and endpoint collection is provided in Figure 4-1.
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A complete list of inclusion and exclusion criteria is provided in Appendix A,
Table A-1. Exclusion criteria included chronic NSAID use, antibiotics treatment within 3
months of the study, or flavonoid supplement consumption within 1 month of the study.
Additionally, those with a medical history of heart disease, hypertension, diabetes,
Crohn’s disease, IBS, colitis, celiac disease, inflammatory or autoimmune disease were
also excluded from the study.

Figure 4-1. Schematic overview of crossover study design.

A high flavonoid beverage (HFB, 490 mg total flavonoids) or macronutrientmatched low flavonoid control (LFB, 5 mg flavonoids) was consumed once daily for
fifteen days. Each serving of the investigational product (64 g powder) was prepared in a
shaker bottle with 240 ml 2% white milk. During the intervention, participants were
instructed to abstain from a provided list of high flavonoid foods, flavonoid supplements,
and NSAIDs. Stool samples were collected once after 9-11 days of supplementation to
determine fecal calprotectin, microbiota composition, and total SCFA. Participants
collected stool samples in pre-labelled, freezer-safe containers, and samples were stored
at -20 °C until the next clinic visit (within four days). Upon receipt at the clinic, samples
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were homogenized by stirring and transferred to 50 ml tubes and stored at -80 °C until
further analysis.
Flavonoid food frequency questionnaire
Prior to the first screening visit, participants were asked to self-administer a
flavonoid food frequency questionnaire (FFQ) adapted from Somerset and Papier [28].
Subjects indicated their average consumption frequency of eight beverages, three cocoa
products, seventeen fruits, and thirty vegetables (see Appendix B, Figure B-1). Each food
serving size was converted to mass (g), and flavonoid content (mg) per 100 g of each
food or beverage was determined from the USDA Database for Flavonoid Content of
Selected Foods [29]. Reported food intake frequency was converted to weekly frequency
for each food/beverage: never or < 1 time/mo = 0.7; 1-3 times/mo = 0.7; 1 time/wk =
0.43; 2-4 times/wk = 1.7; 1 time/day = 5; 2-3 times/day = 15; 4-5 times/day = 31.5; and >
6 times/day = 48. Weekly intake frequency of each item was multiplied by the flavonoid
content to determine total weekly flavonoid intake.
Fecal calprotectin
Fecal calprotectin, a protein released by activated neutrophils or during cell death,
is a reliable biomarker of intestinal inflammation [30]. Fecal calprotectin was determined
in duplicate with a commercial ELISA kit following the manufacturer’s instructions
(Hycult Biotech; Uden, The Netherlands).
Fecal SCFA content
All samples and standards were prepared in duplicate. A series of standards (0.045 mM) containing acetic, propionic, butyric, isobutyric, valeric, isovaleric, and caproic
acids were prepared in deionized water. Ethyl butyric acid was used as an internal
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standard and prepared at 1 g/L in 250 g/L metaphosphoric acid. Approximately 0.1 g of
stool was added to 0.9 ml deionized water. After mixing, 200 μl of the internal standard
was added, and samples were centrifuged at 10,000 × g for 20 min. The supernatant was
removed and filtered with a 0.2 μm syringe filter into a glass vial. Samples were stored at
4 °C prior to GC analysis. Analysis was performed with a Shimadzu GC2010 gas
chromatograph coupled to a flame ionization detector (FID) (Shimadzu Scientific
Instruments; Columbia, MD). The column was a Zebron ZB-FFAP (30 m × 0.53 mm
diameter × 1.00 μm film thickness) capillary GC column (Phenomenex, Torrance, CA,
USA). Hydrogen was the carrier gas, and the column flow rate was 15.94 ml/min, with a
5:1 split ratio. The temperatures of the injection port and FID were 200 °C and 350 °C,
respectively. The column oven temperature program used for compound separation is
shown in Table 4-1. Compound peak areas were normalized by the internal standard and
concentrations were determined from the standard curves.

Table 4-1. GC oven temperature program for SCFA analysis.
Rate (°C/min)
-17

Temperature (°C)
60
260

Hold Time (min)
1
8

Stool microbiota composition
Three replicates from each stool collection were prepared for 16S rRNA
sequencing. Fecal DNA was extracted in duplicate using the DNeasy PowerSoil kit,
following the manufacturer’s instructions (Qiagen; Carlsbad, CA). Following extraction,
4 µl of 5 M NaCl was added to each sample. Samples were centrifuged at 10,000 × g for
5 min, and the supernatant was decanted and residual liquid was removed in a speed
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vacuum evaporator. Precipitated DNA was re-suspended in 10 mM Tris. DNA was
quantified via absorbance, and samples were normalized to 5 ng/μl in Tris-EDTA buffer.
Polymerase chain reaction (PCR) amplification of the V3-V4 hypervariable region of the
16S rRNA gene was completed in triplicate with Platinum Hot Start PCR Master Mix
(Invitrogen; Carlsbad, CA) and DNA primers (IDT; Coralville, IA). Unique index
adapters (barcodes) were added to the DNA amplicon with a second round of PCR
amplification. PCR reaction products were purified, quantified with Quant-iT PicoGreen
dsDNA Assay Kit (ThermoFisher Scientific, Waltham, MA), and pooled at a final
concentration of 1 ng/µl. The library pool was spiked with 5% PhiX as an internal control
and prepared with MiSeq v3 reagents. High through-put sequencing of paired-end 300
base pair (bp) reads was completed in a single run on the Illumina MiSeq platform at the
Center for Integrated BioSystems at USU.
The raw 16S rRNA amplicon sequencing dataset was processed with Quantitative
Insights Into Microbial Ecology (QIIME2) [31]. Filtering, dereplication, chimera
detection, and merging paired-end reads was completed with the Divisive Amplicon
Denoising Algorithm (DADA2) R package [32]. An amplicon sequence variant (ASV)
abundance table was generated, and the QIIME feature-classifier classify-sklearn
command was used with a classifier pre-trained for the V3-V4 region and the most recent
release of the Silva database [33].
Observed, Chao1, and Shannon alpha diversity indices were analyzed and plotted
with MicrobiomeAnalyst [34]. Principal coordinates analysis (PCoA) plots were
generated with unweighted UniFrac distances and visualized with EMPeror [35].
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Statistical analysis
Data that did not meet assumptions of normality (FFQ and calprotectin) were
analyzed with the non-parametric Wilcoxon signed-rank test, with false discovery rate
(FDR) adjustments for multiple comparisons as needed. Since calprotectin values were
below the assay detection limit, instrumental values were used for statistical testing.
Mean flavonoid intake determined from the FFQ was compared to the National Health
and Nutrition Examination Survey (NHANES) reference dataset as reported by Kim et al.
[36]. Individual and total SCFA were analyzed with paired t-tests, with FDR adjustments
for multiple comparisons. Microbiome differential analysis was performed with the
DESeq2 method, with FDR adjustments for multiple comparisons. Group significance for
beta diversity was determined with permutational multivariate analysis of variance
(PERMANOVA), with a p-value < 0.01 considered statistically significant. Data are
expressed as means ± SEM, unless otherwise indicated. Statistical analyses were
performed with QIIME2, MicrobiomeAnalyst, and JMP version 15.2.1 for Windows
(SAS Institute, Cary, NC) with significance at  = 0.05, unless otherwise stated.
Additional output for statistical analyses are provided in Appendix B.

Results
Participant characteristics
Twelve participants completed both arms of the crossover study (Table 4-2). The
investigational product and control beverages were well-tolerated by subjects with no
adverse events reported during the duration of the study (six weeks total).
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Table 4-2. Participant baseline characteristics: age, body mass, body mass index (BMI),
systolic blood pressure (SBP), diastolic blood pressure (DBP), resting heart rate (HR),
blood glucose.

n
Age (years)
Body mass (kg)
BMI (kg/m2)
SBP (mmHg)
DBP (mmHg)
Resting HR (bpm)
Blood glucose (mg/dL)

Men
8
37 (18-55)
79.6 (68.5-100)
25.0 (21.8-29.7)
117 (107-136)
77 (67-90)
58 (40-76)
92 (86-103)

Women
4
35 (18-45)
74.1 (58.2-99.4)
26.8 (23.3-33.2)
111 (104-114)
70 (66-74)
63 (53-72)
82 (75-86)

Combined
12
37
77.8
25.6
115
75
60
89

Average weekly flavonoid consumption
Average intakes of all individual flavonoid compounds are reported in Appendix
B, Table B-1. The estimated total consumption of the five classes of flavonoids is
reported in Table 4-3. The pre-study FFQ estimated that the participants’ average weekly
consumption of total flavonoids was 635 ± 195 mg, with the highest subgroups being
flavan-3-ols, flavonols, and anthocyanidins. The average weekly intake of dietary
flavonoids of US adults aged 19+ years estimated from the NHANES 2007-2010 data
reported by Kim et al., is also included in Table 4-3 [36]. After adjustments for multiple
comparisons, flavan-3-ol and total flavonoid intake were significantly lower than those
from the NHANES dataset (p < 0.05).

Table 4-3. Average weekly consumption of flavonoids.
Flavonoid Class Mean ± SEM (mg) Range (mg)
Flavonols
136.5 ± 21.9
35.3 – 266.3
Flavones
11.9 ± 2.5
3.6 – 29.4
Flavanones
80.5 ± 14.7
4.6 – 193.0
Flavan-3-ols
296.3 ± 169.3*
5.5 – 2031.2
Anthocyanidins
109.6 ± 35.4
8.0 – 452.6
TOTAL
634.7 ± 194.6*
98.1 – 2321.9
*Significantly different from US Average [36] at p < 0.05.

US Adult Average (mg)
111.3 ± 2.8
8.4 ± 0.7
85.4 ± 3.5
1108.8 ± 59.5
80.5 ± 4.9
1400.7 ± 62.3
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Fecal calprotectin
No significant difference between the treatments was observed in fecal
calprotectin (p > 0.05). Mean fecal calprotectin for both conditions was below the assay
detection limit of 16 μg/g.
Fecal SCFA
There was no significant difference between HFB and LFB for individual or total
SCFA (Table 4-4). The most abundant fecal SCFA were acetate, propionate, and
butyrate, present in a ratio of ~3:1:1, respectively. The total SCFA on the HFB and LFB
were 115.1 ± 11.3 mM/g and 107.9 ± 9.7 mM/g, respectively.

Table 4-4. Individual and total SCFA composition of fecal samples (mM/g wet fecal
content), n = 12.
SCFA (mM/g) HFB
LFB
HFB-LFB
Acetic acid
63.3 ± 6.4
59.2 ± 6.5
4.1 ± 6.7
Propionic acid
21.1 ± 2.2
20.7 ± 2.3
0.4 ± 2.3
Butyric acid
21.9 ± 3.3
19.5 ± 2.1
2.4 ± 3.4
Isobutyric acid 2.3 ± 0.3
2.2 ± 0.4
0.1 ± 0.3
Valeric acid
2.6 ± 0.3
2.6 ± 0.3
0.1 ± 0.3
Isovaleric acid
3.1 ± 0.4
3.0 ± 0.6
0.1 ± 0.4
Caproic acid
0.8 ± 0.3
0.7 ± 0.2
0.1 ± 0.4
TOTAL
115.1 ± 11.3 107.9 ± 9.7
7.2 ± 12.4
Values expressed are means ± SEM. *FDR-adjusted p-value.

p-value*
0.8789
0.8789
0.8789
0.8789
0.8789
0.8789
0.8789
0.8789

Intestinal microbiota composition
The average number of reads per sample was 82,944. After normalization
(rarefying to the minimum library size and total sum scaling), the rarefaction curves
showed adequate sequencing depth for all samples (Appendix B, Figure B-2). In total, 18
phyla were detected in the samples, with five phyla above one percent relative
abundance: Firmicutes (81%), Bacteroidetes (10%), Actinobacteria (4.6%), Tenericutes
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(2.4%), Verrucomicrobia (1.3%). No significant differences were observed between HFB
and LFB for the relative abundance at the phylum level (Table 4-5). Likewise, the
relative abundance of Firmicutes to Bacteroidetes was not significantly different between
conditions (Appendix B, Tables B-5 and B-6).
Significant differences were found for two taxa: c_gammaproteobacteria (p =
0.029) and g_Eubacterium_ruminantium_group (p = 0.025) (Table 4-6). Higher
abundance of Eubacterium ruminantium was observed with LFB whereas higher
abundance of Gammaproteobacteria was observed in HFB samples. No differences were
observed at the order, family, or species levels. Over 200 groups were detected at the
genus level, and six potentially beneficial microorganisms (Bacteroides,
Faecalibacterium, Bifidobacterium, Roseburia, Akkermansia, Prevotella) that have been
reported to change with flavonoid intake were further examined with post-hoc withinsubject tests, but no significant effects on relative abundance were observed (Table 4-7).
No significant treatment differences in Chao1, Observed, and Shannon metrics of
alpha diversity were observed at any taxonomic level (Figure 4-2).
Within-subject comparisons based on unweighted UniFrac distance showed that
there were no significant differences in beta diversity between the HFB and LFB samples
(Appendix B, Table B-10). Unweighted UniFrac distances were visualized with PCoA to
show the distance between samples in three-dimensional space. PCoA plots showed no
clear separation between treatment groups (Figure 4-3A), and samples from each
participant appeared to cluster together regardless of treatment (Figure 4-3B).
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Table 4-5. Five most abundant phyla detected in samples (relative abundance).
Phylum
HFB (%)
LFB (%)
Firmicutes
78.61 ± 3.64
82.92 ± 2.69
Bacteroidetes
10.99 ± 2.64
9.83 ± 2.26
Actinobacteria
5.78 ± 1.68
3.49 ± 0.84
Tenericutes
2.79 ± 1.60
1.99 ± 1.60
Verrucomicrobia
1.22 ± 0.93
1.43 ± 0.80
No significant differences with DESeq2 analysis.

HFB-LFB
-4.31 ± 3.30
1.16 ± 2.44
2.29 ± 1.53
0.80 ± 1.80
-0.21 ± 0.64

Table 4-6. Relative percent abundance of significantly different features.
Taxa
Class

HFB (%)
LFB (%)
HFB-LFB p-value*
Gammaproteobacteria 0.32 ± 0.17 0.08 ± 0.02 0.24 ± 0.16 0.0285
Eubacterium
-0.15 ±
Genus
0.04 ± 0.02 0.19 ± 0.14
0.0252
ruminantium
0.12
Differential analysis with DESeq2 algorithm. *FDR-adjusted p-value.

Table 4-7. Relative abundance of six taxa of interest.
Genus
HFB (%)
LFB (%)
Bacteroides
6.87 ± 2.08
5.69 ± 1.74
Faecalibacterium
4.42 ± 1.18
3.51 ± 0.88
Bifidobacterium
4.93 ± 1.58
2.70 ± 0.80
Roseburia
1.82 ± 0.65
1.13 ± 0.34
Akkermansia
1.22 ± 0.93
1.43 ± 0.80
Prevotella
0.20 ± 0.13
1.73 ± 1.07
No significant differences with DESeq2 analysis.

HFB-LFB
1.18 ± 1.87
0.91 ± 1.26
2.23 ± 1.46
0.69 ± 0.65
-0.21 ± 0.64
-1.52 ± 1.07
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Figure 4-2. Alpha diversity indices at the family level for (A) Chao1, (B) Observed
species, and (C) Shannon.
(A)

(C)

(B)
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Figure 4-3. Principal coordinate analysis (PCoA) visualization of unweighted UniFrac
distance colored by (A) treatment and (B) subject. Axes represent the percentage of
variance explained by each coordinate dimension.
(A)

(B)
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Discussion
In the present study, we observed no effect of sub-chronic, moderate (~490
mg/day) supplemental flavonoid intake on measures of intestinal health in a randomized
controlled crossover trial with twelve healthy recreational cyclists. Surprisingly, daily
consumption of a mixture of blueberry, cocoa, and green tea flavonoids did not result in
significant differences in fecal SCFA, gut microbiota profile, or intestinal inflammation
as compared to a low flavonoid control. The research participants were free from chronic
disease and intestinal disorders, as was required by the study inclusion criteria.
Participants were recreational cyclists of differing levels of experience and fitness,
exercising at minimum three hours weekly. Though fecal calprotectin (a common
biomarker of inflammatory intestinal pathologies) may not display measurable
differences in the absence of disease, we expected to see an effect of the intervention on
microbial composition and metabolism (SCFA content) due to the adaptable and
responsive nature of the intestinal ecosystem to dietary intake [8].
Although individual flavonoid consumption is highly variable, the average US
adult consumes an estimated 200-250 mg total flavonoids daily [37]. Overall, our
subjects’ estimated average intake of flavonoids reflected that of the US population for
four of five classes of flavonoids. The estimated weekly intake of flavan-3-ols for our
study participants (296 ± 169 mg) spanned a large range (6-2031 mg/week), and was
significantly lower than that of the average American (1108 ± 60 mg) [36]. A significant
dietary source of flavan-3-ols is brewed tea, and only three of twelve participants
reported any amount of tea consumption, which may explain the difference from the
NHANES dataset [36,37]. Due to this difference in flavan-3-ol intake, estimated total
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flavonoid intake (635 ± 195 mg/week) was also significantly lower than that of the
average American (1401 ± 62 mg/week).
Our subjects’ estimated daily intake of total flavonoids was approximately 91
mg/day, ranging from ~14-332 mg/day among subjects. The HFB provided
approximately 490 mg/day of anthocyanins and flavan-3-ols, an increase in flavonoid
intake of ~1.5-35 times. If the subjects’ dietary intake were closer to that of the NHANES
data (200 mg/day), this would be an increase of about 2.5 times. The NHANES data was
collected through 24-hour dietary recalls, administered by a trained interviewer. Although
informative and convenient, the FFQ is a subjective assessment that is generally limited
by the subjects’ accuracy (e.g., correctly estimating serving sizes) and recall bias [38].
Additionally, the FFQ adapted for this study was developed by Somerset and Papier to be
representative of the major flavonoid dietary sources in the Australian diet [28]. Though
both Australian and American diets fall within the Western dietary pattern, this may have
also contributed to the differences observed between the estimated mean intakes from this
study and the NHANES data. The limitations inherent in these dietary assessments are a
challenge for accurately determining the influence of diet on the intestinal microbiota
[39]. Other studies evaluating the effects of flavonoid intake on intestinal microbiota
have used flavonoid doses ranging from 494-750 mg, but did not provide an estimate of
subjects’ habitual flavonoid intake [13,14,20,21].
Overall fecal SCFA (HFB and LFB samples combined) were compared to those
from participants of the Polyphenol Study (previously described in Chapter II, Section
3.3)—both analyses were conducted with the same methodology in the Ward lab at USU.
Interestingly, SCFA levels from the present study were comparable to samples collected
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from subjects during the low flavonoid intervention and significantly higher than those
from the high flavonoid intervention of the Polyphenol Study (Appendix B, Table B-11).
In the Polyphenol Study, the high flavonoid dietary intervention reduced total and
individual SCFA recovered in the fecal content compared to the control, whereas in the
present study, there were no differences between the treatment and control. Another study
also reported no changes in SCFA following four weeks’ consumption of apple fiber
juice (7.5 g fiber), boysenberry polyphenol juice (750 mg polyphenols), or the
combination thereof [20]. Dietary fiber is fermented by the colonic microflora to produce
straight chain fatty acids while branched chain amino acids are typically metabolized into
branched chain fatty acids. In states of gut dysbiosis, straight chain fatty acids often are
reduced while branched chain fatty acids are elevated. While SCFA are generally
believed to be beneficial to health, the significance of fecal SCFA content and whether
changes in SCFA content are a cause or effect are still unclear. For example, a positive
association was observed with fecal SCFA excretion, measures of gut dysbiosis, and
cardiometabolic disease risk in a recent observational study of 441 adults [40]. On the
other hand, exercise has been observed to increase SCFA excretion in lean but not obese
individuals, and another study reported higher SCFA excretion in elite professional
athletes compared to healthy controls [41,42]. Though determining the effect of exercise
on intestinal microbiota and metabolism (SCFA) was not within the scope of this study,
the potential effects of regular exercise training on microbial metabolism may have
played a part in the subjects’ lack of response to the intervention. A limitation of the
study is that fecal SCFA excretion may not be representative of colonic production, as
SCFA are absorbed and utilized by epithelial cells and other tissues, and absorption
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depends on factors such as the expression of SCFA transporters and intestinal transit time
[40]. As a result, an additional measurement of circulating SCFA may help in future
studies to determine SCFA production, absorption, and excretion.
The gut microbiota varies considerably from one individual to another—microbial
alpha diversity and SCFA content has been shown to vary with age, leanness, and
exercise status [41–43]. Alpha diversity is a measure of the microbial diversity in a
sample, which can be represented with species richness (i.e., the number of unique
features in the sample) and/or evenness (i.e., distribution) [34]. Chao1 and observed alpha
diversity are metrics of species richness, and the Shannon diversity index takes into
account the evenness of species in addition to the overall number [34]. In the present
study, supplemental flavonoid intake did not affect species richness or evenness relative
to the control. Beta diversity compares the microbial community structure between
multiple samples [44]. In particular, UniFrac is a metric used to represent the proportion
of shared phylogenetic branches between samples, in which more similar communities
have UniFrac scores closer to zero, while more divergent or independent samples have
scores closer to one [44]. Within-subject comparisons of the two study conditions on
UniFrac distance showed that there was not a differential effect of the study intervention
on the relatively stable microbiome of each individual. These results were supported by
the PCoA plots of beta diversity—samples tended to cluster by subject, regardless of
treatment. Other studies have reported similar findings (minimal changes in intestinal
microbiota following a dietary intervention), especially in shorter duration trials [22,45–
47]. So, while microbiota compositional shifts due to diet have been reported to occur in
as little as one day, an individual’s microbiome profile is relatively stable over time and
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likely shaped by a multitude of factors, including habitual dietary intake [48]. In a crosssectional study, Wu et al. reported that an individual’s overall microbiome profile had a
greater association with long-term dietary patterns than short-term dietary changes [48].
In addition, a ten-day controlled-feeding study showed that despite producing measurable
changes in microbial composition, the dietary intervention did not overcome interindividual variation in beta diversity [48].
The gut microbiome is a key factor in the bioavailability and transformation of
dietary flavonoids, so it is not surprising that flavonoid intake may have varied effects
among individuals depending on their microbial community composition [49,50]. In
some studies, a polyphenol or flavonoid treatment was shown to differentially affect subgroups of participants. For example, six-week supplementation of freeze-dried blueberry
powder (~392 mg anthocyanins) resulted in a trend of increased alpha diversity in older
women (age: 65-77 years, n = 6) but not in younger women (age: 21-39, n = 11) [51].
Another study in overweight and obese adults found that 12-week supplementation with
epigallocatechin-3-gallate and resveratrol impacted gut microbiota composition in men
but not women [52]. Among the male participants, supplementation tended to reduce
Faecalibacterium prausnitzii and significantly lowered Bacteroidetes, and increased postprandial fat oxidation was significantly correlated to baseline Bacteroidetes abundance
[52].
Interestingly, independent of factors such as age, sex, ethnicity, and general
health, the human gut microbiome appears to naturally cluster in a few distinct patterns,
or enterotypes, rather than on a continuous spectrum [53]. The existence of different
enterotypes or metabotypes (nutrient-metabolizing phenotypes) may explain why human
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clinical data has been inconclusive despite strong preclinical evidence; in some studies,
the sample size may have been insufficient to overcome natural inter-individual variation
among subjects. In fact, the potential effects of different gut microbiota metabotypes
stratifying the human response to polyphenol supplementation has been previously
demonstrated and is an on-going interest in polyphenol research [54–57].
In a study evaluating four weeks of pomegranate juice intake, no differences were
observed in the microbiota composition from baseline to post-intervention, but the
authors reported a correlation of specific intestinal microorganisms with changes in fecal
phenolic metabolites [22]. The intestinal microbiota has a large functional metabolic
capability to metabolize a variety of substrates and generate a variety of products [7].
Potentially, a beneficial change in host phenotype, as a result of the metabolism of the
intestinal microbiome, may occur without requiring significant concomitant change in
microbiota composition—especially in an adult with a stable and diverse microbiome. It
may only be a matter of providing the right substrates in adequate amounts to observe
health benefits, though this would likely require a much longer period (weeks to months)
to see measurable changes in host phenotype [39].
Overall, our subjects had low levels of fecal calprotectin (< 16 μg/g), suggesting
that they had very low intestinal inflammation regardless of the treatment. Mean fecal
calprotectin was well below clinical levels—values lower than 50 μg/g are considered
normal, and abnormal levels are 120 μg/g or higher, which are most often observed with
serious intestinal conditions such as inflammatory bowel disease, Crohn’s disease, and
ulcerative colitis [58]. The flavonoid pre-workout drink did not appear to have an effect
with subjects displaying low intestinal inflammation, which may be a reason why the
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results from this study differed from previous work. In cases of low inflammation, a
recent meta-analysis found that green tea supplementation did not have a significant
effect on the inflammatory marker serum C-reactive protein (CRP) [59]. An important
consideration when comparing findings from different studies is the study population and
whether subjects have pre-existing conditions or are otherwise generally healthy. In many
animal models, intestinal conditions or other pathologies are often the result of genetic
modification, chemical induction, a selective diet (e.g., high fat), or some combination
thereof. Approximately half of the clinical trials investigating the effects of polyphenol
intake have been conducted in healthy subjects versus those with risk factors or disease
[57]. In addition, another characteristic of our study population is that they were active
and trained regularly. Exercise has been reported to have a positive effect on alpha
diversity and the intestinal microbiota, and a six-week cycling protocol was found to
increase Akkermansia abundance in a group of overweight women [60,61]. Elevated
levels of the commensal microorganisms Akkermansia, Lactobacillus, and
Bifidobacterium have been found in multiple observational studies to be associated with
regular exercise [62].
Another reason why the observed results may have differed from previous studies
is due to the amount of control over potentially confounding factors. Preclinical models
are conducted in genetically identical animals, and experiments can be controlled for
environmental, dietary, and other study conditions. For dietary intake, clinical studies can
vary widely—from a controlled diet to a partially restricted diet to general diet
counseling. Other clinical studies may be conducted in controlled settings, such as a
hospital or nursing facility. The form of the dietary intervention (whether a supplement,
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extract, or whole food) is also expected to have an effect; bioavailability of flavonoids
differ depending on the food matrix as well as processing conditions [63]. In the
Polyphenol Study as well as others evaluating dietary polyphenols intake, all study meals
were provided for the treatment and control arms, reducing the potential variation
introduced by diet-related factors [64,65]. An effective minimum dose, whether in
supplement, extract, or whole foods, has yet to be established for flavonoids. Effective
doses of dietary flavonoids versus those from a supplement or extract will likely differ.
Higher fruit, vegetable, cocoa, coffee, and tea consumption will result in higher habitual
polyphenol intake [66]. Whether or not additional flavonoid intake will have an effect in
combination with a background diet high in dietary flavonoids is also unknown. Most
clinical trials, including the present study, restrict high polyphenol foods and supplements
during the course of the study. A few studies have evaluated the effect of supplemental
flavonoid intake without imposing diet restrictions, and in one study, positive flavonoidmediated effects were still observed [22,67].
A limitation of the present study which was mentioned earlier is the sample size.
The analyses presented here were conducted in conjunction with the study as described in
Chapter III, which was statistically powered for the primary endpoints of intestinal
permeability and injury. While the appropriate within-subject comparisons were
conducted, a larger sample size may have been necessary to detect significant changes in
intestinal microbiota, given the large inter-individual variation known to exist [39]. This
variability demonstrates the value of a crossover design for microbiome-related studies,
and a strength of this study is the randomized, controlled, crossover design allowing for
within-subject comparison.
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In conclusion, we investigated the effects of a high flavonoid supplement
containing blueberry, green tea, and cocoa in a randomized, controlled clinical trial. The
purpose for conducting fecal SCFA, intestinal microbiome, and fecal calprotectin
analyses was to determine the localized effects of supplemental flavonoid intake on
intestinal health. We found no differences in a group of twelve generally healthy, amateur
cyclists. We did not observe consistent changes among subjects or a significant change
within a subject, but our results are consistent with previous work suggesting that shortterm supplementation does not overcome inter-individual variation. Instead, long-term
dietary habits appear to have the greatest impact on the microbial community. Our
understanding of the interaction between the gut microbiota and human health is still
lacking, and this relationship may even differ from one individual to the next. It is
important to determine how flavonoid and polyphenol intake can affect gut health, which
can influence future nutritional guidelines and further understanding of personalized
nutrition.

References
1.

Lin, L.; Zhang, J. Role of intestinal microbiota and metabolites on gut homeostasis
and human diseases. BMC Immunol. 2017, 18, 1–25, doi:10.1186/s12865-0160187-3.

2.

Espín, J.C.; González-Sarrías, A.; Tomás-Barberán, F.A. The gut microbiota: A
key factor in the therapeutic effects of (poly)phenols. Biochem. Pharmacol. 2017,
139, 82–93, doi:10.1016/j.bcp.2017.04.033.

3.

Peron, G.; Hidalgo-Liberona, N.; González-Domínguez, R.; Garcia-Aloy, M.;
Guglielmetti, S.; Bernardi, S.; Kirkup, B.; Kroon, P.A.; Cherubini, A.; Riso, P.; et

125
al. Exploring the Molecular Pathways Behind the Effects of Nutrients and Dietary
Polyphenols on Gut Microbiota and Intestinal Permeability: A Perspective on the
Potential of Metabolomics and Future Clinical Applications. J. Agric. Food Chem.
2020, 68, 1780–1789, doi:10.1021/acs.jafc.9b01687.
4.

Le Chatelier, E.; Nielsen, T.; Qin, J.; Prifti, E.; Hildebrand, F.; Falony, G.;
Almeida, M.; Arumugam, M.; Batto, J.-M.; Kennedy, S.; et al. Richness of human
gut microbiome correlates with metabolic markers. Nature 2013, 500, 541–546,
doi:10.1038/nature12506.

5.

Lepage, P.; Häsler, R.; Spehlmann, M.E.; Rehman, A.; Zvirbliene, A.; Begun, A.;
Ott, S.; Kupcinskas, L.; Doré, J.; Raedler, A.; et al. Twin Study Indicates Loss of
Interaction Between Microbiota and Mucosa of Patients With Ulcerative Colitis.
Gastroenterology 2011, 141, 227–236, doi:10.1053/j.gastro.2011.04.011.

6.

Manichanh, C.; Rigottier-Gois, L.; Bonnaud, E.; Gloux, K.; Pelletier, E.; Frangeul,
L.; Nalin, R.; Jarrin, C.; Chardon, P.; Marteau, P.; et al. Reduced diversity of
faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut
2006, 55, 205–211, doi:10.1136/gut.2005.073817.

7.

Thursby, E.; Juge, N. Introduction to the human gut microbiota. Biochem. J. 2017,
474, 1823–1836, doi:10.1042/BCJ20160510.

8.

David, L.A.; Maurice, C.F.; Carmody, R.N.; Gootenberg, D.B.; Button, J.E.;
Wolfe, B.E.; Ling, A. V; Devlin, A.S.; Varma, Y.; Fischbach, M.A.; et al. Diet
rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505,
559–563, doi:10.1038/nature12820.

9.

Oteiza, P.I.; Fraga, C.G.; Mills, D.A.; Taft, D.H. Flavonoids and the

126
gastrointestinal tract: Local and systemic effects. Mol. Aspects Med. 2018, 61, 41–
49, doi:10.1016/j.mam.2018.01.001.
10.

Duda-Chodak, A.; Tarko, T.; Satora, P.; Sroka, P. Interaction of dietary
compounds, especially polyphenols, with the intestinal microbiota: a review. Eur.
J. Nutr. 2015, 54, 325–341, doi:10.1007/s00394-015-0852-y.

11.

Alves-Santos, A.M.; Sugizaki, C.S.A.; Lima, G.C.; Naves, M.M.V. Prebiotic
effect of dietary polyphenols: A systematic review. J. Funct. Foods 2020, 74,
104169, doi:10.1016/j.jff.2020.104169.

12.

Ma, G.; Chen, Y. Polyphenol supplementation benefits human health via gut
microbiota: A systematic review via meta-analysis. J. Funct. Foods 2020, 66,
doi:10.1016/j.jff.2020.103829.

13.

Guglielmetti, S.; Fracassetti, D.; Taverniti, V.; Del Bo’, C.; Vendrame, S.; KlimisZacas, D.; Arioli, S.; Riso, P.; Porrini, M. Differential Modulation of Human
Intestinal Bifidobacterium Populations after Consumption of a Wild Blueberry
(Vaccinium angustifolium) Drink. J. Agric. Food Chem. 2013, 61, 8134–8140,
doi:10.1021/jf402495k.

14.

Tzounis, X.; Rodriguez-Mateos, A.; Vulevic, J.; Gibson, G.R.; Kwik-Uribe, C.;
Spencer, J.P.E. Prebiotic evaluation of cocoa-derived flavanols in healthy humans
by using a randomized, controlled, double-blind, crossover intervention study. Am.
J. Clin. Nutr. 2011, 93, 62–72, doi:10.3945/ajcn.110.000075.

15.

Vendrame, S.; Guglielmetti, S.; Riso, P.; Arioli, S.; Klimis-Zacas, D.; Porrini, M.
Six-Week Consumption of a Wild Blueberry Powder Drink Increases
Bifidobacteria in the Human Gut. J. Agric. Food Chem. 2011, 59, 12815–12820,

127
doi:10.1021/jf2028686.
16.

Kim, H.; Krenek, K.A.; Fang, C.; Minamoto, Y.; Markel, M.E.; Suchodolski, J.S.;
Talcott, S.T.; Mertens-Talcott, S.U. Polyphenolic derivatives from mango
(Mangifera Indica L.) modulate fecal microbiome, short-chain fatty acids
production and the HDAC1/AMPK/LC3 axis in rats with DSS-induced colitis. J.
Funct. Foods 2018, 48, 243–251, doi:10.1016/j.jff.2018.07.011.

17.

Fogliano, V.; Corollaro, M.L.; Vitaglione, P.; Napolitano, A.; Ferracane, R.;
Travaglia, F.; Arlorio, M.; Costabile, A.; Klinder, A.; Gibson, G. In vitro
bioaccessibility and gut biotransformation of polyphenols present in the waterinsoluble cocoa fraction. Mol. Nutr. Food Res. 2011, 55 Suppl 1, S44-55,
doi:10.1002/mnfr.201000360.

18.

Lee, H.C.; Jenner, A.M.; Low, C.S.; Lee, Y.K. Effect of tea phenolics and their
aromatic fecal bacterial metabolites on intestinal microbiota. Res. Microbiol. 2006,
157, 876–884, doi:10.1016/j.resmic.2006.07.004.

19.

Tzounis, X.; Vulevic, J.; Kuhnle, G.G.C.; George, T.; Leonczak, J.; Gibson, G.R.;
Kwik-Uribe, C.; Spencer, J.P.E. Flavanol monomer-induced changes to the human
faecal microflora. Br. J. Nutr. 2008, 99, 782–792,
doi:10.1017/S0007114507853384.

20.

Wallace, A.J.; Eady, S.L.; Hunter, D.C.; Skinner, M.A.; Huffman, L.; Ansell, J.;
Blatchford, P.; Wohlers, M.; Herath, T.D.; Hedderley, D.; et al. No difference in
fecal levels of bacteria or short chain fatty acids in humans, when consuming fruit
juice beverages containing fruit fiber, fruit polyphenols, and their combination.
Nutr. Res. 2015, 35, 23–34, doi:10.1016/j.nutres.2014.11.002.

128
21.

Janssens, P.L.H.R.; Penders, J.; Hursel, R.; Budding, A.E.; Savelkoul, P.H.M.;
Westerterp-Plantenga, M.S. Long-Term Green Tea Supplementation Does Not
Change the Human Gut Microbiota. PLoS One 2016, 11, e0153134.

22.

Mosele, J.I.; Gosalbes, M.-J.; Macià, A.; Rubió, L.; Vázquez-Castellanos, J.F.;
Jiménez Hernández, N.; Moya, A.; Latorre, A.; Motilva, M.-J. Effect of daily
intake of pomegranate juice on fecal microbiota and feces metabolites from
healthy volunteers. Mol. Nutr. Food Res. 2015, 59, 1942–1953,
doi:10.1002/mnfr.201500227.

23.

Wang, H.-B.; Wang, P.-Y.; Wang, X.; Wan, Y.-L.; Liu, Y.-C. Butyrate Enhances
Intestinal Epithelial Barrier Function via Up-Regulation of Tight Junction Protein
Claudin-1 Transcription. Dig. Dis. Sci. 2012, 57, 3126–3135, doi:10.1007/s10620012-2259-4.

24.

Plöger, S.; Stumpff, F.; Penner, G.B.; Schulzke, J.-D.; Gäbel, G.; Martens, H.;
Shen, Z.; Günzel, D.; Aschenbach, J.R. Microbial butyrate and its role for barrier
function in the gastrointestinal tract. Ann. N. Y. Acad. Sci. 2012, 1258, 52–59,
doi:10.1111/j.1749-6632.2012.06553.x.

25.

Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.;
Nakanishi, Y.; Uetake, C.; Kato, K.; Kato, T.; et al. Commensal microbe-derived
butyrate induces the differentiation of colonic regulatory T cells. Nature 2013,
504, 446–450, doi:10.1038/nature12721.

26.

Li, J.; Wu, T.; Li, N.; Wang, X.; Chen, G.; Lyu, X. Bilberry anthocyanin extract
promotes intestinal barrier function and inhibits digestive enzyme activity by
regulating the gut microbiota in aging rats. Food Funct. 2019, 10, 333–343,

129
doi:10.1039/C8FO01962B.
27.

Ríos-Covián, D.; Ruas-Madiedo, P.; Margolles, A.; Gueimonde, M.; de Los
Reyes-Gavilán, C.G.; Salazar, N. Intestinal Short Chain Fatty Acids and their Link
with Diet and Human Health. Front. Microbiol. 2016, 7, 185,
doi:10.3389/fmicb.2016.00185.

28.

Somerset, S.; Papier, K. A Food Frequency Questionnaire Validated for Estimating
Dietary Flavonoid Intake in an Australian Population. Nutr. Cancer 2014, 66,
1200–1210, doi:10.1080/01635581.2014.951728.

29.

Bhagwat, S.; Haytowitz, D.B.; Holden, J.M. USDA Database for the Flavonoid
Content of Selected Foods. U.S. Dep. Argiculture 2011, 1–156.

30.

Derikx, J.P.; Luyer, M.D.; Heineman, E.; Buurman, W.A. Non-invasive markers
of gut wall integrity in health and disease. World J. Gastroenterol. 2010, 16, 5272–
5279, doi:10.3748/wjg.v16.i42.5272.

31.

Bolyen, E.; Rideout, J.R.; Dillon, M.R.; Bokulich, N.A.; Abnet, C.C.; Al-Ghalith,
G.A.; Alexander, H.; Alm, E.J.; Arumugam, M.; Asnicar, F.; et al. Reproducible,
interactive, scalable and extensible microbiome data science using QIIME 2. Nat.
Biotechnol. 2019, 37, 852–857, doi:10.1038/s41587-019-0209-9.

32.

Callahan, B.J.; McMurdie, P.J.; Rosen, M.J.; Han, A.W.; Johnson, A.J.A.; Holmes,
S.P. DADA2: High-resolution sample inference from Illumina amplicon data. Nat.
Methods 2016, 13, 581–583, doi:10.1038/nmeth.3869.

33.

Quast, C.; Pruesse, E.; Yilmaz, P.; Gerken, J.; Schweer, T.; Yarza, P.; Peplies, J.;
Glöckner, F.O. The SILVA ribosomal RNA gene database project: improved data
processing and web-based tools. Nucleic Acids Res. 2013, 41, D590–D596,

130
doi:10.1093/nar/gks1219.
34.

Dhariwal, A.; Chong, J.; Habib, S.; King, I.L.; Agellon, L.B.; Xia, J.
MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual and
meta-analysis of microbiome data. Nucleic Acids Res. 2017, 45, W180–W188,
doi:10.1093/nar/gkx295.

35.

Vázquez-Baeza, Y.; Pirrung, M.; Gonzalez, A.; Knight, R. EMPeror: a tool for
visualizing high-throughput microbial community data. Gigascience 2013, 2, 16,
doi:10.1186/2047-217X-2-16.

36.

Kim, K.; Vance, T.M.; Chun, O.K. Estimated intake and major food sources of
flavonoids among US adults: changes between 1999-2002 and 2007-2010 in
NHANES. Eur. J. Nutr. 2016, 55, 833–843, doi:10.1007/s00394-015-0942-x.

37.

Sebastian, R.S.; Wilkinson Enns, C.; Goldman, J.D.; Martin, C.L.; Steinfeldt, L.C.;
Murayi, T.; Moshfegh, A.J. A New Database Facilitates Characterization of
Flavonoid Intake, Sources, and Positive Associations with Diet Quality among US
Adults. J. Nutr. 2015, 145, 1239–1248, doi:10.3945/jn.115.213025.

38.

Shim, J.-S.; Oh, K.; Kim, H.C. Dietary assessment methods in epidemiologic
studies. Epidemiol. Health 2014, 36, e2014009–e2014009,
doi:10.4178/epih/e2014009.

39.

Johnson, A.J.; Zheng, J.J.; Kang, J.W.; Saboe, A.; Knights, D.; Zivkovic, A.M. A
Guide to Diet-Microbiome Study Design. Front. Nutr. 2020, 7, 79.

40.

de la Cuesta-Zuluaga, J.; Mueller, N.T.; Álvarez-Quintero, R.; Velásquez-Mejía,
E.P.; Sierra, J.A.; Corrales-Agudelo, V.; Carmona, J.A.; Abad, J.M.; Escobar, J.S.
Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome

131
Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors.
Nutrients 2018, 11, 51, doi:10.3390/nu11010051.
41.

Barton, W.; Penney, N.C.; Cronin, O.; Garcia-Perez, I.; Molloy, M.G.; Holmes, E.;
Shanahan, F.; Cotter, P.D.; O&#039;Sullivan, O. The microbiome of professional
athletes differs from that of more sedentary subjects in composition and
particularly at the functional metabolic level. Gut 2018, 67, 625 LP – 633,
doi:10.1136/gutjnl-2016-313627.

42.

Allen, J.M.; Mailing, L.J.; Niemiro, G.M.; Moore, R.; Cook, M.D.; White, B.A.;
Holscher, H.D.; Woods, J.A. Exercise Alters Gut Microbiota Composition and
Function in Lean and Obese Humans. Med. Sci. Sports Exerc. 2018, 50, 747–757,
doi:10.1249/MSS.0000000000001495.

43.

Zhu, Q.; Jiang, S.; Du, G. Effects of exercise frequency on the gut microbiota in
elderly individuals. Microbiologyopen 2020, 9, e1053–e1053,
doi:10.1002/mbo3.1053.

44.

Ursell, L.K.; Metcalf, J.L.; Parfrey, L.W.; Knight, R. Defining the human
microbiome. Nutr. Rev. 2012, 70 Suppl 1, S38–S44, doi:10.1111/j.17534887.2012.00493.x.

45.

Johnson, A.J.; Vangay, P.; Al-Ghalith, G.A.; Hillmann, B.M.; Ward, T.L.; ShieldsCutler, R.R.; Kim, A.D.; Shmagel, A.K.; Syed, A.N.; Walter, J.; et al. Daily
Sampling Reveals Personalized Diet-Microbiome Associations in Humans. Cell
Host Microbe 2019, 25, 789-802.e5, doi:10.1016/j.chom.2019.05.005.

46.

Willis, H.J.; Slavin, J.L. The Influence of Diet Interventions Using Whole, Plant
Food on the Gut Microbiome: A Narrative Review. J. Acad. Nutr. Diet. 2020, 120,

132
608–623, doi:10.1016/j.jand.2019.09.017.
47.

Korem, T.; Zeevi, D.; Zmora, N.; Weissbrod, O.; Bar, N.; Lotan-Pompan, M.;
Avnit-Sagi, T.; Kosower, N.; Malka, G.; Rein, M.; et al. Bread Affects Clinical
Parameters and Induces Gut Microbiome-Associated Personal Glycemic
Responses. Cell Metab. 2017, 25, 1243-1253.e5, doi:10.1016/j.cmet.2017.05.002.

48.

Wu, G.D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y.-Y.; Keilbaugh, S.A.;
Bewtra, M.; Knights, D.; Walters, W.A.; Knight, R.; et al. Linking long-term
dietary patterns with gut microbial enterotypes. Science 2011, 334, 105–108,
doi:10.1126/science.1208344.

49.

Ozdal, T.; Sela, D.A.; Xiao, J.; Boyacioglu, D.; Chen, F.; Capanoglu, E. The
Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on
Bioaccessibility. Nutrients 2016, 8, 78, doi:10.3390/nu8020078.

50.

Catalkaya, G.; Venema, K.; Lucini, L.; Rocchetti, G.; Delmas, D.; Daglia, M.; De
Filippis, A.; Xiao, H.; Quiles, J.L.; Xiao, J.; et al. Interaction of dietary
polyphenols and gut microbiota: Microbial metabolism of polyphenols, influence
on the gut microbiota, and implications on host health. Food Front. 2020, 1, 109–
133, doi:10.1002/fft2.25.

51.

Ntemiri, A.; Ghosh, T.S.; Gheller, M.E.; Tran, T.T.T.; Blum, J.E.; Pellanda, P.;
Vlckova, K.; Neto, M.C.; Howell, A.; Thalacker-Mercer, A.; et al. Whole
blueberry and isolated polyphenol-rich fractions modulate specific gut microbes in
an in vitro colon model and in a pilot study in human consumers. Nutrients 2020,
12, 1–21, doi:10.3390/nu12092800.

52.

Most, J.; Penders, J.; Lucchesi, M.; Goossens, G.H.; Blaak, E.E. Gut microbiota

133
composition in relation to the metabolic response to 12-week combined
polyphenol supplementation in overweight men and women. Eur. J. Clin. Nutr.
2017, 71, 1040–1045, doi:10.1038/ejcn.2017.89.
53.

Arumugam, M.; Raes, J.; Pelletier, E.; Le Paslier, D.; Yamada, T.; Mende, D.R.;
Fernandes, G.R.; Tap, J.; Bruls, T.; Batto, J.-M.; et al. Enterotypes of the human
gut microbiome. Nature 2011, 473, 174–180, doi:10.1038/nature09944.

54.

Bolca, S.; Van de Wiele, T.; Possemiers, S. Gut metabotypes govern health effects
of dietary polyphenols. Curr. Opin. Biotechnol. 2013, 24, 220–225,
doi:10.1016/j.copbio.2012.09.009.

55.

Kang, C.; Zhang, Y.; Zhu, X.; Liu, K.; Wang, X.; Chen, M.; Wang, J.; Chen, H.;
Hui, S.; Huang, L.; et al. Healthy Subjects Differentially Respond to Dietary
Capsaicin Correlating with Specific Gut Enterotypes. J. Clin. Endocrinol. Metab.
2016, 101, 4681–4689, doi:10.1210/jc.2016-2786.

56.

González-Sarrías, A.; García-Villalba, R.; Romo-Vaquero, M.; Alasalvar, C.;
Örem, A.; Zafrilla, P.; Tomás-Barberán, F.A.; Selma, M. V; Espín, J.C. Clustering
according to urolithin metabotype explains the interindividual variability in the
improvement of cardiovascular risk biomarkers in overweight-obese individuals
consuming pomegranate: A randomized clinical trial. Mol. Nutr. Food Res. 2017,
61, 1600830, doi:10.1002/mnfr.201600830.

57.

Marino, M.; Del Bo’, C.; Martini, D.; Porrini, M.; Riso, P. A Review of Registered
Clinical Trials on Dietary (Poly)Phenols: Past Efforts and Possible Future
Directions. Foods 2020, 9, 1606, doi:10.3390/foods9111606.

58.

Pathirana, W.G.W.; Chubb, S.P.; Gillett, M.J.; Vasikaran, S.D. Faecal

134
Calprotectin. Clin. Biochem. Rev. 2018, 39, 77–90.
59.

Haghighatdoost, F.; Hariri, M. The effect of green tea on inflammatory mediators:
A systematic review and meta-analysis of randomized clinical trials. Phytother.
Res. 2019, 33, 2274–2287, doi:10.1002/ptr.6432.

60.

Monda, V.; Villano, I.; Messina, A.; Valenzano, A.; Esposito, T.; Moscatelli, F.;
Viggiano, A.; Cibelli, G.; Chieffi, S.; Monda, M.; et al. Exercise Modifies the Gut
Microbiota with Positive Health Effects. Oxid. Med. Cell. Longev. 2017, 3831972,
doi:10.1155/2017/3831972.

61.

Munukka, E.; Ahtiainen, J.P.; Puigbó, P.; Jalkanen, S.; Pahkala, K.; Keskitalo, A.;
Kujala, U.M.; Pietilä, S.; Hollmén, M.; Elo, L.; et al. Six-Week Endurance
Exercise Alters Gut Metagenome That Is not Reflected in Systemic Metabolism in
Over-weight Women. Front. Microbiol. 2018, 9, 2323,
doi:10.3389/fmicb.2018.02323.

62.

Keirns, B.H.; Koemel, N.A.; Sciarrillo, C.M.; Anderson, K.L.; Emerson, S.R.
Exercise and Intestinal Permeability: Another Form of Exercise-Induced
Hormesis? Am. J. Physiol. Liver Physiol. 2020, doi:10.1152/ajpgi.00232.2020.

63.

Kamiloglu, S.; Tomas, M.; Ozdal, T.; Capanoglu, E. Effect of food matrix on the
content and bioavailability of flavonoids. Trends Food Sci. Technol. 2020,
doi:10.1016/j.tifs.2020.10.030.

64.

Rodríguez-Morató, J.; Matthan, N.R.; Liu, J.; de la Torre, R.; Chen, C.-Y.O.
Cranberries attenuate animal-based diet-induced changes in microbiota
composition and functionality: a randomized crossover controlled feeding trial. J.
Nutr. Biochem. 2018, 62, 76–86, doi:10.1016/j.jnutbio.2018.08.019.

65.

135
Guglielmetti, S.; Bernardi, S.; Del Bo’, C.; Cherubini, A.; Porrini, M.; Gargari, G.;
Hidalgo-Liberona, N.; Gonzalez-Dominguez, R.; Peron, G.; Zamora-Ros, R.; et al.
Effect of a polyphenol-rich dietary pattern on intestinal permeability and gut and
blood microbiomics in older subjects: study protocol of the MaPLE randomised
controlled trial. BMC Geriatr. 2020, 20, 77, doi:10.1186/s12877-020-1472-9.

66.

Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. J.
Nutr. 2000, 130, 2073S–85S, doi:10.1093/jn/130.8.2073S.

67.

Morgan, P.T.; Barton, M.J.; Bowtell, J.L. Montmorency cherry supplementation
improves 15-km cycling time-trial performance. Eur. J. Appl. Physiol. 2019, 119,
675–684, doi:10.1007/s00421-018-04058-6.

136
CHAPTER V

FLAVONOID SUPPLEMENTATION AND PLASMA METABOLOMICS

Introduction
Metabolomics is a comprehensive analysis used to identify and quantify all
detectable small cellular metabolites (substrates, intermediates, products) present in a
biological system, providing a high-resolution snapshot of the active biochemical
processes at a given point in time [1,2]. Compared to the traditional use of individual
biomarkers, metabolomics analyses are thought to better capture the biological impact of
genetic or environmental changes, such as with disease, physical exercise, or a nutritional
intervention [3]. Initially, metabolomics analyses were “targeted”, involving the
quantitation of specific molecules of interest using either an internal or external standard
[2]. In the last decade, rapid technological advances in high-throughput methods,
instrument sensitivity, and data processing have enabled the development of “untargeted”
metabolomics to detect all compounds present in a sample—potentially hundreds or
thousands of molecules in a single analysis [2].
In general, the three most commonly used analytical platforms for metabolomics
are gas chromatography-mass spectrometry (GC-MS), liquid chromatography-MS (LCMS), and nuclear magnetic resonance (NMR) spectroscopy [4]. Of these, MS techniques
are more sensitive and more frequently employed than NMR [5,6]. In comparison to LCMS, GC-MS has a greater number of standardized protocols, open-access availability to
mass spectral deconvolution software, and a larger catalogue of published retention
indices and reference spectra for compound identification. Thus, GC-MS-based
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techniques are well-suited for resolving co-eluting compounds in complicated biological
samples and continues to be the gold standard for metabolomics [2]. The drawback of
GC-based metabolomics analyses is that it requires that analytes are volatile—meaning
that samples containing non-volatile compounds (including the primary metabolites
found in human plasma) require chemical derivatization prior to analysis [2]. Fortunately,
many options for derivatization are available, and trimethylsilylation, the most commonly
used method, can be performed under mild conditions with relatively high yield [5]. This
derivatization replaces the acidic proton in carboxylic acids, amines, thiols, and
hydroxides with a trimethylsilyl (TMS) group, and following derivatization, GC-MS
analysis can detect a wide range of metabolites including sugars, amino acids, lipids,
alcohols, catecholamines, and xenobiotics [2,5]. Generally, GC-MS is preferable for the
separation and identification of sugars and hydroxyl acids, but for larger metabolites,
including flavonoids and complex lipids, LC-MS methods are better suited for analysis
[2]. As a result, these complementary methods are ideally utilized together to obtain
greater coverage in metabolomics analyses [2].
Alongside advances in the capabilities of metabolomics profiling, research groups
have begun to explore the effects of exercise on the human metabolome [1,6]. Large
shifts in over 200 metabolites have been observed with exercise, particularly with longer
duration and higher intensity exercise [1,3]. During exercise, cellular metabolism ramps
up to supply up to ten times more adenosine triphosphate (ATP) than at rest to meet
increased workload demands [6]. Depending on substrate availability, this involves the
mobilization and utilization of glycogen, triglyceride, and amino acid stores [6]. Studies
have consistently reported significant changes in lipids (e.g., plasma medium and long
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chain fatty acids, fatty acid oxidation products, ketone bodies, and triglycerides), amino
acids, bile acids, and tricarboxylic acid cycle intermediates with exercise [1,6].
An ongoing interest in sports nutrition research is in dietary supplements that
complement and support exercise performance and recovery. Among these dietary
supplements of interest are fruit-derived flavonoids for their potential ergogenic effects
(for further discussion, see Chapter II, Section 3.4) [7]. Flavonoids are a diverse class of
plant secondary metabolites, and the number of research publications involving these
phytochemicals has increased rapidly in the last two decades [8]. This is due in part to the
observation that diets abundant in flavonoid-containing fruits and vegetables have
consistently been associated with a reduced risk of cardiometabolic disease and overall
mortality [9–12]. The molecular basis for these effects was initially attributed to the high
free-radical scavenging activity of flavonoids in vitro [13]. However, polyphenols (a
class of phytochemicals of which flavonoids are the largest subgroup) are highly
metabolized through a coordinated effort by both host and microbiota [14]. In general,
with the exception of flavan-3-ols, native flavonoids are glycated, which results in low
absorption in the small intestine and increases flavonoids exposed to the colonic
microflora [15]. Except in the proximal intestinal tract where native polyphenols may
reach high enough concentrations to potentially act as radical scavengers, the current
consensus is that dietary flavonoids are not acting as direct antioxidants in vivo [13].
Instead, a single compound can be transformed into an array of different metabolites, and
these metabolites are considered to be the main bioactive agents driving the physiological
effects observed as a result of flavonoid consumption, and may even display greater
bioactivity than their precursor parent compounds [7,16–18]. In a cell culture model,
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various flavonoid metabolites (protocatechuic acid, 4-hydroxybenzoic acid, vanillic acid,
benzoic acid-glucuronide, benzoic acid-sulfate, protocatechuic acid-3-glucuronide) were
shown to reduce LPS-induced TNF-α production to a greater extent than their precursor
flavonoids [18].
Microbiome-mediated effects have been found to be highly variable among
individuals, likely due to the large microbial diversity from person to person [13].
However, the human intestinal microbiome is also characterized by functional
redundancy, where different members can fill the same function (e.g., butyrate
production) within the microbial community [19]. Characterization of the functional
“metabolome” produced by the microbiome may be more important than the effects of
inter-individual variation in microbiome diversity and abundance. Metabolomics analysis
over a series of time points may allow better understanding of the dynamic changes
occurring as a result of a nutritional intervention. Significant changes in microbiomederived phenolic compounds have been detected in circulation following flavonoid
intake. Several studies conducted by Nieman et al. have explored the effects of fruit and
fruit-derived flavonoid consumption on the exercise metabolome [1,7,20–23]. In one that
study utilized both ultrahigh performance LC-tandem MS (UHPLC-MS/MS) and GCMS, elevated serum levels of the gut phenolic metabolites hippurate and 4methylcatechol sulfate were detected after a 3-day intensive exercise workload with 17day blueberry and green tea intake (equivalent to 3 cups of fresh blueberries and 1.3 cups
of brewed green tea) [20]. However, no differences in oxidative stress or inflammation
were observed between the polyphenol treatment and control [20]. In a 75-km cycling
trial comparing banana consumption versus a 6% carbohydrate drink, GC-MS-based
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metabolomics analysis showed that 56 out of 103 metabolites changed significantly with
exercise, and only one metabolite (dopamine) was different between the banana treatment
and carbohydrate control [21]. In another study comparing banana, pear, and a water
control, cycling time improved 5.0% and 3.3% on the banana and pear treatments,
respectively [22]. Banana and pear intake improved perceptual measures of performance
(energy, focus, and overall well-being) and reduced post-exercise measures of
inflammation (IL-10, cortisol, total leukocytes) [22]. Furthermore, UHPLC-MS/MSbased metabolomics showed that banana and pear ingestion elevated carbohydrate, fruitspecific, and phenolic compounds, while attenuating the exercise-induced metabolite
response in lipid mobilization and oxidation pathways [22]. In a follow-up study, two
different varieties of banana (Cavendish and mini-yellow) were compared with a 6%
carbohydrate drink and water during a 75-km cycling trial [23]. (Mini-yellow bananas
have a similar carbohydrate profile but 63% higher polyphenol content than Cavendish
bananas [23].) Both banana treatments resulted in significant UHPLC-MS/MS-detected
metabolite differences in amino acid and xenobiotic pathways from the water and
carbohydrate controls; the water-only trial also resulted in a significantly greater exercise
perturbation in the metabolite profile as compared to the carbohydrate and banana trials
[23].
Fruit-derived polyphenols appear to have a beneficial effect on exercise
performance and recovery, and metabolomics studies have shown potential in
determining phenolic and other metabolite responses to flavonoid intake [3,7]. While
some exercise studies have incorporated metabolomics analyses, more work is still
needed to better understand the interaction between flavonoid consumption and the
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exercise metabolome [3]. A few different modes of exercise have been employed
(cycling, running, swimming) with different supplementation schemes (acute and
chronic), ranging from “whole food” interventions to purified polyphenols [3]. In the
present study, we investigated changes in plasma metabolites following 15-day
consumption of either a high- or low-flavonoid pre-workout beverage (HFB and LFB,
respectively) in plasma samples from the randomized, controlled crossover trial described
in Chapter III. Plasma samples were collected before exercise, following exercise, and
during the subsequent recovery period to determine metabolite shifts over time with
either treatment. The purpose of this study was to conduct an untargeted GC-MS-based
metabolomics analysis to investigate the effect of flavonoid ingestion on the plasma
metabolome, in order to better direct future recommendations for exercise nutrition. We
hypothesized that flavonoid metabolites would be detected in the plasma following HFB
consumption, and that plasma metabolites associated with exercise (e.g., glucose, lactate,
energy metabolism intermediates, and lipids) would demonstrate the greatest extent of
change from baseline to immediately post-exercise.

Materials and Methods
Research design
This study was conducted as a part of the randomized clinical trial as described
previously in Chapter III. The study was approved by the USU institutional review board
(IRB Protocol #9255). Participants were informed of all study requirements and provided
written informed consent prior to enrollment. A complete list of inclusion and exclusion
criteria is provided in Appendix A, Table A-1.
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In brief, twelve cyclists completed this crossover study with two fifteen-day
treatment arms separated by a two-week washout period. During the intervention,
subjects consumed a pre-workout beverage containing blueberry, cocoa, and green tea
flavonoids (~490 mg total flavonoids) or a low flavonoid control (< 5 mg flavonoids)
daily. On Day 14, participants recorded their evening meal in a provided food journal and
continued recording all foods and beverages consumed through the end of the final
sample collection the following day. Participants were instructed to replicate all food and
beverage intake for the second intervention. Additionally, participants were instructed to
abstain from alcohol and strenuous activity on Day 14. On Day 15, research participants
completed a 1-hour cycling trial (45-min at 70% VO2max + 15-min TT) and provided
four blood samples: pre-exercise, post-exercise, 1-h post-exercise, and 4-h post exercise
(Figure 5-1). Seated venous blood samples were collected via antecubital venipuncture in
potassium ethylenediaminetetraacetic acid (K2EDTA)-treated Vacutainer tubes and
centrifuged (1500 × g, 10 min, 4 °C). Plasma was aliquoted to 1.5-ml polypropylene
microcentrifuge tubes and stored frozen at -80 °C until further analysis.

Figure 5-1. Schematic of study design and endpoint collection. HFB = high flavonoid
beverage; LFB = low flavonoid beverage; TT = time trial.
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Investigational product
The pre-workout supplement was designed to provide for the metabolic demands
of high intensity endurance exercise [24,25]. A general recommendation for endurance
exercise is 1-2 g carbohydrate (CHO) and 0.15-0.25 g protein (PRO) per kilogram of
body weight consumed prior to activity [26]. The macronutrient composition of fluid
bovine milk is particularly well-suited for this purpose, and dairy-derived protein is ideal
for sports nutrition due to its ease of digestion and absorption, branched chain amino acid
content, and protein quality [27]. As a result, the investigational product—prepared from
blueberry, cocoa, and green tea powders and 2% milk—is formulated to supply 66 g
CHO and 9 g PRO per serving.
One serving of the high flavonoid beverage (HFB) provided approximately 490
mg total flavonoids, while the low flavonoid beverage (LFB) contained approximately
4.6 mg flavonoids due to three modifications: alkalized cocoa, blueberry placebo powder,
and the omission of green tea powder. The green tea extract contained approximately 800
mg/g tea catechins (PureBulk, Inc; Roseburg, Oregon). High flavonoid cocoa powder (83
mg/g cocoa flavanols) and alkalized cocoa (10 mg/g flavanols) were provided by Barry
Callebaut (Zurich, Switzerland). Freeze-dried blueberry powder (14.0 mg/g total
anthocyanins) and blueberry placebo powder were supplied by the US Highbush
Blueberry Council (Folsom, California).
Plasma metabolomics
Methods for sample extraction and derivatization for gas chromatography-mass
spectrometry (GC-MS) metabolomics profiling were adapted from Fiehn [2]. Sample
extractions were prepared in duplicate. A method and derivatization blank was prepared
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alongside the samples, but without the addition of plasma. For sample cleanup and
extraction, 30 µL of plasma was mixed with 10 µL of 200 ppm ribitol (internal standard)
and 1 mL of an acetonitrile, isopropanol, and water mixture (3:3:2, v/v/v) at -20C. The
mixture was shaken for 5 min, centrifuged at 14,000 relative centrifugal force (RCF) for
2 minutes. Next, 450 µL of supernatant was removed to a fresh container and evaporated
to dryness in a centrifugal vacuum evaporator. The dried aliquot was re-suspended in 450
µL nitrogen-degassed acetonitrile/water (1:1, v/v), thoroughly mixed, and centrifuged at
14,000 RCF for 2 minutes. The supernatant was removed, evaporated to dryness, and
stored at -20C.
A reagent blank was prepared alongside the samples (without the addition of
plasma) beginning from this point forward. Additionally, a quality control mixture of 25
sugars, amino acids, lipids, and other metabolites was prepared as well (Appendix C).
Samples were derivatized with 20 µL methoxyamine hydrochloride in pyridine (20
mg/ml). Following the addition of methoxyamine, samples were shaken for 1.5 hours.
Next, 80 µL of a mixture of N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA)
and fatty acid methyl esters (FAME) were added to each sample. Samples were then
shaken for another 30 min and then submitted to GC-MS analysis.
The GC-MS platform was a Shimadzu single quadrupole gas chromatograph mass
spectrometer (GCMS-QP2010 SE) with a Zebron ZB-5MSi plus (30 m × 0.25 mm
diameter × 0.25 μm film thickness) capillary GC column (Phenomenex, Torrance, CA,
USA). Helium was used as the carrier gas, and the column flow rate was 1.18 ml/min,
with splitless injection and 5.5 min solvent cut time. The temperatures of the inlet, ion
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source, and transfer line were 250 °C, 230 °C, and 290 °C, respectively. The column
oven temperature program used for compound separation is shown in Table 5-1.

Table 5-1. GC oven temperature program for plasma metabolomics.
Rate (°C/min)
-10

Temperature (°C)
60
325

Hold Time (min)
1
10

Compound peaks were selected by visual comparison of the chromatograms from
the samples and method and reagent blanks, and features unique to the plasma samples
were selected for identification. Peaks were deconvoluted with the automatic mass
spectral deconvolution and identification system (AMDIS), identified with mass spectral
and FAME retention index library comparison, and confirmed with the National Institute
of Standards and Technology (NIST) mass spectral database. A quality control (QC)
standard mixture of selected sugars, amino acids, lipids, and other small metabolites was
also used for identification of these compounds. Peak areas were determined, and
multiple peaks representing the same compound—isomers and those formed from
incomplete TMS derivatization—were grouped into single features. Compounds
determined to be artifacts (e.g., polysiloxanes from moisture introduced during
derivatization, phthalates from plastics, derivatization reagent by-products, and EDTA
from the collection tubes) and FAME were omitted from the final compound table.
Statistical analysis
The final peak intensities table was uploaded to MetaboAnalyst 5.0 and analyses
were completed using the online platform [28]. Missing values were assumed to be below
the limit of detection and were imputed with 1/5 of the compound minimum value.
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Compound peak areas were normalized by the ribitol internal standard, log-transformed,
and auto-scaled (mean-centered, divided by the standard deviation of each feature). A
two-way repeated measures ANOVA was conducted to determine differences in
normalized, scaled metabolite abundance, with the FDR adjusted q-value to take into
account the multiple comparisons across metabolites. Statistical significance was set at q
< 0.05. Log2-transformed within-subject fold changes immediately post-exercise, 1 h
post-exercise, and 4 h post-exercise (relative to pre-exercise) were determined from the
ribitol-normalized peak intensities. Post-hoc testing with Tukey’s HSD was conducted
for metabolites with a significant main effect; post-hoc tests were performed with JMP
version 15.2.1 for Windows (SAS Institute, Cary, NC) with significance at α = 0.05.

Results
Participant characteristics
Twelve subjects (female n = 4, male n = 8; mean ± SD: age 37 ± 11 years, body
mass 78 ± 13 kg, height 1.74 ± 0.09 m, VO2max 43 ± 6 ml/kg/min) completed both arms
of the study. Both trials elicited a similar response in physiological and perceptual
measures (Table 5-2).
Physiological and perceptual responses to exercise
The exercise test elicited a similar change in heart rate (HR), rating of perceived
exertion (RPE), and core temperature regardless of the treatment (Table 5-2). Expired air
samples collected during the steady state exercise confirmed that cyclists were cycling at
~70% VO2max. Performance measures (time trial cycling distance and cadence) were not
significantly different between trials (Table 5-2).
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Table 5-2. Cycling trial: physiological and perceptual measures
HFB

LFB

HFB-LFB

38.53 ± 0.06
38.51 ± 0.23
0.02 ± 0.20
Final core temperature (°C)
HRmax (bpm)
174 ± 4
175 ± 5
-1 ± 2
RPE
4.0 ± 0.4
3.9 ± 0.5
0.08 ± 0.3
TT distance (km)
19.3 ± 0.7
18.9 ± 0.8
0.4 ± 0.3
Cadence (rpm)
93 ± 3
93 ± 3
0±2
HR = heart rate, bpm = beats per minute, RPE = rating of perceived exertion, TT = time
trial, rpm = revolutions per minute.

Untargeted plasma metabolomics
Several hundred features were detected in each sample, but many were
determined to be artifacts (contaminants or extraction/derivatization reagents),
indistinguishable from the background signal, or unidentifiable due to lack of a suitable
library match. Manual inspection of chromatograms yielded 92 metabolites in the plasma
samples that differed from the derivatization and reagent controls. Data cleaning involved
condensing metabolites with multiple peaks, removing artifacts, and peak alignment of
the compound table across all 96 samples. A total of 62 metabolites were tabulated, with
42 identified metabolites and 20 unknown compounds. We identified eight
carbohydrates, sixteen amino acids, twelve lipids, two cofactors and vitamins, two energy
metabolites, and one xenobiotic. Annotated metabolites are listed in Table 5-3, along
with their FAME retention indices (RI), retention times (RT), compound identifiers, and
associated metabolic pathways.
Principle component analysis (PCA) showed that the samples grouped together
according to time, with less distinction between treatments (Figure 5-2). The PC1, PC2,
and PC3 axes explained 17.1%, 14.6%, and 10.2% of the total data set variance,
respectively. There appeared to be a larger separation for the metabolome at time 5 than
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at all other times, and a slight separation with the pre-exercise metabolome (time 0).
Metabolites immediately post-exercise (time 1) and 1-h post exercise (time 2) appeared to
have some separation but were grouped more closely together than other times.
The heatmap generated with Euclidean distance measure and Ward clustering
algorithm is shown in Figure 5-3. Sample groups A-H and sub-groups 1-16 were
designated based on the clusters generated. Groups and sub-group designations are also
included in Table 5-3 along with the general classification of metabolite super and sub
pathways. Group A metabolites include the ketone body 3-hydroxybutyrate along with
four long chain fatty acids (14:0, 16:0, 18:1, 18:2n6); overall, these lipids were lower preexercise compared to immediately post-exercise, with mixed responses at later times.
Carbohydrates and energy metabolism-associated compounds (group B) were elevated
immediately post-exercise and lower 1-h and 4-h post-exercise. A few different
metabolite classes are represented in group C with relatively higher abundance
immediately post-exercise and 1-h post-exercise for myo-inositol and citrate. Seven
unknown compounds were grouped in D with the lipids palmitelaidic acid, α-tocopherol,
and cholesterol with most metabolites being more abundant at times 1 and 2 compared to
0 and 5. Interestingly, metabolites in groups E and F appear to be consistently elevated at
time 5, 4-h post-exercise. A few different metabolite classes are represented in Group G,
and these metabolites appear to be most abundant pre-exercise. Finally, Group H consists
of eleven amino acids and related compounds, in addition to an unknown, carbohydrate,
and vitamin/cofactor metabolite.
The two-way repeated measures ANOVA (log-transformed and auto-scaled
values) showed that 56 of 62 total features were significant with respect to time (FDR-
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adjusted q-value < 0.05) (Appendix C, Table C-1). Metabolites without significant time
effects were aspartate, benzoate, glycolic acid, 2-hydroxy-3-methylpentanoic acid
(HMVA), methionine, and unknown 9. No significant treatment effects or treatment by
time interactions were observed for any of the metabolites.
Of particular interest were select metabolites from three super pathways expected
to change most with exercise: compounds involved in glycolysis and energy metabolism,
lipids and ketone bodies, and amino acids. The response over time for a few selected
compounds are shown in Figure 5-4. Since only the time effect was significant, values
plotted are HFB and LFB combined.
The log2-transformed mean fold changes from pre-exercise for these metabolites
are reported in Tables 5-4 through 5-6. Increases and decreases in abundance relative to
pre-exercise is reflected in values > 0 and < 0, respectively. Since only the main effect of
time was significant, differences determined from post-hoc tests are indicated for overall
fold changes and not for either treatment individually.
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Figure 5-2. Three-dimensional PCA of untargeted metabolomics analysis colored by
treatment (A) and time (B).
(A)

(B)
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Figure 5-3. Heatmap visualization of plasma metabolites grouped by time, then treatment. Samples are arranged in columns. Darker
red indicates higher abundance and darker blue indicates lower abundance.
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Table 5-3. Identified plasma metabolites: retention index (RI), retention time (RT), Human Metabolome Database (HMDB) number,
PubChem identifier, Kyoto Encyclopedia of Genes and Genomes (KEGG) identifier, super and sub pathway association.
RI

RT

HMDB

PubChem

KEGG

Group

Subgroup

Class/Super
pathway

Sub pathway

1169

8.420

HMDB0000357

441

C01089

A

1

Lipid

Ketone bodies

2212
2217
1847
2044
1983

20.390
20.442
16.870
18.850
18.259

HMDB0000673
HMDB0000207
HMDB0000806
HMDB0000220

5280450
445639
11005
985

C01595
C00712
C06424
C00249

A
A
A
A
B

2
2
2
2
3

Lipid
Lipid
Lipid
Lipid
Carbohydrate

Long chain fatty acids
Long chain fatty acids
Long chain fatty acids
Long chain fatty acids
Disaccharides and oligosaccharides

2058

18.977

B

3

Carbohydrate

Monosaccharides

Pyruvate

1063

6.843

HMDB0000243

1060

C00022

B

4

Carbohydrate

L-Lactate

1076

7.041

HMDB0000190

61503

C00186

B

4

Carbohydrate

Phosphate

10.095
17.745
17.937
18.486
17.047
17.390

HMDB0001429

57424078

C00009

B

4

Energy

HMDB0000122

5793

C00221

B

4

Carbohydrate

Unknown 9
L-Tyrosine

1285
1932
1950
2006
1864
1896

HMDB0000158

6057

C00082

C
C

5
5

Amino acid

Creatinine

1571

13.790

HMDB0000562

588

C00791

C

6

Amino acid

Citrate
Myo-inositol
Unknown 4
Unknown 10
Palmitelaidic acid
trans-16:1
Unknown 16
Unknown 17

1839
2127
1469
2160

16.790
19.623
12.537
19.926

HMDB0000094
HMDB0000211

311
-

C00158
C00137

C
C
D
D

6
6
7
7

Energy
Carbohydrate

Tyrosine metabolism
Creatine metabolism
Biogenic amine
Tricarboxylic acid cycle
Galactose metabolism

3934

32.240

HMDB0012328

5282745

-

D

7

Lipid

Long chain fatty acids

3599
3925

30.050
32.165

D
D

7
7

Metabolite
3-Hydroxybutyrate
(BHBA)
Linoleic acid C18:2n6
Oleic acid C18:1
Myristic acid C14:0
Palmitic acid C16:0
Unknown disaccharide 1
Unknown
monosaccharide

D-Glucose

Glycolysis, gluconeogenesis, pyruvate
metabolism
Glycolysis, gluconeogenesis, pyruvate
metabolism
Oxidative phosphorylation
Glycolysis, gluconeogenesis, pyruvate
metabolism
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Table 5-3 continued. Identified plasma metabolites: retention index (RI), retention time (RT), Human Metabolome Database (HMDB)
number, PubChem identifier, Kyoto Encyclopedia of Genes and Genomes (KEGG) identifier, super and sub pathway association.
KEGG

Group

14985
5997

C02477
C00187

D
D
D
D
D

Subgroup
8
8
8
8
8

HMDB0000172

6306

C00407

E

9

HMDB0001870
HMDB0000115

243
757

C00539
C03547

HMDB0000827

5281

C01530

HMDB0000719
HMDB0061925
HMDB0000613

12647
2781043

C00263
-

E
E
E
E
F
F
F
F
F
F

9
10
10
10
11
11
11
11
11
12

HMDB0000008

11266

C05984

F

12

F
G

12
13

C02912

G

13

Carbohydrate

239

C00099

G

13

Nucleotide
Amino acid

Glycolysis, gluconeogenesis, pyruvate
metabolism
Pyrimidine metabolism, uracil
containing

3893

C02679

G
G

13
13

Lipid

Free fatty acids

Metabolite

RI

RT

HMDB

PubChem

Unknown 14
Unknown 15
Unknown 11
α-tocopherol
Cholesterol

2785
2820
2248
3168
3198

24.933
25.191
20.691
27.515
27.707

HMDB0001893
HMDB0000067

L-Isoleucine

1184

8.634

Unknown 2
Benzoate
Glycolic acid
Unknown 7
Unknown 6
Stearic acid C18:0
Unknown 13
Homoserine
Dehydroabietic acid
Erythronate

1422
1253
1090
1696
1553
2241
2593
1687
2410
1578

11.930
9.630
7.249
15.253
13.567
20.666
23.513
15.147
22.077
13.874

2-Hydroxybutyrate

1138

7.960

Unknown 8
Unknown 3

1705
1433

15.341
12.028

1,2-Propanediol

1018

6.183

HMDB0001881

1030

Beta-alanine

1436

12.113

HMDB0000056

Unknown 1
Lauric acid C12:0

1152
1663

8.173
14.727

HMDB0000638

Class/Super pathway

Sub pathway

Cofactors and vitamins
Lipid

Tocopherol metabolism
Sterol
Leucine, isoleucine, valine metabolism;
Glucogenic/ketogenic

Amino acid

Xenobiotic
Lipid

Benzoate metabolism
Hydroxy fatty acid

Lipid

Long chain fatty acids

Amino acid
Lipid
Carbohydrate
Amino acid
Lipid

Methionine, threonine, isoleucine
Aminosugar metabolism
Glutathione metabolism
Ketone bodies
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Table 5-3 continued. Identified plasma metabolites: retention index (RI), retention time (RT), Human Metabolome Database (HMDB)
number, PubChem identifier, Kyoto Encyclopedia of Genes and Genomes (KEGG) identifier, super and sub pathway association.
Metabolite

RI

RT

Unknown 12
Unknown
disaccharide 2

2378

21.810

2758

24.753

L-Methionine

1416

11.838

Sorbitol

1904
1918
1874

17.455
17.61
17.166

Glycine

1317

10.528

1264
1370
1302
1398
1494
1554
1639
1099
1226
1163
1280

9.803
11.253
10.323
11.626
12.856
13.58
14.585
7.386
9.233
8.343
10.016

1189

Fructose

L-Serine
L-Threonine
Unknown 5
L-Phenylalanine

HMDB

PubChem

KEGG

Class/Super
pathway

Sub pathway

G

Subgroup
14

G

14

Carbohydrate

Disaccharides and oligosaccharides

Group

HMDB0000696

6137

C00073

G

14

Amino acid

Methionine, cysteine, SAM, and taurine
metabolism; Glucogenic

HMDB0000660

439709

C02336

G

14

Carbohydrate

Fructose, mannose, and galactose metabolism

HMDB0000247

5780

C00794

H

15

Carbohydrate

HMDB0000123

750

C00037

H

15

Amino acid

HMDB0000187

5951

C00065

H

15

Amino acid

HMDB0000167

6288

C00188

H

15

Amino acid

Fructose, mannose, and galactose metabolism
Glycine, serine, threonine metabolism;
Glucogenic
Glycine, serine, threonine metabolism;
Glucogenic
Glycine, serine, threonine metabolism;
Glucogenic/ketogenic

H

16
Phenylalanine metabolism;
Glucogenic/ketogenic
Leucine, isoleucine, valine metabolism;
Glucogenic
Leucine, isoleucine, valine metabolism;
Ketogenic

HMDB0000159

6140

C00079

H

16

Amino acid

HMDB0000883

6287

C00183

H

16

Amino acid

HMDB0000687

6106

C00123

H

16

Amino acid

8.769

HMDB0000317

10796774

-

H

16

Lipid/Amino
acid

Hydroxy fatty acid; Product of ketogenic amino
acid metabolism

1247

9.515

HMDB0000294

2447

C00086

H

16

Urea cycle; Arginine and proline metabolism

Oxalic acid

1141

8.015

HMDB0002329

971

C00209

H

16

L-Lysine
L-Alanine
L-Aspartic acid

1937
1115
1539

17.809
7.621
13.402

HMDB0000182
HMDB0000161
HMDB0000191

5962
5950
5960

C00047
C00041
C00049

H
H
H

16
16
16

Amino acid
Cofactors and
vitamins
Amino acid
Amino acid
Amino acid

L-Valine
L-Leucine
2-Hydroxy-3methylpentanoic acid
(HMVA)
Urea

Ascorbate and aldarate metabolism
Lysine metabolism; Ketogenic
Alanine and aspartate metabolism; Glucogenic
Alanine and aspartate metabolism; Glucogenic
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Figure 5-4. Plasma metabolites pre- and post-exercise. Overall mean is plotted in red,
black lines are individual subjects. Since treatment effects were not significant, overall
means are plotted for HFB and LFB combined, at each time. Different letters indicate
significantly different groups (Tukey’s HSD).
(A)

(B)

(C)

(D)

(E)

(F)
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Figure 5-4 continued. Plasma metabolites pre- and post-exercise. Overall mean is plotted
in red, black lines are individual subjects. Since treatment effects were not significant,
overall means are plotted for HFB and LFB combined, at each time. Different letters
indicate significantly different groups (Tukey’s HSD).
(G)

(H)

Table 5-4. Fold changes from baseline (immediately, 1 hour, and 4 hours post-exercise)
in glycolysis and energy metabolites.
Sub pathway

Time

Overall

HFB

LFB

Glucose

Glycolysis,
gluconeogenesis,
pyruvate metabolism

Lactate

Glycolysis,
gluconeogenesis,
pyruvate metabolism

Pyruvate

Glycolysis,
gluconeogenesis,
pyruvate metabolism

Citrate

Tricarboxylic acid
cycle intermediate

Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex

0.25
-0.40
-0.08
1.76
-0.14
-0.50
0.92
-0.18
-0.23
0.47
0.35
0.04

0.10
-0.60
-0.24
1.66
-0.23
-0.63
0.63
-0.22
-0.34
0.42
0.27
0.00

0.34
-0.26
0.04
1.75
-0.12
-0.48
1.04
-0.16
-0.20
0.50
0.40
0.08

HFBLFB
-0.24
-0.34
-0.28
-0.08
-0.11
-0.16
-0.41
-0.06
-0.13
-0.08
-0.13
-0.08

Data are log2-transformed values. Post-hoc testing: overall values lsmeans significant
differences from pre-exercise determined by Tukey’s HSD are highlighted.
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Table 5-5. Fold changes from baseline (immediately, 1 hour, and 4 hours post-exercise)
in lipid-related metabolites.
Sub
pathway
Lauric acid
(12:0)

Medium
chain fatty
acid

Myristic acid
(14:0)

Long chain
fatty acid

Palmitic acid
(16:0)

Long chain
fatty acid

Stearic acid
(18:0)

Long chain
fatty acid

Oleic acid
(18:1)

Long chain
fatty acid

Linoleic acid
(18:2)

Long chain
fatty acid

3Ketone
Hydroxybutyrate
body
(BHBA)

Time

Overall

HFB

LFB

Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex

-0.61
-0.60
-0.58
0.72
0.06
0.27
0.81
0.22
1.15
0.24
0.23
1.79
2.67
1.49
1.66
2.34
1.02
1.43

-0.49
-0.50
-0.56
0.76
0.15
0.12
0.74
0.21
1.00
0.27
0.22
1.71
2.26
1.29
0.95
1.98
0.93
0.72

-0.89
-0.89
-0.73
0.55
-0.27
0.22
0.80
0.15
1.22
-0.01
0.17
1.81
2.83
1.48
1.99
2.51
0.87
1.76

HFBLFB
0.40
0.39
0.17
0.20
0.41
-0.10
-0.06
0.06
-0.22
0.28
0.05
-0.11
-0.57
-0.19
-1.04
-0.52
0.06
-1.04

Post-ex
1 h post-ex
4 h post-ex

1.24
0.39
0.99

1.33
0.59
0.83

1.08
0.06
0.96

0.25
0.53
-0.13

0.38
0.47
-0.43
-0.21
1.95
2.10

0.28
0.38
-0.44
-0.37
1.73
1.81

0.39
0.48
-0.54
-0.31
1.99
2.15

-0.11
-0.10
0.10
-0.05
-0.26
-0.33

Post-ex
α-tocopherol
Vitamin
1 h post-ex
4 h post-ex
Post-ex
2Glutathione
1 h post-ex
Hydroxybutyrate metabolism
4 h post-ex

Data are log2-transformed values. Post-hoc testing: overall values lsmeans significant
differences from pre-exercise determined by Tukey’s HSD are highlighted.
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Table 5-6. Fold changes from baseline (immediately, 1 hour, and 4 hours post-exercise)
in selected amino acids.
Sub
pathway
Alanine

Glucogenic
amino acid

Glycine

Glucogenic
amino acid

Serine

Glucogenic
amino acid

Valine

Glucogenic
amino acid

Isoleucine

Phenylalanine

Tyrosine

Glucogenic
and
ketogenic
amino acid
Glucogenic
and
ketogenic
amino acid
Glucogenic
and
ketogenic
amino acid

Leucine

Ketogenic
amino acid

Lysine

Ketogenic
amino acid

Time

Overall

HFB

LFB

Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex

-0.16
-1.10
-1.18
-0.07
-0.31
0.01
-0.31
-0.48
-0.24
-0.31
-0.71
-0.23
0.91
0.68

-0.22
-1.19
-1.20
-0.05
-0.25
0.00
-0.39
-0.58
-0.40
-0.28
-0.69
-0.29
0.87
0.58

-0.25
-1.11
-1.35
-0.13
-0.41
-0.03
-0.37
-0.44
-0.20
-0.37
-0.75
-0.21
0.51
0.43

HFBLFB
0.03
-0.08
0.15
0.08
0.17
0.03
-0.03
-0.14
-0.20
0.09
0.06
-0.09
0.36
0.15

4 h post-ex

1.50

1.17

1.37

-0.19

Post-ex
1 h post-ex

-0.14
-0.43

-0.15
-0.49

-0.16
-0.40

0.01
-0.09

4 h post-ex

-0.03

-0.16

0.06

-0.22

Post-ex
1 h post-ex

0.26
0.12

0.18
-0.06

0.30
0.22

-0.12
-0.28

4 h post-ex

-0.01

-0.21

0.11

-0.32

Post-ex
1 h post-ex
4 h post-ex
Post-ex
1 h post-ex
4 h post-ex

-0.54
-1.37
-0.53
-0.34
-1.09
0.30

-0.70
-1.63
-0.90
-0.60
-0.91
-0.28

-0.46
-1.34
-0.41
-0.31
-1.46
-0.67

-0.24
-0.29
-0.49
-0.29
0.56
0.38

Data are log2-transformed values. Post-hoc testing: overall values lsmeans significant
differences from pre-exercise determined by Tukey’s HSD are highlighted.

Discussion
In the present study, we investigated the plasma metabolome before and after a
bout of cycling exercise. A well-controlled exercise trial was conducted in a laboratory
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setting during which participants cycled for 45 minutes at a fixed intensity (70%
VO2max), followed by a 15-minute time trial. Food intake beginning in the evening prior
to the trial through the end of the recovery period was recorded by the participant and
replicated during the second arm. Study aims were two-fold: to investigate the plasma
metabolome pre- and post-exercise and to determine if flavonoid-derived metabolites can
be detected from pre-workout flavonoid intake. In the discussion that follows, samples
collected immediately (time 1), one hour (time 2), and four hours (time 5) post-exercise
are considered early, intermediate, and late recovery phase samples, respectively [6].
The PCA and heatmap visualization showed metabolome differentiation with
respect to time and not treatment, despite our hypothesis that the HFB and LFB would
differentially impact metabolism. Metabolite profiles clustered distinctly according to
time with the greatest separation in the late recovery phase than at any other time—
several metabolites like homoserine only appeared at time 5. This may be due to the
longer length of time between times 2 and 5, as well as the result of lunch and snacks
consumed during this time. In terms of food intake, the participants consumed breakfast
and the HFB/LFB two hours prior to sampling at time 0, a standardized sugar solution
after sampling at time 1, and lunch/snacks were allowed between times 2 and 5.
Breakfast, lunch, and snacks were individually-determined and replicated in the second
trial. Nonetheless, individual differences in food intake are not likely to have changed the
overall trends observed in the plasma metabolome as a whole, since food intake does not
impact metabolic flux to the same extent as a bout of exhaustive endurance exercise [29].
The heatmap generated with the clustering algorithm grouped the metabolites into
eight clusters based on similarities in their responses. Reviewing the associated metabolic
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super and sub pathways, metabolites involved in similar pathways clustered together in
the analysis. Overall, these metabolite patterns are consistent with the findings from a
systematic review of exercise metabolomics studies: early phase post-exercise increases
in carbohydrates and energy metabolism metabolites (lactate, pyruvate, TCA
intermediates), a large elevation in lipids, and a mixed response in amino acids [6].
Large fold changes were observed in lactate, pyruvate, and citric acid
immediately following exercise. Lactate, as a product of anaerobic glycolytic
metabolism, has historically been used as an indicator of endurance capacity at a given
exercise intensity [30]. High levels of pyruvate, in addition to lactate, accumulate as a
result of glycolysis and anaerobic metabolism [6]. The time course profile of lactate and
pyruvate (elevated immediately post-exercise, followed by a decline to baseline after an
hour of recovery), reflect the responsiveness of these metabolic pathways to the energy
demands of exercise. Several different pathways contribute to glucose flux:
glycogenolysis and gluconeogenesis in the liver increase glucose availability while
glucose uptake increases in muscle tissues through insulin-independent mechanisms
[31,32]. Following cessation of exercise, glucose uptake continues to be elevated during
recovery, which reduces circulating glucose and may explain the reduction in plasma
glucose observed after one hour of recovery [33]. The TCA intermediate citrate was
elevated during the early and intermediate phases of recovery but returned to baseline
after four hours of recovery. Other than citrate, we did not detect any other TCA cycle
intermediates (e.g., malate, aconitate, fumarate, succinate, and α-ketoglutarate), though
they would be expected to respond similarly.
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Endurance exercise elicits a strong response in circulating free fatty acids and
ketone bodies as alternative fuel sources to glucose [6]. During prolonged moderate
intensity exercise, lipids are mobilized for energy production, and lipid metabolism
contributes a considerable amount to energy production through β-oxidation and ketone
body formation [29]. Nieman et al. found that metabolites involved in lipolysis and lipid
oxidation are strong predictors of the metabolic response to intensive endurance exercise
[34]. Similarly, all 37 fatty acids reported in the systematic review by Schranner et al.
increased following exercise [6]. In the present study, the greatest fold changes of all
metabolites were observed in lipid-related compounds. In particular, long chain free fatty
acids (palmitic, stearic, oleic, and linoleic) and the ketone body 3-hydroxybutyrate
displayed large fold increases and sustained responses to exercise. This may demonstrate
that lipolysis and lipid oxidation was increased as a result of exercise and continued to be
pronounced during the late recovery phase. Prior data for responses of ketone bodies is
somewhat mixed, but they more often appear to increase following exercise. Ketone
bodies are synthesized from ketogenic amino acids and acetyl CoA as alternative fuel for
the brain and muscle tissues during long-duration exercise when carbohydrates become
limited [35]. Other lipid metabolites (triacylglycerols, dicarboxylate and monohydroxy
fatty acids, acylcarnitines, and other ketone bodies) were not detected or identified in the
analysis.
The patterns and directions of change for amino acids following exercise are not
as consistent across studies in comparison to lipids, but in general, lower amino acid
concentrations are reported following exercise [6]. Amino acids are in constant flux
through multiple and even opposing metabolic pathways, depending on their metabolic
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potential and sub pathway association. As glycogen stores are depleted and β-oxidation
pathways become saturated during prolonged exercise, glucogenic and ketogenic amino
acids may be transformed to glucose and ketone bodies, respectively, to provide the
necessary substrates for continued energy metabolism [6,36]. The majority of the
detected amino acids decreased relative to baseline with the exception of isoleucine,
which was elevated ~3.7-fold at time 5. In the heatmap visualization, most proteinogenic
amino acids clustered together in group H while isoleucine was in group E. This is
somewhat surprising since isoleucine is a branched chain amino acid (BCAA) along with
leucine and valine, but the reason for the difference in response to exercise is unclear.
Aside from isoleucine, the fold changes of the amino acids were relatively small.
Carbohydrate intake, such as with the pre-workout HFB and LFB, will reduce the rate of
gluconeogenesis and ketogenesis, which also reduces amino acid demand [6]. Thus,
smaller responses in amino acid mobilization and depletion would be expected with food
intake.
Following exercise, two different antioxidant-related metabolites were elevated.
Antioxidants are necessary to maintain cellular redox balance and prevent oxidative
damage to DNA, lipids, and proteins [37]. There was a strong response of 2hydroxybutyrate at the intermediate and late recovery phases where the metabolite
increased 4-fold and 4.6-fold, respectively. Elevated lipid β-oxidation, NADH/NAD+
imbalance, and oxidative stress following intensive endurance exercise causes 2hydroxybutyrate to increase [38]. Glutathione is a major endogenous antioxidant that is
primarily responsible for reducing lipid peroxidation, and 2-hydroxybutyrate is a
byproduct of supplementary glutathione synthesis via homocysteine [37,39]. The
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presence of 2-hydroxybutyrate at these later times suggests continued and elevated
glutathione demand despite the cessation of exercise several hours prior, which
demonstrates the longer lasting effects of submaximal endurance exercise on oxidative
stress and lipid metabolism. In contrast, 2-hydroxybutyrate was elevated one hour
following a sprint session (three 80-meter maximal sprints), but returned to baseline
within 30 minutes [39]. Another contributor to the antioxidant response is α-tocopherol
(vitamin E). An exogenous lipid-soluble antioxidant, α-tocopherol is notably elevated
from baseline in the early and intermediate recovery phases (potentially due to exerciseassociated lipolysis), but lower in the late phase, which may be due to increased cellular
uptake [40]. Both the responses in 2-hydroxybutyrate and α-tocopherol suggest an
increased demand for cellular antioxidants in the intermediate and late recovery stages—
the antioxidant response to exercise remained elevated even four hours later.
These findings lead to a related discussion regarding the adaptive response to
exercise and exogenous antioxidant supplementation. Exercise increases reactive oxygen
species (ROS) production by several times, but the adaptive response to this stimuli
(elevated ROS) includes the activation of endogenous antioxidant defense systems,
resulting in the upregulation of enzymatic and non-enzymatic antioxidants [41]. Within
skeletal muscle, exercise-induced metabolic stress results in additional positive
adaptations by activating native anti-inflammatory mechanisms, protein turnover,
mitochondrial biogenesis, and the heat shock protein response [42]. The exercise and
hormesis theory presents the idea that both a lack of exercise and over-training can have
negative effects, while some moderate volume of exercise with adequate recovery is
beneficial [43]. With regular training, the adaptive response to exercise can increase
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resting antioxidant enzyme levels and reduce oxidative stress following subsequent bouts
of exercise [41]. Though it may seem advisable to decrease exercise-induced oxidative
stress by increasing antioxidant intake, ingesting large dose antioxidant supplements
during regular exercise training may be counterproductive. Large dose vitamin C and E
supplementation has been reported to interfere with these cellular adaptations by
scavenging ROS, thus blunting the ROS-activated adaptive response to exercise [42]. In
fact, supra-physiological doses of vitamins C and E have been shown to cause negative
effects and reduced performance. Vitamin C supplemented at 1 g/day reduced positive
training adaptations to an 8-week exercise training program—supplementation reduced
antioxidant enzymes (superoxide dismutase and glutathione peroxidase) and
mitochondrial biogenesis in a group of sedentary men [44]. In contrast, flavonoid
supplementation has not been shown to inhibit positive exercise adaptations to the same
extent, and as opposed to vitamins C and E, circulating flavonoids and their metabolites
do not behave as direct antioxidants [45]. For example, 30-day supplementation with
lychee fruit extract containing catechins and proanthocynaidins improved running time to
exhaustion and the subjects’ mean anaerobic threshold, whereas a combination of
vitamins C and E resulted in a reduction in VO2max [46]. In another study comparing
vitamin C (1 g/day) and blackcurrant juice (300 mg anthocyanins/day) intake, oxidative
markers (catalase, superoxide dismutase, protein carbonyls) were elevated following
vitamin C supplementation but not the blackcurrant or placebo [47]. Finally, in a
randomized controlled crossover trial evaluating seven day supplementation of 150 g
blueberries, 1250 mg vitamin C, and a placebo, only the blueberry treatment reduced
lipid hydroperoxides following a treadmill run at 70% VO2max at 35°C, while no benefit
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was observed with vitamin C [48]. Both blackcurrants and blueberries are high dietary
sources of anthocyanins, a sub-class of flavonoids [13].
In the present study, we did not observe any performance benefits or differences
in antioxidant-related metabolites due to the HFB treatment in comparison to the LFB
control. Flavonoids exhibit anti-inflammatory and anti-oxidative effects, likely through
downregulation of NF-κB signaling and the activation of the Nrf2/ARE pathway,
respectively (see Chapter II, Section 3.4) [49]. The number of publications on flavonoids
and their effects on human health and disease continues to grow [50]. Still, specifics
regarding optimal flavonoid intake (minimum effective dose, supplement timing with
exercise, and length of supplementation required) to have measurable changes on various
outcome measures are still unknown [3]. In studies where the dietary intervention was
provided chronically, it is difficult to ascertain whether beneficial effects on exercise
were due to the last dose or an effect due to a cumulative effect of chronic intake [49].
Since the intestinal microbiota plays an essential role in flavonoid bioavailability and
transformation, more time may be required for the effects of dietary flavonoid intake to
be reflected physiologically [16].
The metabolomics analysis did not reveal any host- or microbiota-derived
flavonoid metabolites in the plasma. Previously, metabolites of cocoa flavan-3-ols, tea
catechins, and berry anthocyanins have been identified in blood and urine [20,22,51–54].
These studies relied on the use of LC-MS, HPLC, and UPLC to separate and detect
flavonoid and phenolic metabolites, with a few using a combination of both GC-MS and
LC-MS. Gas chromatography is a reliable method for simultaneous measurement of
sugars, amino acids, and medium to long chain fatty acids, as was shown in this study.
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We observed strong effects of exercise on the metabolome but were unable to capture
nutritional differences. Unfortunately, GC methods are not optimized for separating
larger metabolites, and the use of multiple analytical methods may be justified in order to
cover broader range of compounds—including phenolic and flavonoid metabolites.
However, this is often constrained by cost and limited sample volume for conducting
multiple analyses. Ideally, multiple extraction conditions, derivatization agents, and
analytical platforms could be employed to ensure greater coverage of the spectrum of
metabolites as each method can be optimized for a specific class of compounds.
Another challenge encountered in this study was with compound identification.
While metabolomics is excellent for profiling global changes, a common challenge is that
hundreds of features may be detected in a sample, with limited resources for compound
identification [4]. For example, in another study, 238 metabolites were detected with a
combination of LC-MS and GC-MS, of which 75 remained unidentified [55]. In this
study, initial untargeted analysis yielded over 300 metabolites, which proved to be a
major challenge in data cleaning and compound identification. An extensive catalog of
purified standards is required for identification and quantification, but this requires
significant dedication of time and resources [4].
Overall, metabolomics analysis of small molecules in biological samples is a
powerful method for profiling the metabolic response to an intervention. In this study,
untargeted GC-MS-based metabolomics following metabolite trimethylsilylation was
used to profile the whole array of small molecular metabolites in plasma. The metabolic
perturbation following a one hour, submaximal cycling trial had a different response
during the early, intermediate, and late phases of recovery. Metabolites involved in
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similar pathways, such as long chain fatty acids, responded in a similar manner. Multiple
classes of compounds (sugars, free fatty acids, and amino acids) changed in different
directions in response to endurance exercise, suggesting that multiple fuel substrate
pathways are activated to varying degrees at different times in exercise and recovery.
Changes in energy metabolites, sugars, lipids were consistent with previous literature.
Though some metabolites like lactate and pyruvate responded rapidly to exercise and
returned to baseline during the intermediate recovery phase, several others, many
unidentified, were relatively low but increased significantly in the late recovery period.
As a result, it may be interesting to explore at later times following exercise, and future
work could include an additional measurement 24 hours post-exercise. This would be
especially relevant for detecting more microbiome-derived metabolites, as they take
longer to appear in circulation. In addition, the responses of the antioxidant-related
metabolites 2-hydroxybutyrate and α-tocopherol are interesting, and it may be
worthwhile in future work to include measures of endogenous antioxidant mechanisms
such as glutathione peroxidase, superoxide dismutase, and oxidized/reduced glutathione.
Finally, depending on the resources available, future studies may find that the benefits of
utilizing multiple analytical platforms and methods could outweigh the costs.
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CHAPTER VI

CONCLUSION

The body of work on dietary flavonoids in health and nutrition continues to grow,
and emerging clinical evidence is promising [1,2]. The primary activities of flavonoids
are anti-inflammatory, antioxidative, and vasoprotective—both in the GI tract and
systemically [3]. Due to these potential bioactive effects, flavonoid intake is of interest in
exercise nutrition research [4]. In the case of exercise-induced GI syndrome, transient
changes in intestinal permeability, injury, and inflammation can negatively impact
athletic performance and recovery [5]. Thus, the purpose of this project was to investigate
the local and systemic effects of supplemental flavonoid intake in combination with
submaximal cycling exercise. Two additional methodologies contributed to this project:
studies of the intestinal microbiome and circulating metabolome.
Methods in culture-independent microbiome analysis have advanced rapidly over
the last two decades, and new discoveries are continually made in how the intestinal
microbiome shapes human health and disease [6]. Specifically, the gut microbiome plays
an essential role in the biotransformation and biological effects of flavonoids [7]. For
example, anthocyanins were originally believed to have very low bioavailability (less
than 1%), but bioavailability was later estimated to be closer to 12% after finding over 30
different metabolites derived from one isotopically-labelled anthocyanin, many
attributable to the action of the gut microbiota [8]. Inter-individual variation in the gut
microbiome also plays a significant role in flavonoid metabolism. For example,
microbiota-determined metabotypes are thought to differentially metabolize pomegranate
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ellagitannins, resulting in different downstream health effects related to cardiovascular
risk [9].
Metabolomics profiling is a powerful tool in nutrition research that provides a
comprehensive analysis of the metabolic response to dietary intake [10]. Polyphenols are
structurally diverse, and one challenge in comparing different studies is that the flavonoid
intervention can vary from purified compounds, to processed ingredients, to whole foods.
Despite this variation, metabolomics allows for characterization of host- and microbiotaderived metabolites, which can be correlated to observed outcomes. Peripheral tissues are
not likely to be exposed to native flavonoids but to conjugated and transformed
metabolites instead, and the effects of these metabolites have been found to be quite
different from those of the parent compounds [8]. Typical levels of polyphenols in the GI
tract are in the μM/mM range while their metabolites in circulation are expected to be in
nM/μM range, which should be taken into account when comparing flavonoid doses in
cell culture, animal, and clinical studies [11].
Overall, the subjects’ estimated average flavonoid intake reflected that of the US
population, though total flavonoids were significantly lower than the national average due
to lower flavan-3-ol intake. Daily supplementation of 490 mg blueberry, green tea, and
cocoa flavonoids, while similar to the amount provided in other studies, may have
increased daily intake by 1.5 to 35 times. The subjects had low intestinal inflammation,
which perhaps overshadowed the effects, if any, of supplemental flavonoid consumption.
No effects of the flavonoid intervention were found on the intestinal microbiota or
SCFA—suggesting that supplemental flavonoids may not have the same effects as
flavonoids consumed in fresh, whole foods.
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To evaluate the effects of sub-chronic supplemental flavonoid intake, we
conducted a double-blind, randomized, controlled crossover trial with twelve
recreationally-active cyclists (VO2max 43.2 ± 5.9 ml/kg/min). Following submaximal
cycling exercise, specific metabolite patterns were observed with respect to time,
resulting in clustering of samples collected pre-exercise, post-exercise, 1-h post-exercise,
and 4-h post-exercise. Metabolites like pyruvate and lactate changed immediately postexercise, while long chain fatty acids had a larger response over a longer period of time,
and circulating amino acids decreased to a smaller extent post-exercise. Antioxidantrelated compounds like 2-hydroxybutyrate were elevated even after four hours of
recovery, suggesting a large demand for antioxidants following exercise. With the HFB,
we observed a trend for cyclists exerting greater force during the time trial, though no
measures of intestinal injury, inflammation, and permeability or plasma metabolites were
statistically significant with respect to treatment.
One potential reason why no treatment effects were observed may be that the
bioactive effects of flavonoids are relatively modest, requiring longer supplementation
periods or larger sample sizes to detect a treatment effect [12]. Additionally, previous
studies recruited subjects with pathological conditions, presumably with significantly
greater inflammatory stress and redox imbalance, where flavonoid supplementation may
improve these measures to a greater extent [13]. Another consideration is the degree of
exercise intensity and stress elicited by the study design. Gastrointestinal distress is most
commonly observed in ultra-endurance events, and studies demonstrating an elevation in
core temperature greater than 39 °C always reported elevated intestinal permeability
[14,15]. Moreover, exercise-induced oxidative stress is generally considered to be
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beneficial, resulting in positive adaptations through ROS-dependent mechanisms [16].
Thus, flavonoid supplementation may only be necessary for cases of extreme oxidative
imbalance and strenuous exercise—when ROS production overcomes native antioxidant
capacity, when perfusion is inadequate to meet demand, or when delaying fatigue is
critical during competition. Consequently, future studies should consider utilizing more
strenuous trials. Although this may prove to be a challenge for subject recruitment and
retention, other studies have successfully implemented such trials, and it may provide the
best and most practical insight into the effect of flavonoid intake on athletic performance.
A strength of this study was that it was a well-controlled, crossover clinical trial
seeking to address an unmet need. The flavonoid pre-workout product was well-received
by study participants. The aim of the study was appropriate and practical, with potential
findings that could affect a large population of both amateur and professional athletes.
Additionally, this study applied multiple methods to characterize the physiological
response to the dietary intervention by utilizing traditional biomarkers as well as -omics
techniques. Though we observed no apparent benefit of the flavonoid pre-workout, many
factors may have influenced these results, and previous studies demonstrating effects
have been conducted with curcumin, fruits, and juices [17–21]. Further study is
warranted, alongside microbiome and metabolomics analyses, if resources allow.
Ultimately, dietary flavonoid intake through the consumption of varied fruits and
vegetables may be the best recommendation. A diverse and well-balanced diet supplying
natural plant bioactives through whole foods is preferable to supplementation with single
antioxidants [3]. Unsurprisingly, the effects of a diet rich in whole fruits and vegetables,
which also contain other important nutrients (vitamins, minerals, dietary fiber) in addition
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to polyphenols, appear to differ from those of a diet supplemented with isolated
flavonoids or extracts. The beneficial effects reported in epidemiological studies may be
partially due to other food components or all components acting synergistically;
flavonoids have been shown to interact with the food matrix during digestion, which can
alternately increase or decrease their bioavailability [22–24].
Finally, responses to nutritional changes are highly individualized. In the field of
sports nutrition, tailoring to personal preferences is often recommended, and individuals
are known to respond differently to nutritional intake. Some practical considerations are
differences in food preferences, sport-specific needs, training schedules, and seasons.
With advances in bioinformatics and high-throughput data processing, there is potential
to develop individualized dietary recommendations. Characteristics such as microbiome
enterotypes may predict an individual’s response to nutrition, which leads to differential
metabolite production, potentially explaining the varied responses within human clinical
trials. Future studies should investigate these characteristics that determine individual
responses and work towards developing personalized recommendations for improving
human health and athletic performance.
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Appendix A. Exercise-Induced Intestinal Injury, Permeability, and Inflammation

Figure A-1. Study recruitment diagram.

Figure A-2. Study recruitment materials.
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Figure A-2 continued. Study recruitment materials.

Figure A-3. Guidelines provided to study participants for each intervention.
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Figure A-4. Schedule for clinic visits and assessments. For the food record: B – breakfast, L – lunch, D – dinner. One stool sample
was collected during Days 9-11. On Day 15, blood draws were taken pre-, post-, 1 h post-, and 4 h post-exercise.
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Figure A-5. Sample schedule for Day 15, the exercise trial.

Figure A-6. Rating of perceived exertion (RPE) visual scale.

Table A-1. Study inclusion and exclusion criteria.
Inclusion criteria
Male or female of any race or ethnicity between 18 to 55 years of age
Competed in a road race or triathlon in past 12 months
Free of chronic disease and GI conditions
Train at least 3 times per week, 1 hour at a time on average
Willing to prepare and consume provided pre-workout beverage daily
Willing to avoid consumption of high flavonoid foods/supplements and NSAIDs
during study period
Willing to provide urine, stool, and blood samples
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Table A-1 continued. Study inclusion and exclusion criteria.
Exclusion criteria
Age <18 or >55 years
Medical history of heart disease, hypertension, diabetes, Crohn’s disease, IBS, colitis,
celiac disease, inflammatory or autoimmune disease, and lactose intolerance
Uncontrolled hypertension: diastolic blood pressure >95 mm Hg or systolic blood
pressure >160 mm Hg
For women: pregnancy, breast feeding or postpartum <6 months
Food allergies or restrictions to treatment/placebo beverages
Chronic use of NSAIDs
Consumption of flavonoid supplements <1 month prior to study start
Other conditions (medical, psychiatric, or behavioral) that may present a safety hazard
to the participant or interfere with study participation, as determined by the principal
investigators

Table A-2. Standard curves for sugar test probes.
Sugar
Sucrose
Lactulose
Sucralose

Slope
0.0257
0.0245
0.0249

Intercept
-0.0422
0.0355
-0.0017

R2
0.9996
0.9960
0.9986
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Appendix B. Gut Microbiota Profile, Short Chain Fatty Acid Excretion, and
Intestinal Inflammation

Figure B-1. Adapted flavonoid FFQ self-administered by study participants.
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Figure B-1 continued. Adapted flavonoid FFQ self-administered by study participants.
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Figure B-2. Rarefaction curves of raw (A) and normalized (rarefied to minimum library
size and total sum scaling) data (B).
(A)

(B)
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Table B-1. Estimated weekly intake of individual flavonoids.
Class

Flavonoid
Isorhamnetin
Kaempferol
Flavonols
Myricetin
Quercetin
Apigenin
Flavones
Luteolin
Eriodictyol
Flavanones
Hesperetin
Naringenin
(-)-Epicatechin
(+)-Catechin
(-)-Epicatechin 3-gallate
(-)-Epigallocatechin
(-)-Epigallocatechin 3-gallate
Flavan-3-ols
(+)-Gallocatechin
Theaflavin
Theaflavin-3, 3'-digallate
Theaflavin-3'-gallate
Thearubigins
Cyanidin
Delphinidin
Malvidin
Anthocyanidins
Pelargonidin
Peonidin
Petunidin

Mean ± SEM (mg/week)
7.94 ± 2.14
26.41 ± 5.34
3.63 ± 1.41
98.49 ± 16.79
7.23 ± 2.16
4.65 ± 0.86
0.93 ± 0.20
38.01 ± 7.54
41.50 ± 9.15
57.31 ± 11.42
22.87 ± 4.97
22.48 ± 16.20
36.87 ± 25.57
76.03 ± 54.14
2.65 ± 1.90
1.46 ± 1.12
1.57 ± 1.20
1.36 ± 1.04
73.65 ± 56.37
41.06 ± 15.15
17.88 ± 6.40
29.23 ± 10.09
0.05 ± 0.01
8.59 ± 2.82
12.81 ± 4.40

Table B-2. Wilcoxon signed rank sum test for flavonoid intake.
Parameter
Flavonols
Flavones
Flavanones
Flavan-3-ols
Anthocyanidins
Total

Test Statistic
12.0
13.0
-6.0
-36.0
-1.0
-34.0

p-value
0.3804
0.3394
0.6772
0.0024
0.9697
0.0049

FDR-adjusted p-value
0.5706
0.5706
0.8126
0.0144
0.9697
0.0147
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Table B-3. Dependent t-test performed for fecal SCFA content.
Parameter
Acetic acid
Propionic acid
Butyric acid
Isobutyric acid
Valeric acid
Isovaleric acid
Caproic acid
Total SCFA

t ratio
-0.60675
-0.17074
-0.69556
-0.24649
-0.22855
-0.15598
-0.3123
-0.58098

p-value
0.5563
0.8675
0.5011
0.8098
0.8234
0.8789
0.7607
0.5730

FDR-adjusted p-value
0.8789
0.8789
0.8789
0.8789
0.8789
0.8789
0.8789
0.8789

Table B-4. Wilcoxon signed rank sum test performed for fecal calprotectin.
Parameter
Calprotectin

Test statistic
2.0

p-value
0.9097

Table B-5. Firmicutes to Bacteroidetes (F:B) ratio for each subject.

101
102
103
104
105
106
107
108
109
111
112
113

HFB
2.15
4.29
133.40
6.02
2.50
86.23
19.66
88.53
30.38
3.83
7.37
6.90

LFB
8.05
4.33
141.46
10.72
3.25
23.95
10.81
9.49
41.76
35.89
8.50
2.73

HFB-LFB
-5.90
-0.04
-8.06
-4.70
-0.74
62.28
8.84
79.04
-11.38
-32.07
-1.13
4.17

Table B-6. Wilcoxon signed rank sum test performed for F:B.
Parameter
F:B

Test statistic
4.0

p-value
0.7910
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Table B-7. Alpha diversity: Chao1

Taxa

Test statistic

p-value

Phylum
Class
Order
Family
Genus
Species
Feature-level

1.024
0.8607
0.29786
-0.14726
0.23771
0.10624
0.10624

0.30995
0.39306
0.76682
0.88337
0.81282
0.91571
0.91571

FDRadjusted pvalue
0.91571
0.91571
0.91571
0.91571
0.91571
0.91571
0.91571

Table B-8. Alpha diversity: Observed

Taxa

Test statistic

p-value

Phylum
Class
Order
Family
Genus
Species
Feature-level

0.99212
0.90242
0.86811
0.30339
0.24628
0.083003
0.083003

0.32518
0.37049
0.3888
0.76258
0.80622
0.93409
0.93409

FDRadjusted pvalue
0.9072
0.9072
0.9072
0.93409
0.93409
0.93409
0.93409

Table B-9. Alpha diversity: Shannon

Taxa

Test statistic

p-value

Phylum
Class
Order
Family
Genus
Species
Feature-level

1.1667
0.56692
0.65107
0.30047
-0.37216
-0.11229
-0.11229

0.24744
0.57265
0.51722
0.76474
0.71101
0.91095
0.91095

FDRadjusted pvalue
0.91095
0.91095
0.91095
0.91095
0.91095
0.91095
0.91095
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Table B-10. PERMANOVA test for unweighted UniFrac distance, within-subject
pairwise comparisons of HFB vs. LFB (n = 3).
Subject
1
2
3
4
5
6
7
8
9
11
12
13

pseudo-F
1.64
2.48
1.74
1.64
1.24
1.78
1.58
1.24
1.66
1.18
2.60
1.65

p-value
0.111
0.092
0.111
0.090
0.101
0.118
0.100
0.228
0.324
0.191
0.102
0.118

FDR-adjusted p-value
0.128
0.128
0.128
0.128
0.128
0.128
0.128
0.232
0.329
0.196
0.128
0.128

Table B-11. Results for independent t-tests comparing individual and total SCFA from
the Cycling Study (CS) and the Polyphenol Study (PO).
SCFA
CS vs. LFD
CS vs. HFD
CS
LFD (PO)
HFD (PO)
(mM/g)
p-value*
p-value*
Acetic acid
61.3 ± 5.5
56.2 ± 3.8
0.425
44.4 ± 2.6 0.027
Propionic acid 20.9 ± 1.9
17.6 ± 1.4
0.154
12.5 ± 0.9 0.008
Butyric acid
20.7 ± 2.2
16.0 ± 1.1
0.101
13.2 ± 1.0 0.020
Isobutyric
2.2 ± 0.3
1.7 ± 0.2
0.154
1.5 ± 0.1
0.067
acid
Valeric acid
2.6 ± 0.2
1.9 ± 0.2
0.021
1.6 ± 0.1
0.008
Isovaleric
3.1 ± 0.5
2.4 ± 0.2
0.232
2.1 ± 0.1
0.116
acid
Caproic acid
0.7 ± 0.2
0.9 ± 0.2
0.456
0.6 ± 0.1
0.643
TOTAL
111.5 ± 8.5 96.7 ± 5.9
0.154
75.8 ± 4.5 0.008
Note: Samples from HFB and LFB were combined together since they were not
statistically different.
LFD = Low flavonoid diet, HFD = High flavonoid diet. Values expressed are means ±
SEM. *FDR-adjusted p-value for multiple comparisons.
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Appendix C. Plasma Metabolites
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Table C-1. Two-way repeated measures ANOVA for plasma metabolites.

1,2-Propanediol
2-Hydroxybutyrate
3-Hydroxybutyric acid
alpha-tocopherol
Beta-alanine
Cholesterol
Citrate
Creatinine
Dehydroabietic acid
D-Glucose
Disaccharide 1 RI:1983
Disaccharide 2 RI:2758
Erythronate
Fructose
Glycine
Homoserine
L-Alanine
Lauric acid
Linoleic acid C18:2
L-Isoleucine
L-Lactate
L-Leucine
L-Lysine
L-Phenylalanine
L-Serine
L-Threonine
L-Tyrosine
L-Valine
Monosaccharide RI:2058

Treatment
(F.val)
2.270
0.004
0.065
0.068
1.454
0.400
0.008
0.269
0.397
3.089
0.027
0.027
1.472
0.005
0.291
0.002
0.204
0.128
1.736
0.452
0.204
0.094
0.624
0.175
1.035
0.091
1.722
0.341
0.048

Treatment
(raw.p)
0.146
0.949
0.801
0.796
0.241
0.534
0.929
0.609
0.535
0.093
0.872
0.871
0.238
0.943
0.595
0.965
0.656
0.724
0.201
0.508
0.656
0.762
0.438
0.679
0.320
0.765
0.203
0.565
0.828

Treatment
(adj.p)
0.968
0.981
0.974
0.974
0.968
0.968
0.981
0.968
0.968
0.968
0.976
0.976
0.968
0.981
0.968
0.981
0.968
0.974
0.968
0.968
0.968
0.974
0.968
0.968
0.968
0.974
0.968
0.968
0.976

Time
(F.val)
20.154
56.918
24.787
48.512
22.489
47.041
30.053
9.344
362.820
23.617
28.157
4.188
4.110
3.689
9.474
184.590
29.373
15.778
31.899
9.283
95.312
23.052
9.807
13.848
5.922
3.049
4.028
27.564
16.871

Time
(raw.p)
2.21E-09
2.76E-18
7.41E-11
1.11E-16
3.82E-10
2.22E-16
2.29E-12
3.13E-05
6.18E-41
1.69E-10
7.68E-12
8.94E-03
9.80E-03
1.61E-02
2.74E-05
4.95E-32
3.51E-12
7.70E-08
7.32E-13
3.33E-05
6.09E-24
2.54E-10
1.96E-05
4.19E-07
1.22E-03
3.46E-02
1.08E-02
1.13E-11
3.06E-08

Time(adj.p)
5.47E-09
2.45E-17
2.30E-10
8.61E-16
9.87E-10
1.37E-15
9.45E-12
4.61E-05
1.91E-39
4.77E-10
2.80E-11
1.11E-02
1.17E-02
1.82E-02
4.14E-05
1.02E-30
1.36E-11
1.65E-07
3.24E-12
4.80E-05
9.44E-23
6.84E-10
3.03E-05
7.64E-07
1.57E-03
3.83E-02
1.24E-02
3.90E-11
6.78E-08

Interaction
(F.val)
0.230
0.246
1.820
0.676
0.567
0.215
0.420
1.547
0.869
1.832
1.449
0.850
0.533
1.542
0.561
0.196
0.168
1.236
2.430
0.452
0.104
0.636
1.475
0.975
0.286
0.206
1.366
0.462
0.691

Interaction
(raw.p)
0.875
0.864
0.152
0.570
0.639
0.885
0.739
0.211
0.462
0.150
0.237
0.471
0.661
0.212
0.642
0.898
0.918
0.304
0.073
0.717
0.958
0.595
0.230
0.410
0.835
0.892
0.261
0.710
0.561

Interaction
(adj.p)
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
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Table C-1 continued. Two-way repeated measures ANOVA for plasma metabolites.

Myo-inositol
Myristic acid
Oleic acid C18:1
Oxalic acid
Palmitelaidic acid
Palmitic acid C16:0
Phosphate
Pyruvate
Sorbitol
Stearic acid C18:0
Unknown 1 RI: 1152
Unknown 10 RI:2160
Unknown 11 RI:2248
Unknown 12 RI:2378
Unknown 13 RI:2593
Unknown 14 RI:2785
Unknown 15 RI:2820
Unknown 16 RI:3599
Unknown 17 RI:3925
Unknown 2 RI:1422
Unknown 3 RI:1433
Unknown 4 RI:1469
Unknown 5 RI:1494
Unknown 6 RI:1553
Unknown 7 RI:1696
Unknown 8 RI:1705
Urea

Treatment
(F.val)
0.167
0.065
1.093
0.023
2.756
1.499
0.230
1.205
0.000
3.887
0.329
9.104
0.251
0.479
0.594
2.543
0.730
0.798
0.319
1.956
0.324
4.664
0.823
0.749
1.550
0.757
0.007

Treatment
(raw.p)
0.687
0.801
0.307
0.882
0.111
0.234
0.636
0.284
0.988
0.061
0.572
0.006
0.621
0.496
0.449
0.125
0.402
0.381
0.578
0.176
0.575
0.042
0.374
0.396
0.226
0.394
0.935

Treatment
(adj.p)
0.968
0.974
0.968
0.976
0.968
0.968
0.968
0.968
0.988
0.968
0.968
0.393
0.968
0.968
0.968
0.968
0.968
0.968
0.968
0.968
0.968
0.968
0.968
0.968
0.968
0.968
0.981

Time
(F.val)
40.172
8.898
44.751
17.712
8.347
47.338
24.857
12.297
4.274
60.558
11.877
88.906
14.348
4.071
833.830
14.171
8.022
14.475
8.276
17.253
14.049
24.324
10.494
41.179
4.107
11.975
13.752

Time
(raw.p)
6.86E-15
4.94E-05
6.69E-16
1.53E-08
8.76E-05
1.93E-16
7.06E-11
1.74E-06
8.09E-03
6.29E-19
2.59E-06
3.86E-23
2.68E-07
1.03E-02
2.20E-52
3.14E-07
1.23E-04
2.40E-07
9.44E-05
2.23E-08
3.50E-07
1.03E-10
9.87E-06
4.06E-15
9.84E-03
2.36E-06
4.57E-07

Time(adj.p)
3.27E-14
6.96E-05
3.77E-15
3.65E-08
1.21E-04
1.33E-15
2.30E-10
3.00E-06
1.02E-02
6.50E-18
4.23E-06
4.79E-22
5.36E-07
1.20E-02
1.36E-50
6.08E-07
1.63E-04
4.95E-07
1.27E-04
5.12E-08
6.57E-07
3.03E-10
1.57E-05
2.10E-14
1.17E-02
3.96E-06
8.10E-07

Interaction
(F.val)
0.161
1.103
2.148
0.785
1.374
0.646
0.345
0.387
0.102
0.593
0.640
1.088
0.534
0.789
0.187
2.542
2.639
2.950
1.307
0.734
0.088
0.691
1.110
0.093
0.315
0.125
0.442

Interaction
(raw.p)
0.922
0.354
0.103
0.507
0.258
0.588
0.793
0.763
0.958
0.622
0.592
0.360
0.660
0.504
0.905
0.064
0.057
0.039
0.280
0.536
0.967
0.561
0.352
0.963
0.815
0.945
0.724

Interaction
(adj.p)
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
0.967
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